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University of New Hampshire, December, 2017
I used molecular dynamics (MD) simulations as a primary tool to study folding and dynamics
of signaling and regulatory proteins. Specifically, I have studied two classes of proteins: the first
part of my thesis reports studies on peptides and receptors of the insulin family, and the second
part reports on studies of regulatory proteins from the G-protein coupled receptor family. The
first problem that I investigated was understanding the folding mechanism of the insulin B-chain
and its mimetic peptide (S371) which were studied using enhanced sampling simulation methods.
I validated our simulation approaches by predicting the known solution structure of the insulin
B-chain helix and then applied them to study the folding of the mimetic peptide S371. Potentials
of mean force (PMFs) along the reaction coordinate for each peptide are further resolved using the
metadynamics method. I further proposed receptor-bound models of S371 that provide mechanistic
explanations for competing binding properties of S371 and a tandem hormone-binding element of
the receptor known as the C-terminal (CT) peptide. Next, I studied the all-atom structural models
of peptides containing 51 residues from the transmembrane regions of IR and the type-1 insulin-like
growth factor receptor (IGF1R) in a lipid membrane. In these models, the transmembrane regions
of both receptors adopt helical conformations with kinks at Pro961 (IR) and Pro941 (IGF1R),
but the C-terminal residues corresponding to the juxta-membrane region of each receptor adopt
unfolded and flexible conformations in IR as opposed to a helix in IGF1R. I also observe that
the N-terminal residues in IR form a kinked-helix sitting at the membrane-solvent interface, while
homologous residues in IGF1R are unfolded and flexible. These conformational differences result in
a larger tilt-angle of the membrane-embedded helix in IGF1R in comparison to IR to compensate
for interactions with water molecules at the membrane-solvent interfaces. The metastable/stable
states for the transmembrane domain of IR, observed in a lipid bilayer, are consistent with a known
NMR structure of this domain determined in detergent micelles, and similar states in IGF1R are
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consistent with a previously reported model of the dimerized transmembrane domains of IGF1R.
I further studied dimerization propensities of IR transmembrane domains using three different
constructs in a lipid bilayer (isolated helices, ectodomain-anchored helices, and kinase-anchored
helices). These studies revealed that the transmembrane domains can dimerize in isolation and
in kinase-anchored forms, but not significantly in the ectodomain construct. The final studies in
my thesis are focused on interplay of protein dynamics and small-molecule inhibition in a set of
regulatory proteins known as the Regulators of G-protein Signaling (RGS) proteins. Thiadiazolidi-
none (TDZD) compounds have been shown to inhibit the protein-protein interaction between RGS
and the alpha subunit of G-proteins by covalent modification of cysteine residues in RGS proteins.
However, some of these cysteines in RGS proteins are not surface-exposed. I hypothesized that
transient binding pockets expose cysteine residues differentially between different RGS isoforms.
To explore this hypothesis, long time-scale classical MD simulations were used to probe the dynam-
ics of three RGS proteins (RGS4, RGS8, and RGS19), and characterize flexibility in various helical
motifs. The results from simulation studies were validated by hydrogen-deuterium exchange (HDX)
studies, and revealed motions indicating solvent exposure of buried cysteine residues, thereby pro-
viding insights into inhibitor binding mechanisms. In addition, I used different published HDX
models which have resulted in a comprehensive comparison of existing models. Furthermore, I
developed the new HDX models with optimized parameters which had comparable accuracy and
more computational efficiency compared to other models. Overall, my thesis has resulted in the
development and applications of several state-of-the-art computational methods that have provided
a detailed mechanistic understanding of peptide and small-molecule based inhibitors and their in-





Biological systems are known to be relevant entities via several complex processes. A common
strategy to understand and solve complex problems is to divide the entire system into smaller
and more simpler pieces. In this thesis, I have strived to understand complex biological processes
underlying diseases by studying molecular components in cells, such as proteins. Proteins are
biopolymers of 20 different types of amino acids. Each amino acid has an N-terminus and a C-
terminus which can form peptide bonds with the preceding or the following amino acids. Therefore,
various proteins or peptides differ by the number and the type of amino acid blocks (called residues).
These two characteristics determine the spatial structure of each protein and its function. As an
introduction, I focus on three key concepts that are directly related to proteins: protein folding
and dynamics, cell signaling, and receptors.
1.1.1 Protein Folding and Dynamics
Protein folding is a vital physicochemical process that is required for each protein in cells [1].
Folding happens when a protein with a particular sequence (or primary structure) structurally
evolves to a three-dimensional structure (or secondary/tertiary structure) that is energetically fa-
vorable. The final structure of the protein is distinct from its initial structure, is unique, and
reproducible (Figure 1.1).
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Protein folding can be studied under various conditions: (i) in a living organism or in vivo, (ii)
outside a living organism in a test tube or in vitro, and (iii) via a computer simulation or in silico.
Most studies reported in the literature on protein folding are carried out under in vitro or in silico
conditions [1].
Figure 1.1: Initial (unfolded) and final (folded) conformations of a 16-residue pep-
tide
1.1.2 Cell Signaling
Cell signaling is the process of transduction of signals from the outside to inside of cells and
across the cellular membrane, a fatty lipid-based envelope holding cells together. Cell signaling is
a complex process by which each cell receives signals and responds accordingly. The signals are in
the form of biomechanical signals [2] or biochemical signals [3](e.g. smelling an odorant initiates
a cascade of molecular events within an olfactory cell). Cell signaling is often mediated by small
molecules that are secreted from one cell and target other cells. Signaling molecules are classified
based on their targets and functions such as hormones that are secreted into blood and target
remote cells, or neurotransmitters, that target cells in the nervous system. A ligand is a signaling
molecule that often does not diffuse into targeted cells and instead targets a class of proteins on
the surface of targeted cells called receptors. Any malfunction in proteins that mediate signaling
pathways causes diseases such as cognitive disease, cancer, and diabetes [4–7].
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1.1.3 Receptor
Cell surface receptors, as their name indicates, are proteins that reside on the surface of biolog-
ical lipid membranes. The extracellular parts of these proteins are sensitive to particular signaling
molecules or ligands. As soon as a ligand binds to the extracellular part of a receptor, a message
in the form of mechanical changes allosteric (conformational) changes is transduced to intracellular
components of a receptor. The internal part of the receptor perceives the allosteric changes from
the extracellular or membrane-spanning domains and changes the behavior of the cell. The cell
surface receptors are categorized into three main families based upon the mechanism by which
signals from ligands turn into cellular responses [8]: (1) Ligand-gated ion channel receptors, (2)
Enzyme-coupled receptors, and (3) G-Protein-Coupled Receptors (GPCRs).
In ligand-gated ion channel receptors, the signal transduction function is encoded within the
protein that is triggered by a ligand. The binding of a ligand to these receptors results in opening
or closing of the ion-channel pore and causes imbalance or balance of ionic charge between the
intracellular and the extracellular parts of a cell. Enzyme-linked receptors possess binding site(s)
on the extracellular part, and the intracellular part contains enzymatic subunits, the activity of
which is regulated via extracellular ligand binding. Protein kinases are a big subfamily of this
kind of receptors in which the intracellular part carries out phosphorylation activities and changes
cellular functions. IR and Type-1 Insulin-like Growth Factor Receptor (IGF1R) are categorized in
this group. GPCRs control cellular signaling using an intermediate molecule on the intracellular
side, called a G-protein. All GPCRs share unique structural features: they have 7 helices embedded
in the lipid membranes. For example, rhodopsin, a light-sensitive receptor, is a GPCR protein.
1.2 Historical Accounts Of Research In Protein Folding And Dy-
namics
Most proteins need to be in their folded native states to exert functional outcomes [9], and as
a result, protein folding and misfolding is related to various diseases [10, 11]. In early studies of
4 Chapter 1. INTRODUCTION
proteins, it was assumed that protein folding is a straightforward process, but with the emergence
of new experimental and computational technologies, we now know that the folding and dynamics
in proteins are complex processes [12]. Early experimentalists believed that a protein folds through
distinct intermediate states in a distinct pathway. Consequently, researchers proposed different
mechanisms for folding of proteins: protein folding can be a spontaneous process, a random process,
or a predetermined process. Finally, novel views based on statistical and thermodynamics theories
emerged [13–17].
The usual experimental methods for refining the structures of proteins are X−ray crystallogra-
phy and NMR spectroscopy [18] as the structures of proteins have remained challenging to determine
using other spectroscopic methods (such as fluorescence and circular dichroism). The challenges
associated with experimental technologies in probing protein folding and dynamics have triggered
theoretical notions by which sequences of proteins are simulated and the folding process is modeled
using modern computers. The oldest studies of computational protein folding date back to 1968
by Levinthal [10]. He described that when a protein is denatured from its native structure into
any disordered and unfolded conformers, it can refold into a unique structure in which it is biolog-
ically functional. He speculated that the unique structure of proteins has at least a local minimum
configurational energy but not necessarily an absolute minimum. He highlighted computational
statistical approaches as a way for finding pathways of folding [12].
Pauling et al. [19] attacked the problem of the structure of proteins in several ways. One of
those ways was to determine the crystal structures of amino acids and peptides that form proteins
by understanding interatomic distances, bond angles, and other configurational parameters. They
used these parameters to construct two reasonable hydrogen-bonded helical configurations for the
polypeptide chain. Anfinsen et al. [12] showed that the the three-dimensional structure of a protein
can be understood as a physicochemical process solely based upon amino acid sequences. Since then
protein folding problem, in which a particular three-dimensional structure of a protein emerges only
from sequence of amino acids, has engaged biologists, physicists, chemists, and mathematicians.
These efforts rapidly led to a major success specifically when the importance of hydrophobic forces
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in protein folding and secondary structure formation revealed[20, 21]. An alternative view toward
the protein folding was the energy landscape theory [22]. The energy landscape theory of protein
folding is a statistical description of a protein’s potential energy surface. It assumes that folding
occurs through organizing an ensemble of structures rather than through only a few uniquely
defined structural intermediates. It suggests that the most probable model of a protein is a funneled
landscape biased toward the native structure. This view also suggests how the theory helps in the
interpretation of results from fast folding experiments and in the practical task of protein structure
prediction [23].
More recently, different theories and algorithms have resulted in various computational ap-
proaches such as Brownian Dynamics (BD), MD, and Monte Carlo (MC) modeling techniques [24].
These techniques are capable of computing rigorous and meticulous trajectories of discrete particles
with which protein folding and their probable discrete structures can be predicted. In this thesis,
MD is used as a technique to investigate protein folding, dynamics, and for understanding mecha-
nisms. MD technique computes all forces exerted on each particle by other particles and predicts
the time evolution of atomic positions using classical Newtonian mechanics.
1.3 Background
In the following, a brief background of systems and methods that have been used in various
studies outlined in different chapters of this thesis are presented.
1.3.1 Insulin
Insulin is a peptide hormone produced in the β cells of the pancreatic islets [25]. Any malfunction
in insulin binding or insufficient production of insulin leads to diabetes mellitus, a disease resulting
from poor glucose homeostasis. People with insufficient insulin in their blood (type 1 diabetes)
routinely inject insulin, but insulin malfunction (type 2 diabetes), which is more complicated,
happens when secreted hormone cannot effectively bind to its receptor. Therefore, a molecular
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level understanding of insulin recognition by its receptor is required in the treatment of diabetes
[26]. Insulin is comprised of two peptide chains (A-chain and B-chain) which in total contain 51
residues [27, 28]. These two peptide chains have three helices (two in the A-chain and one in
the B-chain) and are linked via three (two intermolecular and one intramolecular) disulfide-bonds
(Figure 1.2).
Figure 1.2: Cartoon representations of the crystal structure of the human insulin
showing the A−chain (blue), B-chain (red), and disulfide bonds (PDB: 3I40).
1.3.2 Insulin and Type-1 Insulin-Like Growth Factor Receptors
IR and the IGF1R are cell surface receptors that belong to receptor tyrosine kinase superfamily,
and can be activated by insulin and homologous insulin-like growth factors (IGF1 and IGF2) [29].
Structurally, IR is composed of three large protein fragments (Figure 1.3): the extracellular part, the
intracellular part, and a single-pass Transmembrane Domain (TMD) that connects extracellular and
intracellular fragments. TMD potentially plays a critical role in mediating signaling via IR because
insulin binding to extracellular subunits leads to conformational changes that are conveyed (via
TMD) to intracellular domains, thereby activating downstream signaling cascades. Any malfunction
in signaling via hormone insulin or its receptor causes diabetes.
IGF1R has a higher affinity for IGF1 and IGF2, but insulin can also bind to IGF1R with a low
affinity [30]. Despite similarities in structures, from a metabolic view, IR plays an important role
in the regulation of glucose in blood, while IGF1R plays an important role in growth by inducing
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Figure 1.3: Representation of hormone insulin and three parts of its receptor, IR.
the enlargement of an organ or tissue. Despite a high degree of homology, experiments indicate
that IR and IGF1R belong to distinct genes and they are controlled by different regulatory signals
[31, 32].
1.3.3 Regulator of G-protein Signaling Protein
Regulator of G-protein Signaling (RGS) proteins play an important role in regulation of signaling
pathways through GPCRs that are implicated in many diseases. The human RGS protein family
consists of nine family members that differ in targeting various Gα substrates and also in their
tissue expression profiles [33]. In this thesis, I have studied RGS4, RGS8, and RGS19 proteins.
RGS4 protein is expressed in the central nervous system such as cortex, amygdala, and thalamus
[34]. RGS8 accelerates the modulation of GPCRs in addition to negatively regulating G-proteins
which is crucial for neuronal excitability [35]. In vitro and in vivo experiments show that RGS19
influences cardiac development, down regulates Gαi signaling and affects heart function [36]. All
RGS proteins are structurally similar and have a relativity conserved 120 amino acid long RGS−box
domain (Figure 1.4) [37].
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Figure 1.4: Sequence (panel A) and structural (panel B) alignment of RGS4, RGS8,
and RGS19.
1.4 Brief Review of Selected Previous Computational Studies
In the following, I briefly review previous computational and simulation studies on protein fold-
ing, particularly on insulin, TMDs of IR and IGF1R, and RGS proteins. The early computational
studies on isolated insulin monomers, its dimer and aggregates, were conducted by Wodak et al.
[38] in which all-atom resolution structures were studied by energy minimization calculations. Even
though they speculated that the hydrogen atoms are important in folding of insulin, their simu-
lations led to deformation of insulin due to the lack of solvent molecules (vacuum condition). A
few years later an MD simulation of insulin monomer in vacuum was carried out [39]. The unre-
alistic simulation of insulin changed to a realistic one when Mark et al. conducted the first MD
simulations of an insulin monomer and a dimer in the presence of explicit water molecules for 100
ps [40]. Researchers have conducted simulations of insulin at high temperatures [41], using steered
MD [42], and bias exchange metadynamics [43] to investigate the dynamics of insulin monomers
and dimers.
Early studies on TMDs in a lipid-bilayer environment started in 1995 when Edholm et al.
[44] simulated bacteriorhodopsin trimer in an explicit lipid bilayer using MD. Woolf et al. [45,
46] studied gramicidin channel in a phospholipid bilayer using MD in which they reported that
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tryptophans located adjacent to bulk-membrane interface play an important role in forming both
hydrogen bonding interactions with the lipid glycerol backbone and water. Shen at al. [47] carried
out a few ns all-atom MD simulation of a TMDs (poly−alanine; 32 residues) which was fully
embedded in a dimyristoyphosphatidylcholine (DMPC) bilayer. Their simulations showed that the
N− and C−terminus of the peptide interact both with water and lipids to form random coils,
whereas the residues in the middle which interact only with the lipids maintain a helical structure.
Petrache et al. [48] conducted MD simulations of glycophorin A in monomeric/dimeric states
starting from an NMR structure. They simulated the monomer and dimer in four different lipids
and found that the most important lipid property that modulates the structural and energetic
properties of the TMD is the bilayer thickness. Even though the simulations were of short time-
scale, they asserted that MD simulation is an excellent method for investigating the folding of
TMDs in lipids. Other researchers have used coarse−grained MD methods to explore the dynamics
of TMDs in lipids to accelerate sampling [49]. Johansson et al. [50] performed simulations of poly-
Leu in a lipid membrane to model a helix. They observed that hydrogen bonding networks, and
protein-lipid, protein-water, water-lipid interactions are complex to the extent that modeling the
system with non−atomic level simulation approaches (simplified or implicit solvent) is not possible.
Miyashita at al. [51] carried out replica−exchange MD (REMD) of two amyloid precursor proteins
(APP) in implicit water and a membrane model based upon the CHARMM19 force-field. They
could determine dimerization states of the TMDs protein. Psachoulia et al. [52] deployed both
coarse−grained and atomistic MD simulations to model dimerization of transmembrane α−helices
to test and evaluate the presence of a GxxxG sequence motif for mediation of helix−helix packing
which is well-characterized experimentally.
The first effort for simulation and study of the insulin receptor family was reported by Vashisth
et al. in 2010 [53, 54]. First, they studied conformational flexibility of the IR ectodomain
and used an open-pocket conformation to dock insulin in two different forms (T and R) [54].
They also used homology model of IGF1R to model all-atom structures of IGF1/IGF1R∆β and
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IGF2/Type-2 Insulin-like Growth Factor Receptor (IGF2R)∆β complexes. Besides, they imple-
mented explicit−solvent MD of apo−IGF1R∆β accompanied with a Monte Carlo docking proce-
dure which showed growth factors IGF1 and IGF2 have access to one of the two binding pockets.
Also, their model indicated the existence of electrostatic complementarity between IGF1 and IGF1R
receptor. Two years later, they characterized conformational dynamics of the insulin receptor ki-
nase (IRK) domain in an all-atom model studied with temperature-accelerated MD (TAMD) and
the free-energy refined using the string method [55]. Furthermore, Vashisth and Abrams [56] car-
ried out several simulations of IR and hormone insulin complex to investigate how insulin and IR
interact specifically, and to explore the effect of a motif called the C-terminal (CT) peptide on
interactions between IR and insulin.
For RGS proteins, Snow et al. [57] constructed a model of the interface between RGS11 and
Gβ5 using MD simulations. Vashisth et al. [58] studied the interaction of a lead inhibitor drug
candidate of RGS proteins with RGS4 using atomic resolution MD simulations. They applied
TAMD on apo-RGS4 to accelerate its conformation sampling that resulted in the exposure of a
buried cysteine site targeted by the inhibitor, and they found that two adjacent helices fluctuate
between a closed and an open conformation. They also conducted a simulation which included
RGS4−Gα complex and the inhibitor molecule. The simulation indicated that the presence of
inhibitor makes the interface of RGS4 and Gα unstable.
1.5 Specific Aims
The main goal in this thesis is to investigate folding and dynamics of proteins in aqueous and
lipid-bilayer environments using MD simulations. To achieve this goal, I have extensively studied
the dynamics of the native insulin B-chain and its mimetic peptide, TMDs of IR, and IGF1R, and
RGS proteins. In the following, specific aims for this thesis are outlined.
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1.5.1 Specific Aim 1: Determine the Structure of an Insulin-Mimetic Peptide
Hypothesis: Insulin mimetic peptide S371 competes with insulin and the C-terminal IR pep-
tide due to its helical structure.
In this study, I have investigated the folding properties and structure of a site-1 insulin mimetic
peptide S371 that has sequence similarities with the insulin B-chain as well as with a critical
hormone-binding element of the receptor known as the C-terminal (CT) peptide using enhanced-
sampling MD. I first validated our simulation approaches by predicting the known solution structure
of the insulin B-chain helix and then applied them to study the folding of the mimetic peptide S371.
1.5.2 Specific Aim 2: Determine the Structure of the Transmembrane Regions
of IR and IGF1R
Hypothesis: Transmembrane regions of IR and IGF1R likely fold into helical states in the
membrane.
I tested this hypothesis by applying an enhanced-sampling MD simulation technique, called
metadynamics, on all-atom structural models of peptides containing 51 residues from the trans-
membrane and juxtamembrane regions of IR and IGF1R to explore the mechanisms of folding. I
used a solution structure of the TMDs of IR (PDB code 2MFR) using NMR spectroscopy in do-
decylphosphocholine (DPC) micelles to validate our model for IR-TMD. Then, I applied the same
simulation protocol on TMD of IGF1R to model its structure in a lipid-bilayer.
1.5.3 Specific Aim 3: Understand the Role of Transmembrane Helices in the
Insulin Receptor Activation
Hypothesis: Conflicting experimental evidence has suggested that IR-TMDs are pre-dimerized
in apo-IR, an observation contrary to the only known structural data on IR ectodomain (PDB code
4ZXB) that indicates a dramatic separation of membrane-proximal legs by 100 A˚ as well as the
evidence of primarily monomeric states of isolated IR-TMD in DPC micelles.
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I propose that classical unbiased MD simulations of IR TMDs in three different states namely
isolated, ectodomain-anchored, and kinase-anchored states will likely resolve many outstanding
major questions in IR activation. These three constructs (Figure 1.5), briefly described in the
following, are closely related to each other and are focused on understanding the dimerization
propensity of IR TMDs in different functional states of IR.
Figure 1.5: Solvated and ionized simulation domains investigated in specific aims
are shown.
In the first part, I conducted a single long timescale classical MD simulation of two TMD helices
in the lipid membrane environment to observe the dimerization propensity of isolated IR TMDs.
The sequences of IR TMD and IGF1R TMD have many common structural motifs including a
conserved proline residue near the N-terminus that is known to induce a kink and potentially play
a role in TMD dimerization. It has also been speculated that the presence of one SXXXG sequence
motif in IR-TMD could play a role in dimerization similar to the GXXXG motif [59, 60]. On the
other hand, not observing dimerization would strongly support a recent NMR study indicating
largely monomeric states of IR TMDs in a micellar environment although possibility of dimer for-
mation was not completely excluded based upon the detergent/protein ratio. The second and third
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part included studies of ectodomain-anchored and kinase-domain-anchored dimerization/dissocia-
tion of IR TMDs: In these aims, I conducted one long timescale MD simulation of IR TMDs in
each of the two different constrained states. In the second part, the TMDs are placed C-terminal
to the high resolution ectodomain structure of IR that indicates a 100 A˚ distance between them.
Observing dimerization of IR TMDs or a significant decrease in distance between TMDs in this
construct could provide tremendous insights into conformational changes occurring in the receptor
ectodomain, particularly at the inter-domain interfaces, proximal to which the ligand binding sites
are located. These conformational changes are also key to a proposed “see-saw” mechanism as well
as a harmonic oscillator model of receptor activation which suggest an asymmetry in receptor struc-
ture that leads to negative cooperativity in ligand binding as well as signaling via TMDs. The third
part simulation is afforded by recent availability of a novel X-ray structure of the activated dimeric
arrangement of IR kinase domains that suggests exchanged juxta-membrane regions. However, it
could not be resolved whether IR TMDs would be dimerized or dissociated. My third simulation of
TMDs anchored to a kinase dimer was aimed at revealing not only the dimerization propensity of
IR TMDs under kinase-dimer constraints, but also the stability of dimerized kinase configuration
as well as underlying conformational changes.
1.5.4 Specific Aim 4: Determine Differences in Dynamics of RGS-Proteins and
Relate them to Inhibitor Potency and Specificity
Hypothesis: Transient allosteric binding pockets in RGS proteins expose cysteine residues
differentially between homologous RGS proteins.
To test this hypothesis, I used MD simulations to probe the dynamics of three RGS proteins
(RGS4, RGS8, and RGS19). I conducted more than 20 µs of long classical MD simulations of three
RGS proteins. I used two different force-fields (AMBER, CHARMM) to evaluate their performances
in the prediction of HDX trends. In addition, I used 7 models of HDX accompanied with the long
MD simulations to compare these models in terms of their predictive accuracy. Furthermore, I
proposed two new models for HDX based on the solvent accessible area of amide hydrogens and
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the distance of the amide hydrogen from the closest polar atoms, and optimized their parameters
based on experimental values of HDX data.
1.6 Thesis Organization
This thesis is organized as follows: Chapter 2 describes the mathematical models, governing
equations, and software tools for simulations of biomolecules. Chapter 3 describes results on fold-
ing calculations of the insulin B-chain and its mimetic peptide in aqueous conditions. Chapter 4
describes folding studies of the TMDs of IR and IGF1R in a lipid-bilayer environment. In chapter
5 results of microsecond scale MD simulations of the following systems by Anton (a supercomputer
that has been designed for large scale MD simulations) are described: (i) the membrane-embedded
apo ectodomain of IR, (ii) membrane-embedded active kinase-domains of IR, (iii) Two IR-TMDs.
Followed by that is chapter 6 that describes results from MD simulations of RGS4, RGS8, and
RGS19 proteins. In chapter 7, a comparison of MD predictions with HDX experiments are high-
lighted. In chapter 8, I share my ideas for anyone who pursues implementing future research
directions. At the end of the thesis are pertinent references, appendices including codes, tutorials,





The purpose of this chapter is to introduce simulation techniques, numerical models, differ-
ent software, and computational resources that were used in simulation studies. In particular, we
present numerical techniques that include classical MD, enhanced sampling, and steered MD meth-
ods. The software used are: VMD (Visual Molecular Dynamics) which is used for file preparation,
visualization and analysis, NAMD (NAnoscale Molecular Dynamics), and Anton 2 for simulations,
and AMBERTOOLs (AMBER stands for Assisted Model Building with Energy Refinement [61]),
CHARMMGUI (CHARMM is an acronym for Chemistry at HARvard Molecular Mechanics),
and MODELLER (for modeling). Analyses were carried out using Python, MATLAB (stands for
MATrix LABoratory), TCL, and Linux bash scripting. The calculations in this thesis were carried
out on local supercomputing resources at UNH (Premise and Trillian), and external supercomput-
ing resources: Anton 2 and Kollman (at Pittsburgh Supercomputing Center), and Comet (San
Diego Supercomputer Center). For additional details on these softwares and MD simulation, the
reader is referred to the following articles [62–71].
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2.2 Introduction
With the emergence of new technologies, particularly in the field of computer science, a chil-
dren’s computer game is able to perform computations faster than the most advanced computers
from previous decades. The developments in computational technologies from one side, and lim-
itations of experimental methods (such as X-Ray and NMR) in revealing the mechanisms and
dynamics of biomolecules from another side, have made computer simulation a unique technique
for exploring protein folding, dynamics, and biomolecular interactions. Currently, computer sim-
ulation is a ubiquitous tool to study many varieties of systems in materials science, chemistry,
pharmaceutical science, and molecular biology in both academic and industrial research [72, 73].
Experiments typically detect macroscopic properties such as temperature, pressure, and static
structures of biomolecules by means of X-ray crystallography [74], NMR spectroscopy [75], and
Raman spectroscopy [76]. However, microscopic properties of biomolecules such as atomic motions
are not easily detectable with experimental tools but computer simulations can provide microscopic
details which can be mapped to macroscopic properties by averaging over time or the number of
particles [66]. The mathematical tool for connecting macroscopic observations to microscopic pre-
dictions is Statistical Mechanics [77]. Statistical Mechanics uses two major scientific concepts to
create a connection between the macroscopic and the microscopic properties: (a) classical physics
which mainly includes thermodynamics laws and Newton’s laws of motion, and (b) mathematics
involving probability theories.
In this thesis, I have used MD simulations to study complex biomolecules such as proteins in
aqueous and lipid environments. Although quantum mechanical theories that consider electronic
degrees of freedom can be applied to biomolecular systems in principle, the calculations are pro-
hibitively expensive. Therefore, quantum calculations are ignored in favor of classical theories, even
though some parameters that are used in classical models are obtained via quantum calculations on
simple molecules [66]. MD simulation is a complementary method for exploring dynamic motions
inherent to biomolecules, which are challenging to probe using experimental means (Figure 2.1).
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Figure 2.1: Resolution of different methods for probing protein dynamics [78, 79]
2.3 Foundations of Molecular Dynamics Simulations
MD simulation is a numerical technique for solving equations of motions of a system of large
number of particles. An instance of a simple equation of motion is Newton’s second law:
~fi = mi~ai, fi = −∂U
∂rj
(2.1)
where ~fi is the force on a particle with a mass of mi, ~a is the particle’s acceleration, U is
the potential energy, and r is representative of atomic coordinates (for example, in Cartesian
coordinates (r1, r2, r3) are (x, y, z)). This basic equation originates from classical physics. The
potential energy (U) is described in the following.
2.3.1 Potential Energy (U)
In MD simulations, potential energy plays a significant role in determination of a system’s behav-
ior. This importance is to the extent that different potential energy functions have been generated
based on different quantum calculation approaches and assumptions such as the CHARMM and
AMBER potential functions [80–83]. Potential energy consists of several terms including bonded
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interactions (the first five terms in equation 2.2) and nonbonded interactions (the last two terms
in equation 2.2). The form of the potential energy function that common MD software (such as
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The first term in the energy function accounts for the bond stretches where kb is the bond force-
constant and b− b0 is the net displacement from equilibrium that a pair of atoms have experienced.
The second term in the equation accounts for bond angles where kθ is the angle force-constant and
θ − θ0 is the angular deviation from equilibrium for three bonded atoms. The third term is for
dihedrals (also known as torsion angles) where kφ is the dihedral force-constant, n is the multiplicity
of the function, φ is the dihedral angle and δ is the phase shift. The fourth term accounts for the
impropers, that is out of plane bending, where kω is the force constant and ω − ω0 is the out
of plane angle deviation. The Urey-Bradley component (cross-term accounting for angle bending
using 1,3 nonbonded interactions) comprises the fifth term, where ku is the respective force constant
and u is the distance between the 1,3 atoms in the harmonic potential. Nonbonded interactions
between pairs of atoms (i, j) are represented by the last two terms. By definition, the nonbonded
forces are only applied to atom pairs separated by at least three bonds. The Van Der Waals
(VDW) energy is calculated with a standard 12-6 Lennard-Jones potential and the electrostatic
energy with a Coulombic potential. ij , Rminij , rij are the Lennard-Jones well depth, the distance
at which inter-particle potential is zero, and the inter-particle separation, respectively. 0 is the
dielectric constant and qi is the partial charge on each atom. The potential energy does not include
a term for hydrogen bonds because it is automatically taken into account by VDW and Coulombic
forces. In order to run an MD simulation, we need to be sure that the parameters of all terms
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in the energy function (Equation 2.2) are specified. These parameters are validated by comparing
rigorous quantum-mechanical calculations with the experimental data [85].
Sections 2.6.1, 2.6.2 and 2.6.3 describe how to use a parameter file for NAMD, AMBER and
Anton simulations, respectively. In this thesis, I have used the AMBER force-field only for MD
simulations of RGS proteins (Chapter 6), however, the CHARMM force-field was used extensively
for all other MD simulations. CHARMM is a widely used force-field with primary applications
on proteins, peptides, lipids, small molecule ligands, and nucleic acids in aqueous solution [86].
AMBER is the name of a simulation software and a force-field (force-field). The force-field in this
package is called AMBER force-field which is different than CHARMM force-field in terms of po-
tential function correlations and also corresponding parameters [83]. AMBER and CHARMM are
two different approaches to parametrize a classical force-field. For example, even though they have
common potential energy terms, AMBER lacks three bonded terms that exist in the CHARMM
potential function including two-body Urey-Bradley terms, four-body quadratic improper terms,
and a cross term, named CMAP. Besides, they have different approaches for fitting potential func-
tion coefficients to empirical data that causes different parameter values such as partial atomic
charges, and the peptide carbonyl group is less polar in CHARMM22 rather than AMBER (ff94)
[87]. These inconsistencies and differences prevent any user to combine these two force-field in one
simulation system and therefore for MD simulations a single force-field should be determined be-
forehand. However, fortunately, it is possible to run CHARMM and AMBER force-field simulation
in NAMD, the primary MD simulation software used here. The comparison of MD simulation of
short peptides and resulting conformational populations with corresponding experiments (gained
mainly from circular dichroism or from NMR) show that AMBER force-field (ff94) over-stabilizes
helical peptide conformers and over-estimated melting temperatures [87], which is consistent with
what I have found in comparison of AMBER and CHARMM force-field for simulations of apo-RGS
proteins (see Sec. 6). Others have carried out force-field comparisons too [81, 82, 87–91].
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2.3.2 Ensembles and Langevin Equation
In statistical mechanics and thermodynamics, an ensemble is defined as a macroscopic state of
a system that corresponds to a particular probability distribution of particles in the system [92].
To numerically integrate differential equations that represent forces on particles of a system, a
correct ensemble must be chosen to control temperature or pressure in the system. For example in
the NPT ensemble, the Number of particles, Pressure and Temperature are kept constant and in
the NVT ensemble, the Volume of the system is kept constant instead of pressure which requires
less computational effort. For the fulfillment of this goal, the Newton’s equation of motion (Eq.
2.1) is modified to an equation, called Langevin equation, that is partially stochastic (Eq. 2.3).
For example, NAMD, a simulation software, uses this stochastic approach because it is easier to
implement and the friction terms tend to enhance the dynamical stability [85, 93]. The general
form of Langevin equation is:





where M is the mass of a particle, ~ai is the acceleration, ~fi is the force, r is the position vector,
γ is the friction coefficient, kB is the Boltzmann constant, T is the temperature, and R(t) is a
univariate Gaussian random process. Stochasticity of the model is implemented by adding the
fluctuating (the last term) and dissipative (γv term) forces to the Newton’s equations of motion
(Eq. 2.1).
2.3.3 Numerical Integration
In numerical calculations, integration of differential equations is the inseparable part of algo-
rithms for calculating the value of variables of the modeled system. Differential equations are
valid for infinitesimal time-steps, particularly in bimolecular simulations, the time-step becomes
extremely small on the order of a femtosecond (10−15 s). The evolution of biological systems is
stochastic which adds an adverse effect to the convergence of numerical integration algorithm. The
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very short time-step from one side and the stochastic feature, from another side, make the nu-
merical integration in biological systems a difficult task. Furthermore, apart from the convergence
of numerical integration, accuracy of the integration is one of the important key features of an
accurate numerical calculation. For example, in the NPT ensemble macroscopic properties such
as temperature and pressure should be kept constant while the integration process updates the
position of each particle in the system. In this case, a good algorithm keeps the pressure and tem-
perature around the specified values with an acceptable accuracy and besides performs a converged
integration even with the existence of fluctuations in the system [85]. This tedious task has been
resolved by advanced numerical algorithms. The integration of the Langevin equation (Eq. 2.3)
is performed by Bru¨nger-Brooks-Karplus (BBK) method [94] which is a natural extension of the
Verlet method [66] in NAMD. The position of each particle is updated by the recurrence relation
of the BBK method which is:
xn+1 = xn +
1− γ∆t/2








Zn is a set of Gaussian random variables with a mean of zero and a variance of one. Each
degree of freedom requires one random number in the BBK method. The steady state distribution
generated by the BBK method has an error proportional to ∆t2 [95], although the error in the time
correlation function is proportional to ∆t [96].
2.3.4 Choice of Integration Time-step (∆t)
One of the parameters that is important in numerical integration of differential equations in
which time is the independent variable, is the time-step (∆t). It is important because it determines
the extent of accuracy and convergence in MD simulations. Large values of ∆t lead to numerical
instabilities of integration and small values of ∆t results in high computational expenses for the
exploration of the phase-space. These limitations require benchmarking ∆t in such a way that
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convergence of integration and yet numerical stability of simulation are satisfied [97]. The recom-
mended ∆t to comply with these criteria is 1-fs when bonds to hydrogen atoms are flexible and
2-fs when bonds to hydrogen atoms are fixed at their equilibrium values.
Larger time-steps may be used for NVT or NPT ensemble simulations such as 6 fs with rigid
bonds. Utilization of a multiple-time-stepping strategy may increase computational efficiency by a
factor of 2 [85, 97]. Multiple-time-stepping algorithms compute slow-varying-forces such as long-
range electrostatics forces less frequently than fast-varying-forces such as Lennard-Jones and short-
range electrostatics [97]. This algorithm cannot conserve energy within a simulation system, there-
fore it is not applicable for simulations in the NVE ensemble which is not used in this thesis. Anton,
a special-purpose supercomputer, uses more accurate and efficient integration algorithm for MD
simulations and the time-step is set to 2.5 fs [98].
2.3.5 Initial Conditions
A system of differential equations in which the independent variable is time should have sets
of initial values for all dependent variables. MD simulation, in particular, solves the trajectories
of many thousands of atoms versus time, and the initial coordinate of each atom is required.
The initial coordinates of all particles in MD simulations cannot be a random value due to well-
organized biomolecular structures. The main source of obtaining initial conformation of different
proteins is Research Collaboratory for Structural Bioinformatics (RCSB)1 which is powered by the
Protein Data Bank (PDB) archive-information about the crystallographic database for the three-
dimensional structural shapes of proteins, nucleic acids, and complex assemblies, typically obtained
by X-ray crystallography, and NMR spectroscopy. Other initial values that should be assigned
along with the initial configuration of the system is the velocities of all atoms. Initial velocities are
randomly assigned to each atom in MD simulations from a Maxwell-Boltzmann distribution (Eq.
2.5) which relates the temperature of interest to velocity distribution [99].
1http://www.rcsb.org/pdb/home/home.do









where m is the particle mass and kBT is the product of Boltzmann’s constant and thermody-
namic temperature.
2.3.6 Boundary Conditions
In modeling physical systems using MD simulations, boundary conditions (BC) should be de-
fined for the system. Here we define three scenarios for BC: (i) vacuum, (ii) a reflecting wall,
and (iii) periodic boundary conditions (PBC). Vacuum is the simplest scenario for BC, however,
in vacuum global properties computed will not be representative of the condensed phase [73]. In
reflecting wall BC solid boundaries with a potential that keeps the atomic particles inside the
simulation box are applied [100].
Figure 2.2: A representation of a periodic simulation domain in two dimensions.
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In PBC scenario, which is used in this thesis, particles are enclosed in a simulation box that
is replicated to infinity by periodic translations [73]. In two dimensions, each unit-cell simulation
box has eight neighboring boxes (Figure 2.2), however, the number of these neighbors increases to
26 in three-dimensions. When an atom or a particle interacts under PBC, the particle leaves the
simulation box from the corresponding interface between replicated boxes and the same particle
enters into the simulation box from the opposite site of the interface. In this scenario, the number of
particles in a simulation box is conserved. The important point in using PBC is that the simulation
box should be large enough to prevent interaction of the biomolecules in a simulation box with its
image in the neighboring boxes.
2.3.7 Minimization
Initial structures obtained from PDB may require preparation for MD simulations such as
guessing the positions of missing hydrogen atoms, including mutations, homology modeling (see
Sec. 2.4.2) of some missing residues, solvation, and ionization (See sec 2.6.4) of the biomolecules
of interest. Therefore, the structure of a protein must be energy-minimized and prepared for an
MD simulation using methods such as steepest descents or conjugate gradient schemes [43]. In this
thesis, I used the conjugate gradient method to minimize all systems prior to MD simulation.
2.3.8 Temperature and Pressure Control
The temperature control for MD simulations is implemented explicitly by a Langevin thermostat
where additional damping and random forces are introduced to the system (Eq 2.3). This method
frequently adjusts momenta of all atoms in the system by which the entire system temperature
is kept at a desired value. Other computational techniques have been introduced for temperature
control such as Lowe-Andersen dynamics [101] and Berendsen thermostat [102]. To control pressure,
the Nose-Hoover barostat algorithm has been used [103–105]. To keep pressure constant in an
MD simulation, PBCs are required. The size of the simulation box is dynamically adjusted for
maintaining constant pressure. The instantaneous pressure for a biomolecular system represents
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internal forces that are based on interacting atoms which fluctuate frequently, however, the average
pressure of all particles in the system shows the overall pressure of the system with less fluctuations.
2.4 Software Packages for Biomolecular Simulations
2.4.1 Molecular Dynamics Simulation
In this thesis, NAMD (versions 2.10-2.12) has been used as a major tool to carry out MD
simulations. NAMD is a parallel MD simulation package designed for high-performance simulations
of biomolecular systems [85]. NAMD is able to use hundreds of CPU processors on computational
nodes as well as on GPU architectures which provides significant acceleration in computations.
NAMD has been used to simulate very large systems such as HIV-1 capsid that has ∼64 million
atoms [106].
The NAMD source code implements various techniques for efficient numerical integration of
Newton’s equations of motion, uses accurate statistical mechanics methods to control temperature
and pressure, and evaluates electrostatic interactions through Particle Mesh Ewald (PME) summa-
tions. This software implements Steered Molecular Dynamics (SMD) simulations (see Sec. 2.5.3)
and biased collective variable-based simulations and enhanced sampling methods such as metady-
namics (see Sec. 2.5). It is freely available to academic users2, and is an open source code package
where users have the flexibility to modify it for some new implementations of their interest. The
users can readily extend NAMD through scripting languages such as Tcl/Tk and Perl.
I also used Anton, a special-purpose supercomputer for MD simulations designed by D. E.
Shaw Research (DESRES) to simulate a large protein structure (∼700,000 atoms). Anton is able
to carry out MD simulations of biomolecular systems nearly two orders of magnitude faster than
the previous state-of-the-art. Anton is designed primarily to accelerate classical MD simulations
of solvated biomolecular systems with PBC and it supports lipids, the CHARMM force-field, and
novel parameterization of residues. Anton uses specialized hardware to perform MD simulations
2 http://www.ks.uiuc.edu/
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that are orders of magnitude faster than GPU and CPU based clusters running traditional MD
software [107]. Anton has its own MD software, therefore it does not run other MD tools (such as
Desmond, AMBER, NAMD, GROMACS) although it uses a Desmond structure (DMS) file as an
initial input and its trajectory output is compatible with Desmond’s DTR files.
2.4.2 Modeling and Analysis
I used the software tool VMD (version 1.9) [63] to prepare input files for NAMD and Anton,
visualize and analyze the trajectories generated by NAMD and Anton, and calculate various prop-
erties from simulation trajectories or crystallographic structures. The software can be run on CPU
or GPU clusters and is also able to do parallel computations.
I used MATLAB (versions 2015-2017) to carry out numerical calculations, analyze outputs of
MD simulations and make figures. An outstanding feature of MATLAB is that it has a lot of
optional toolboxes such as optimization, curve-fitting and it includes built-in functions. MATLAB
is equipped with well-documented help which has a powerful search engine that makes it a highly
user-friendly software. All MATLAB codes in this thesis are provided in Appendix B.
I used Python (versions 2.1 to 3.6) for computations and presenting results in figures. I deployed
Anaconda package which is a free open source distribution of the Python and R programming lan-
guages for large-scale data processing, predictive analytics, and scientific computing [108]. A key
feature of Python is that it has large and comprehensive standard libraries (such as optimization,
statistical analysis, and plotting functions), multi-threading ability to scale computations to thou-
sands of cores, and platform compatibility (Windows and Linux). The Python codes are presented
in Appendix C. Even though Python has powerful and fast computational libraries, it lacks an
original graphical user interface (GUI). However, different companies have developed Integrated
Development Environments (IDE) for Python users such as PyCharm, Spider, and PyDev. I chose
PyCharm because it supports Windows, MacOS, and Linux machines and importantly has powerful
debugging tools for code development.
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Ambertools (version 16) was used in this thesis to prepare files for the AMBER force-field and
create simulation systems. The suite consists of several independently developed packages. Note
that all systems that were created by Ambertools with the AMBER force-field were simulated
by NAMD as the computational software. The related Ambertools instructions are provided in
Appendix D.
I used Linux-based platform (openSUSE) for running all local software and manage jobs on
clusters, copy and paste data, and also for analyzing data. Terminal is a program that provides
a graphical interface between a program that manages and starts other programs (called shell) in
Linux. The bash shell is a popular terminal language in Linux for command line operations, calling
other software, running codes for analyzing data, and parallel calculations. The useful bash codes
and the related Linux software that were used in this thesis are provided in Appendix E. I used
MobaXterm software (version 9.4) as a GUI interface on my personal laptop to connect with other
Linux machines and computational resources.
I used MODELLER3 for homology modeling of missing residues. An alignment of a sequence
should be provided for the software to be modeled based upon known structures and MODELLER
automatically calculates a model containing all non-hydrogen atoms. MODELLER implements
comparative protein structure modeling by applying spatial restraints, and can perform many
additional tasks, including de novo modeling of loops in protein structures, optimization of various
models of protein structure with respect to a flexibly defined objective function, multiple alignment
of protein sequences and/or structures, clustering, searching of sequence databases, and comparison
of protein structures. I used MODELLER for modeling of a loop in the insulin receptor to be used
as an initial coordinate for MD simulations. The corresponding code is provided in Appendix C.3.
I used CHARMM-GUI, a web-based graphical user interface, to build coordinates of a lipid-
bilayer.4 I also used MATCH web server to generate both the topology and parameter file for small
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single dcd file. It can be used to write only selected atoms to a new final dcd file. It has been built
as a part of the VMD and also as a separate program that can be run in the Linux environment.
Catdcd can read or write any of the structure and trajectory formats that are supported by VMD
(See Appendix E.3).
2.5 Advanced Molecular Dynamics Methods
The main purpose of MD is to predict conformational trajectories of all atoms in complex
molecular systems. Due to large degrees of freedom in biomolecular systems, a large part of the
conformational space remains unexplored [109]. Therefore, several enhanced sampling methods
have been developed to overcome the limitations of classical MD simulations. Enhanced sampling
methods such as metadynamics, adaptive biasing force (ABF), umbrella sampling, temperature-
accelerated MD (TAMD), and steered MD (SMD) are biased MD simulation methods to resolve
free energy, calculate unbinding force, accelerate sampling, and overcome energy barriers for further
conformational exploration [85, 109]. Free energy, which determines the direction of a spontaneous
process, is a central concept in thermodynamics since the time of Helmholtz and Gibbs. The
free energy at a constant temperature (T) and volume (V) is known as the Helmholtz free energy
F(T,V), while at constant T and pressure (P) is known as the Gibbs free energy G(T,P). The
calculation of the free energy plays a significant role in characterizing thermodynamics and kinetics
of biomolecular systems. To calculate the free energy change in MD simulations, sampling of
configurational phase space of the system is required, which makes such calculations extremely
challenging [66]. In this thesis, I used metadynamics and SMD to carry out enhanced sampling
MD simulations which are described in the following sections.
2.5.1 Collective Variable
Before describing the details of advanced MD methods (metadynamics and SMD), it is impor-
tant to know the concept of a Collective Variable (CV). Usually MD simulations consist of large
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number of atoms which leads to a large number of degrees-of-freedom in such systems. To reduce
the number of degrees of freedom, it is common to define one or more parameters to either analyze
the system or bias the dynamics of the system in a controlled manner. These parameters are called
“order parameters”, “collective variables” (shortened to colvar or CV), or “reaction coordinates”
(or RC). CVs are typically defined using geometric features such as distances between two atoms
or two groups of atoms, an angle between three atoms or three groups of atoms. The root mean
squared deviation (Root Mean Squared Deviation (RMSD)) and the radius of gyration (Rg) are the
only CVs that were used in this thesis, even though I have used the other CVs for the evaluation of
the effectiveness in conformational sampling which are not reported in this thesis such as applying
an angle CV in the metadynamics method for RGS proteins to study the free-energy profile for
conformational changes in RGS proteins.
2.5.2 Metadynamics
Metadynamics method is an enhanced-sampling method that improves the conformational space
sampling by overcoming energy barriers separating different states of a system. The method mod-
ifies the potential energy landscape by adding energy wells that are below a certain threshold
level, while leaving those above this level unaffected. As a result, barriers separating adjacent
energy basins are reduced, allowing the system to sample conformational space that cannot be
easily accessed in a classical MD simulation. I briefly note that metadynamics algorithm has been
successfully applied to study a number of conformational sampling problems [110–118] including
peptide-folding studies in the insulin family [22, 119].
In metadynamics, enhanced conformational sampling is carried out in a specified set of CVs
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where ξi is the current value of the CV and ξi(t′) is the value of the CV at time t′. Vmeta is
constructed as a sum of Ncv-dimensional repulsive Gaussian functions, which are of a chosen height
(W ) and width (δ), and added at a desired frequency τG. Therefore, the efficiency and accuracy
of the free-energy reconstruction in metadynamics is controlled by three parameters W , δ, and τG
[122]. The parameters δ and τG should be varied to explore their effect on the reconstruction of
free-energy profiles. These three parameters affect the accuracy and efficiency of the free-energy
reconstruction; for example, larger Gaussians leads to faster exploration of free-energy surface, how-
ever, reconstructed profile may deviate from the free-energy surface. Conversely, if the Gaussians
and/or frequency be small the profile is more accurate although reconstructing the profile takes a
longer time.
To understand the underlying details of the metadynamics, I developed a MATLAB code (which
is provided in Appendix B.1) in which metadynamics method along with one-dimensional Langevin
equation is used to reconstruct a hypothetical free energy landscape Vg. In this example, Langevin
equation is in the form of md2ξ
dt2 = −γ dξdt + fr(t) −
dVg
dξ here γ is the friction coefficient, fr(t) is a
random force, ξ is the collective variable, and Vg is the free energy landscape [123]. The result of
the computational efforts for reconstruction of free-energy surface (Vg) is shown in Figure 2.3.
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Figure 2.3: Reconstruction of the free-energy landscape using metadynamics
method in a one-dimensional system evolved by the Langevin equation. (A) state
of the system after adding ∼400 Gaussians, (B) state of the system after adding
∼1400 Gaussians.
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The figure has two panels: panel a represents metadynamics progress after adding 400 Gaussians
to free-energy wells and panel b shows the progression after adding 1400 Gaussians. In this example,
the system evolves through an overdamped Langevin equation with a time-step, dt=0.1, friction
coefficient γ=5, a random force of strength between -4 to 4, and m=50. The free energy profile
Vg(ξ) is known to be a curve with two maxima and three minima (the red curve in figure 2.3).
The collective variable (ξ) is constrained to -5 to 5. The dynamics are started from the central
minimum. The red circle shows the current point of walker (solver) over the free energy landscape.
Without metadynamics method the walker (red point) stays in the central part and the probability
of escaping from the central minimum is very low because going over energy barriers at ξ=-2 and
ξ=2 requires high thermal energy. The top figures in panels a and b show the Gaussians (are
shaded by blue color) that are added by the metadynamics method. The metadynamics method
adds Gaussians with height W=0.1 and width δ=0.2 with a frequency of τG=10. After ∼ 300
Gaussians (or ∼ 3000 steps) the central well is filled with Gaussians and the system escapes from
the well over the lowest saddle point ξ=-2.5. The second well (the center is on ξ=-4.2) is filled after
metadynamics adding ∼ 600 Gaussians. After that the system become diffusive in the range of ξ=-5
to ξ=2. Adding Gaussians is continued until after ∼ 1050 Gaussians, the system could scape from a
saddle point at ξ=2.1. The third well is filled with Gaussians and the walker becomes diffusive in the
whole range of of ξ=-5 to ξ=5 which indicates that the reconstructed free-energy profile (−Vmeta)
is fully explored. As the Figure 2.3 indicates, proceeding walker through more iterations, results in
refining potential energy. This example is an illustrative example for showing how metadynamics
can be used for escaping from a free energy well. Furthermore, it demonstrates how metadynamics
reconstructs the free-energy profile in a predefined region of CV. In this example, diffusive motion
of the walker is a good indicator for termination of the metadynamics method. See Appendix A.3
for sample scripts and instructions for the metadynamics method in NAMD. The metadynamics
output files may include Potential of Mean Force (PMF) data which can be generated using user-
defined settings. I developed a MATLAB code to obtain the PMF profile using trajectories of CVs
(see Appendix B.2) and for plotting the resulting PMF (see Appendix B.3).
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2.5.3 Steered MD
Another method for resolving the PMF along the CVs is to use multiple independent SMD
simulations and then apply Jarzynski’s equality [124]. In an SMD simulation, an SMD atom is
attached to a dummy atom via a virtual spring. This dummy atom is moved at a constant velocity
and then the force between both is measured using:
~F = −∇U (2.7)
U = 12k[vt− (~r − ~r0) · ~n]
2 (2.8)
where, U → Potential energy, k → Spring constant, v → Pulling velocity, t → Time, ~r → Actual
position of the SMD atom, ~r0 → Initial position of the SMD atom, ~n → Direction of pulling. In
practical situations, multiple atoms are pulled in an SMD simulation, therefore, a dummy atom is
attached to the center of mass of a group of atoms.
From the second law of thermodynamics, we know that the increase in the Gibbs free energy
from a state A to a state B (∆G = GB −GA) is linked to the mean work 〈W 〉 by:
∆G ≤W (2.9)
The equality holds only when the process is carried out in a quasi-static way or infinitely slowly
and hence reversibly from state A to state B. As much as the process evolves irreversibly, such
as converting the kinetic energy to heat, average work further exceeds the free energy difference.
Recovering equilibrium free-energy from non-equilibrium processes has remained an unsolved task
[125]. However, Jarzynski expressed an equality that relates free energy difference (∆F ) to the
work regardless of the speed of the process:
e−∆F/kT = 〈e−W/kT 〉 (2.10)
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Therefore, this equality has the ability to calculate free-energies from non-equilibrium processes
which differ from quasi-static processes in which ∆F = W . In addition, this equality has been
validated using computer simulations and experiments [124, 125]. Kirkwood developed the concept
of free energy or PMF as a function of a reaction coordinate [126]. I used non-equilibrium SMD
combined with the Jarzynski’s equality to compute PMFs.
In appendix A.2, a sample NAMD script for conducting SMD simulation is given. The log file of
SMD simulations were subjected to a TCL code (Appendix F.1) and a MATLAB code (Appendix
B.4) for plotting the required work and the PMF versus distance of a ligand dissociation from
protein (these codes were used for the dissociation of the peptide from the L1 domain of IR; see
Figure 3.5).
2.6 File Formats and Procedures for Submitting and Analyzing
Simulation
In this thesis, I have used NAMD (App. A) and Anton (App. G) for carrying out MD simula-
tions. To run such simulations, it is required to (i) prepare a solvated and ionized initial system,
(ii) simulate the system using the MD software, and (iii) analyze output files. These steps are
described below.
2.6.1 CHARMM Force-field: NAMD
In order to run any MD simulation, NAMD requires at least four input files:
1. A protein Data Bank (PDB) file which stores atomic coordinates for the system. PDB files
can be read and edited using a text editor. Initial coordinates for proteins are also available
via the Internet for many proteins.6 Note that the protein PDB should be refined and solvated
in a saline water box to be used in MD simulations (see Sec. 2.6.4)
6http://www.pdb.org
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2. A Protein Structure File (PSF) which contains structural information of the protein, such as
various types of bonding interactions. Note that the PDB file contains only coordinates, and
connectivity information is saved in the PSF file.
3. A force field parameter file which contains all empirical coefficients for bonded and non-bonded
interactions for potential energy calculation, given a PSF structure file and atomic coordi-
nates. Some examples of these file names are par all36 prot.prm for proteins, par all36 lipid
.prm for lipids, and par all36 na.prm for nucleic acids, toppar water ions namd.str for water
and ions.
4. A configuration file (config), in which the user specifies all the options that NAMD should
adopt in running a simulation. The configuration file tells NAMD how the simulation is to
be run (see Appendix A.1).
From all files mentioned above, an initial PDB file is typically obtained through the Protein Data
Bank, and the parameter and topology files may be obtained via web.7 A sample configuration
file is given in Appendix A.1 in which typical settings exist. The PSF file must be generated by
the user from the initial PDB and topology files using PSFGEN (see Sec. 2.6.4). NAMD produces
a dcd format trajectory file which is a single precision binary FORTRAN file, so it is transferable
between computers and should be read along with the PSF file using VMD to carry out analyses.
2.6.2 AMBER Force-field: NAMD
I used NAMD as the primary software for AMBER force-field simulations. Similar to the
CHARMM force-field, carrying out MD simulations using AMBER force-field by NAMD requires
four files. However, it has its own specific procedure that I describe below in three steps:
1. The PDB file of the solvated and ionized protein (generated by PSFGEN) is used as initial
coordinates. The PDB file is modified to be compatible with the Ambertools package (the
code is provided in Appendix E.4).
7http : //mackerell.umaryland.edu/charmm ff.shtml
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2. Use pdb4amber (a program in Ambertools) to prepare PDB files for use in LEaP (The cor-
responding code is provided in Appendix D.1).
3. Use LEaP program (which is included in Ambertools package) to add AMBER force-field,
missed hydrogens, and ions to the system (The corresponding code is given in Appendix D.2).
The LEaP program generates two files: (i) a set of parameter and topology files, and (ii) a
coordinate file. These two files altogether are sufficient for running an MD simulation using NAMD
(the script for running AMBER force-field simulation by NAMD program is given in Appendix
A.4).
2.6.3 Anton
Anton is a special purpose supercomputer designed by D. E. Shaw Research (DESRES). Below
are the steps to carry out an MD simulation using Anton.
1. Prepare simulation folders using guidelines in Appendix G.1. In order to add forcefields to a
system and run simulations on Anton 2, one should be familiar with the DESRES Software
Garden (see Appendix G.2).
2. Convert equilibrated trajectory to the DMS format. All MD simulations were initially equi-
librated using NAMD software for 5 to 10 ns. The NAMD input and output files (including
PSF file, as well as binary coordinate (.coor), binary velocity (.vel), and extended system file
(.xsc)) were used to generate the DMS file (see Appendix G.3).
3. Add force field parameters to the DMS file using viparr program (see Appendix G.4).
4. Carefully check that the DMS file has all the force field parameters (see Appendix G.5).
5. Prepare the Ark file. Ark files are used as input to the Anton simulation and describe the
desired simulation conditions. Ark files are plain text files and can be conveniently edited
with any text editor (see Appendix G.6).
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6. Run the simulation (see Appendix G.7)
7. Convert the trajectory to NAMD dcd format (see Appendix G.8)
2.6.4 Preparation of Initial Files for an MD Simulation
Biomolecular systems need to be solvated in a water box and then neutralized by adding ions
to resemble the cellular environment. The water molecules that are resolved by experimental
techniques can also be retained in protein structures and additional bulk water molecules are
added to create a solvation shell. The number of water molecules that are added in the vicinity
of proteins determines the size of the simulation box and thereby the computational cost. Lack of
enough water molecules in the simulation box creates unwanted artifacts of self interactions with
periodic images, therefore, the simulation box should be carefully assessed. The solvate plugin
in the VMD software provides both a graphical user interface and text commands for automatic
solvation of proteins for MD simulations.
Some proteins may be (and sometimes are) sensitive to the presence of ions in their surrounding
solvent environment. Therefore, ions are added to the simulation box to make the net electric charge
of the system zero because in MD simulations with PBC, the energy of electrostatic interactions is
computed using PME [127] method in which the total charge of the system should be zero. The
Autoionize plugin in VMD provides a quick and easy tool to make the net charge of the system
zero by adding ions to the solvent. VMD is a software for molecular visualization, animating, and
analyzing biomolecular systems. Besides it is used for the preparation of PDB files, solvating and
ionizing proteins in a simulation box. In a simple case, there are four steps by which a raw protein
PDB file (that is obtained via the protein data bank) is converted to a suitable initial coordinate
file for MD simulations:
1. Remove extra molecules from or insert atoms of interest to the raw PDB file or apply changes
according to PDB file’s remarks (see Appendix F.3.1).
2. Generate a PSF file using PSFGEN program via VMD (see Appendix F.3.2).
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3. Solvate the desired molecule in a water simulation box and then delete overlapping water
molecules (see Appendix F.3.3)
4. Ionize the solvated simulation box (see Appendix F.3.4)
5. Determine the size of simulation box to include in NAMD configuration file (see Appendix
F.3.5)
If the system was a complexed structure, such as one containing more than one protein chains,
including lipids in the system, or demanding alignment modifications, the number of steps to set
up simulation increases.
2.6.5 Analyzing MD Simulations
The dcd file which stores coordinates of all atoms is read by VMD to carry out visualization
and analyses. Approximately, all of the primary analysis of MD simulations were carried out using
VMD such as the calculation of RMSD, Root Mean Squared Fluctuation (RMSF), SASA (see
Appendix F.4) and modeling HDX (see Appendix F.2), then the other software (such as Python
and MATLAB) were deployed for further studies of data that were generated by VMD.
2.7 Computational Resources
The computational resources are important part of research studies in this thesis because they
were complementary to software and computational theories, and without them, I could not have
performed most of the work. The main six resources that were used in different sections of this
thesis are shown in Table 2.1. Maxwell is a local linux workstation assigned to me in our labratory
at the University of New Hampshire equipped with 20 processors (model name : Intel(R) Xeon(R)
CPU E5-2630 v4 @ 2.20GHz), 2 GB RAM, and a 2 TB internal hard-drive. All raw data were
generated by other computational resources and finally transferred to Maxwell for further analysis
using MATLAB, VMD, TCL, Python, or bash scripts. Clusters of computers, or “nodes”, such as
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Trillian, Premise, Comet and Kollman, work on a task in unison to provide more power and speed
than can be achieved by a single computer. Trillian cluster was acquired through an NSF Major
Research Instrumentation (MRI) grant, with cost sharing from the UNH Space Science Center,
Senior Vice Provost for Research, the College of Engineering and Physical Sciences (CEPS), and the
Research and Instrumentation Center (RCI). This supercomputer has 132 compute nodes, each with
2 AMD 16 core ‘Abu Dhabi’ 2.4 GHz CPUs, for a total of 4,224 cores. The script that is provided in
Appendix E.2 was used for NAMD job submission. Premise is a high-performance computing (HPC)
cluster which uses the parallel processing for running advanced application programs efficiently,
reliably and quickly.
Table 2.1: Computational resources used in this thesis
No. Chapter Resource name Used for
1 3 Trillian TMD, mimetic insulin simulation
2 4 Comet IR, RGS simulations
3 4, 5 Anton IR, RGS simulations
4 4, 5 Kollman IR, preparing files for Anton
5 5 Premise RGS simulations
6 all chapters Maxwell Analyzing results locally
The Premise cluster is made up of 14 compute nodes connected together using 56 Gb FDR
Infiniband networking, each node has two 12-core CPUs, all nodes have at least 128GB of main
memory. Four nodes have NVIDIA K80 GPUs which I used mainly in MD simulations because of
the higher performance compared to compute nodes. The entire cluster shares 225TB of usable
Lustre storage. The scripts for submitting NAMD jobs on GPU and compute nodes on Premise
are provided in Appendix E.2. The Extreme Science and Engineering Discovery Environment
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(XSEDE) is a powerful collection of integrated digital resources and services such as supercomput-
ers, visualization and storage systems, collections of data, software, networks, and expert support
that scientists, engineers around the world use to advance solving complex problems.8 Comet is a
dedicated XSEDE cluster designed by Dell using Intel’s Xeon Processor E5-2600 v3 family, with
two processors per node and 12 cores per processor running at 2.5GHz. Each compute node has 128
GB (gigabytes) of traditional DRAM and 320 GB of local flash memory. Since Comet is designed
to optimize capacity for modest-scale jobs, each rack of 72 nodes (1,728 cores) has a full bisection
InfiniBand FDR interconnect from Mellanox, with a 4:1 over-subscription across the racks. There
are 27 racks of these compute nodes, totaling 1,944 nodes or 46,656 cores. In addition, Comet has
four large-memory nodes, each with four 16-core sockets and 1.5 TB of memory, as well as 36 GPU
nodes, each with four NVIDIA GPUs (graphic processing units). The GPUs and large-memory
nodes are for specific applications such as visualizations, MD simulations, or de novo genome as-
sembly. For details of submission of NAMD jobs on Comet, see Appendix E.2. Kollman cluster is
an NIH-funded computational resource at Pittsburgh Supercomputing Center (PSC) that provides
analysis capabilities to complement local simulation capabilities. Kollman currently consists of four
Intel Westmere-EP based nodes, each with twelve compute cores, ninety-six gigabytes of memory,
and a QDR 4x Infiniband path to AntonFS and other nodes. Some Kollman systems also contain
448-core NVIDIA “Fermi” Tesla cards for acceleration and development of key analysis packages.
I used Kollman cluster only for conversion of NAMD files to DMS format (Appendix G.3). Anton
2, that replaced the original Anton 1 system in the Fall of 2016, is the next-generation Anton su-
percomputer has a 128 node system, made available without cost by DESRES for non-commercial
research use by US universities and other not-for-profit institutions, and is hosted by PSC with
support from the NIH’s National Institute of General Medical Sciences. The corresponding scripts




PEPTIDE FOLDING IN AQUEOUS
ENVIRONMENT
3.1 Abstract
In this chapter, the dynamics of structures of insulin and an insulin-memetic peptide in aqueous
environment have been investigated by MD simulations. Insulin plays a crucial physiological role
in glucose control by initiating a number of signaling events on binding and activating its cell
surface receptor. Insulin mimics have therefore become promising agents for treating diabetes and
to probe the mechanism of interaction of insulin with its receptor. Specifically, many insulin-
mimetic peptide sequences have been discovered and found to selectively function as agonists and
antagonists,1 but their structures and the mechanistic details of their interactions with the receptor
remain challenging to characterize. In this work, I have studied the folding properties and structure
of a Site 1 insulin mimetic peptide S371 that has sequence similarities with the insulin B-chain as
well as with a critical hormone-binding element of the receptor known as the C-terminal (CT)
peptide. I first validated my simulation approaches by predicting the known solution structure of
the insulin B-chain helix and then applied them to study the folding of the mimetic peptide S371.
My data predict a helical fold for the first 16 residues of S371 that has a resemblance to the helical
1An agonist is a chemical molecule (like insulin hormone) that binds to a receptor and triggers biological response
on binding. However, antagonist obstructs the action of the agonist.
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motifs in the insulin B-chain and CT. I also propose receptor-bound models of S371 that provide
mechanistic explanations for competing binding properties of S371 and CT to the Site 1 of IR.
3.2 Background
Insulin is a small peptide hormone that plays a central role in glucose homeostasis2 in higher
organisms, and binds to the IR, a large transmembrane glycoprotein comprising extracellular,
intracellular, and membrane-spanning domains [129–133]. Specifically, insulin and IR each has two
complementary binding epitopes termed as “Site 1” and “Site 2” [134–147], where both chains in the
hormone contribute residues to each binding site but in IR, residues in the first leucine-rich domain
(L1) along with residues in a tandem hormone-binding element known as the α-chain C-terminal
(αCT) peptide contribute to Site 1, and residues in the loops of two fibronectin domains (F1 and
F2) contribute to Site 2. While the exact mechanism of signal transduction in IR remains elusive,
several crystal structures of extracellular fragments of IR in apo or liganded forms have provided
detailed insights into the location of binding sites and conformational rearrangements occurring in
insulin as well as in IR [148–155].
Insulin mimics have become promising agents for the treatment of diabetes as well as for un-
derstanding the mechanism of insulin action. Some non-peptidyl mimics, such as sodium selenate,
vandate, and a small molecule termed L-783,281 capable of activating IR with varying selectivity,
have been discovered [156–158]. However, the detailed knowledge of insulin/IR binding hotspots
has inspired the design of novel insulin analogues and mimetic peptides targeting not only putative
binding sites, [159–165] but also allosteric sites in transmembrane domains [166]. Among insulin-
mimetic peptides discovered by phage display [159],3 an affinity-optimized Site 1 peptide S371 and
a Site 2 peptide S446 were chosen as building blocks and combined in four possible end-to-end
2 Insulin and glucagon are potent regulators of glucose metabolism. In glucose homeostasis, glucose concentration
is actively regulated. Insulin is the key regulatory hormone of glucose disappearance, and glucagon is a major
regulator of glucose appearance [128].
3Phage display is a technique for the study of protein-protein or protein-peptide interactions that takes advantage
of viruses that infect bacteria (called bacteriophages) to connect proteins with the genetic information that encodes
them [167].
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orientations (C-N, N-C, C-C, N-N) to create several homodimers and hetereodimers, some of which
worked as specific receptor agonists or antagonists [160, 162]. In particular, a single-chain Site
2−Site 1 optimized peptide S519 with one internal disulfide bridge was found to have a receptor
affinity of 20 pM compared with 8 pM of insulin in IR competition binding assays [160]. Similarly,
a single-chain Site 1−Site 2 peptide antagonist S661 bound to IR with an affinity comparable to
that of insulin [162].
Although these mimetic peptides were shown to exhibit agonistic or antagonistic properties,
their structures and mechanism of action on IR have been challenging to decipher. However,
the following observations have led to the speculation that mimetic peptides fold into helical mo-
tifs which can further assemble into an anti-parallel sandwich arrangement [29]: (a) insulin is a
dual-chain disulfide-linked peptide with the A- and B-chain helices assembled in an anti-parallel
arrangement (Figure 3.1A); (b) the apo and hormone-bound crystal structures of IR reveal a close
interplay between binding of the B-chain helix of insulin and the displacement of the critical ligand-
binding element of IR, the αCT-peptide (Figure 3.1 B); (c) a comparison of sequences of Site 1
peptide S371, insulin B-chain, and αCT shows a number of common residues, in particular two
phenylalanines in S371 and αCT that are separated by three residues (Figure 3.1C); and (d) ITC
experiments4 indicate that the Site 1 peptide S371, which is also a part of the potent receptor
agonist S519, competes with αCT for binding to the L1 domain of IR [169]. Given these observa-
tions, understanding the structure and the binding mode of S371 at the Site 1 of IR is necessary to
decipher the agonistic or antagonistic properties of other mimetic peptides in which S371 is incor-
porated via linkers and/or disulfide bonds. To understand the flexibility mechanisms of receptors of
the insulin family and elucidate the details of hormone/receptor interactions, it has been previously
shown that all-atom MD simulations are a highly promising tool [54, 170–174].
4Isothermal titration calorimetry (ITC) is a bio-physical technique that is used for determination of the thermody-
namic parameters of molecular interactions in a solution.This technique, is used for measuring the binding equilibrium
by directly determining the heat evolved on interaction of a ligand with its binding partner [168].













Figure 3.1: (A) Structure of an insulin monomer (PDB code 4INS) is depicted with
the A-chain and B-chain helices highlighted in yellow and black cartoons, respectively.
The flexible termini of the B-chain are shown in white cartoon representations. Two
inter-chain disulfide bonds are shown in green sticks and the side-chains of seven
residues common between the B-chain and S371 (see Figure C) are depicted in black
stick representations. (B) The position of αCT (red/magenta cartoon) on the L1
surface (brown cartoon) is highlighted in apo (PDB code 3LOH) and insulin-bound
states of IR (PDB code 3W11) indicating the displacement of αCT on insulin binding.
The side-chains of two key αCT residues (Phe701 and Phe705) and a key site-1 residue
of insulin B-chain (TyrB16) are also highlighted in red and black stick representations,
respectively. (C) The alignment (carried out using ESPript [175]) of sequences of
S371, insulin B-chain, and αCT is shown. The residues common between peptides
are highlighted in red.
In addition, I have combined MD simulations with metadynamics, an enhanced conformational
sampling algorithm, [120] to predict all-atom structural models of both the transmembrane domains
of receptors of the insulin family in a membrane environment and insulin mimetic peptide in an
aqueous environment. In this current chapter, I report the studies on folding properties and struc-
ture of a potent Site 1 insulin-mimetic peptide S371 in all-atom detail with explicit-solvent using
metadynamics. To benchmark the folding studies of S371 and validate the predictive capability of
CVs that I used, I first carry out folding studies of the native insulin B-chain, which is known to
form a canonical α-helix. I then extend similar metadynamics studies to predict the folded state
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of S371 and find that a large part of this peptide forms an α-helix, as several metastable/stable
states obtained from reconstructed free-energy landscapes reveal structural features of an α-helix
with flexible termini. I further used all metastable conformations of S371, identified via multiple
independent metadynamics simulations, to propose models of S371 binding to the Site 1 of IR.
Finally, metadynamics is suggested as a promising conformational sampling algorithm to study
folding properties and structures of other insulin mimetic peptides in future studies.
3.3 Materials and Methods
3.3.1 System Preparation and Initial Equilibration
I used NAMD [176] as the simulation engine to generate all MD and metadynamics trajectories
using the CHARMM force-field with the CMAP correction [177–179]. I used VMD [180] for system
preparation, protein rendering, and analyses of trajectories. The reader is referred to Sec. 2.6.1 and
Sec. 2.6.4 for the detailed steps in carrying out MD simulation by NAMD and using VMD respec-
tively. The native insulin B-chain has 30 residues (1−FVNQHLCGSHLVEALYLVCGERGFFYTPKT−30)
out of which I modeled 18 residues (underlined) that are part of an α-helix in the insulin structure
(black cartoon in Figure 3.1A). The insulin mimetic peptide S371 was modeled based upon its 18-
residue sequence (1−GSLDESFYDWFERQLGKK−18) optimized during phage display studies [159].
The alignment of 18 residues of the insulin B-chain and S371 reveals 7 common residues (Fig-
ure 3.1C) including a tyrosine residue known to participate in the interaction of the insulin B-chain
with IR at Site 1 (Figure 3.1A,B). The initial structure of each peptide was taken as fully unfolded
and modeled using the psfgen tool in VMD, which was further solvated in a ∼ 48 A˚ × 67 A˚ × 80 A˚
box of TIP3P water molecules and neutralized with NaCl at an ionic strength of 0.05 M. The final
solvated and ionized simulation domains contained 25119 atoms (insulin B-chain) and 24438 atoms
(S371), respectively. The box volume was then optimized in the NPT ensemble by initially applying
500 cycles of a conjugate-gradient minimization scheme followed by a short 200-ps MD run with a
2-fs time step in which the temperature was controlled using the Langevin thermostat (at 310 K)
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and the pressure was controlled by the Nose´-Hoover barostat. All simulations in this work have
employed periodic boundary conditions. These briefly equilibrated systems of each peptide were
further subjected to extensive conformational sampling using metadynamics, as described below.
3.3.2 Metadynamics Simulations
In metadynamics, enhanced conformational sampling is carried out in a specified set of CVs
by augmenting the force-field with a history-dependent biasing potential (Vmeta) [120, 121] using
Equation 2.6. Vmeta is constructed as a sum of Ncv-dimensional repulsive Gaussian functions,
which are of a chosen height (W ) and width (δ), and added at a desired frequency τG. Therefore,
the efficiency and accuracy of the free-energy reconstruction in metadynamics is controlled by
three parameters W , δ, and τG [122]. I carried out all metadynamics simulations with a 1-fs
time step and using the Gaussian height (W ), width (δ), and frequency (τG) of 0.1 kcal/mol,
0.1 or 0.2 A˚, and 0.2 or 1 ps, respectively. The parameters δ and τG were varied to explore
their effect on the reconstruction of free-energy profiles. The RMSD of the backbone Cα atoms
with respect to a perfect α-helix (defined with φ=-57◦ and ψ=-47◦ per Molefacture plugin in
VMD) and the Radius of Gyration (Rg) computed over all non-hydrogen atoms of peptides were
chosen as CVs in my metadynamics runs. The RMSD-CVs was bounded between 0 A˚ and 9.5
A˚, while the Rg-CVs was bounded between 8.7 A˚ and 18.7 A˚. These ranges of CVs span fully
folded helical conformations (occurring at lower bounds), unfolded conformations (occurring at
upper bounds), and a combination of partially folded, kinked, or unfolded states (occurring in
between the lower and upper bounds). I carried out four metadynamics runs for each peptide (the
native insulin B-chain and S371), the details of which are summarized in Table 3.1. I briefly note
that metadynamics algorithm has been successfully applied to study a number of conformational
sampling problems [110–118] including peptide-folding studies in the insulin family [22, 119]. The
truncated S371 metadynamics simulation system was created by solvating and ionizing a fully
unfolded conformation of the first 16 residues of S371 (1−GSLDESFYDWFERQLG−16) generated by
the PSFGEN tool in VMD. The final simulation domain of 49 A˚ × 67 A˚ × 73 A˚ contained 22822
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atoms. This simulation was conducted similar to other metadynamics runs of S371 reported in the
Figure 3.4, and used a Gaussian height (W ), width (δ), and frequency (τG) of 0.1 kcal/mol, 0.1 A˚,
and 0.5 ps, respectively.
Table 3.1: Details of all metadynamics runs. For each peptide, run1 to run4
correspond to PMFs in Figs. 3.3 and 3.4 B to E, respectively.






run1 ∼117 0.2 1.0
run2 ∼118 0.2 1.0
run3 ∼114 0.2 1.0
run4 ∼122 0.2 1.0
S3
71
run1 ∼105 0.2 1.0
run2 ∼70 0.1 0.2
run3 ∼110 0.2 1.0
run4 ∼70 0.1 0.2
The solvated and ionized system of S371 for the AMBER force-field metadynamics simulation
was identical to metadynamics simulations reported in the Figure 3.4. I used AmberTools (tleap)
for the conversion of file formats and employed the revised AMBER force-field (ff14SB). This
simulation used a Gaussian height (W ), width (δ), and frequency (τG) of 0.1 kcal/mol, 0.05 A˚, and
0.5 ps, respectively.
3.3.3 MD Equilibration and SMD Simulations of the L1/S519C16 Complex
The experimental structure of the complex of the insulin mimetic peptide S519C16 and the insulin
receptor L1 domain (PDB code 5J3H) was used to perform conventional and steered MD simula-
tions with NAMD using the TIP3P water model and the CHARMM force-field.
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MD: The peptide/L1 complex was solvated and ionized (0.05M NaCl) in a 61 A˚ × 61 A˚ × 61 A˚
simulation domain and contained 20938 atoms. The box volume was then optimized in the NPT
ensemble by initially applying 500 cycles of a conjugate-gradient minimization scheme followed by
a short 40-ps MD run with a 2-fs time step in which the temperature was controlled using the
Langevin thermostat (at 310 K) and the pressure was controlled by the Nose´-Hoover barostat.
This briefly equilibrated system was then subjected to a ∼570 ns long MD equilibration in the
NVT ensemble.
SMD: The intermolecular axis of the peptide/L1 complex was aligned along the z-direction and
the complex was solvated and ionized in a 64 A˚ × 62 A˚ × 97 A˚ simulation domain. The final
solvated and ionized system contained 35925 atoms. The box volume was adjusted in the NPT
ensemble as described above for the MD equilibration. The equilibrated system was then subjected
to 20 independent SMD simulations in the NPT ensemble. Each SMD simulation was 5 ns long
and was conducted with a 1-fs time step. During each constant velocity SMD run, I applied weak
harmonic restraints on the Cα atoms of the L1 domain to prevent its drift, and pulled all Cα atoms
of S519C16 along the z-direction with a constant velocity of 0.005 A˚/ps and using a spring constant
of 7 kcal mol−1 A˚−2.




















Figure 3.2: Three different models of docking of S371 on the apo αCT conforma-
tion (panel A), on the displaced αCT conformation (panel B), and on the bound
conformation of the helix of the insulin B-chain (panel C) are shown. A total of 200
metastable/stable conformations of S371 sampled using metadynamics are overlayed
in each model, where each predicted S371 conformation was aligned based upon the
Cα atoms of residues common between S371 and the insulin B-chain or αCT (see
Figure 3.1C). Only those residues of the insulin B-chain and αCT that are common
with S371 and also resolved in crystal structures were considered in structural align-
ments. (D) The crystal structure of the L1/S519C16 complex is depicted in a cartoon
representation (PDB code 5J3H). (E and F) Snapshots depicting the overlay of con-
formations of S519C16 on the surface of the L1 domain from each frame of the ∼570
ns long MD simulation are shown with the peptide rendered in a cylindrical repre-
sentation (panel E) and as scattered points (panel F). The area on the L1 surface
covered by the movement of S519C16 is marked approximately using a red line (see
Figure 3.7 for other conformational metrics of the interaction of S519C16 with the L1
domain).
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3.4 Results
3.4.1 Free Energy Profiles and Conformational Ensembles of the Native Insulin
B-chain
Because the B-chain helix of insulin forms direct contacts with the Site 1 of IR, displaces the
critical hormone binding element, the αCT peptide (Figure 3.1A,B), and has sequence similarity
with the mimetic peptide S371 (Figure 3.1C), I first used the set of CVs (RMSD, Rg) to study
the folding of this 18-residue peptide (see Methods and Figure 3.1C for details on sequences and
alignment). Starting with a fully unfolded conformation of insulin B-chain, I carried out four
independent metadynamics runs (see Table 3.1) to sample various conformations by reconstructing
the underlying free-energy landscape from each run. These free-energy landscapes or PMFs as well
as the time- traces of both CVs are shown in Figure 3.3, and indicate that during each metadynamics
run, the peptide is able to exhaustively sample conformations within the full CVs-range (0 to 9.5
A˚ for RMSD and 8.7 to 18.7 A˚ for Rg; lower and upper bounds, respectively, indicate fully folded
and unfolded conformations). Because a spontaneous decrease in RMSD leads to a more compact
and folded structure of the peptide, corresponding to a lower value of Rg, it is important to note
that conformations in the top-left quadrant on each PMF map are physically not accessible, as a
higher value of Rg cannot occur simultaneously with a lower RMSD value. On the other hand, it
is possible for the peptide to adopt several unfolded conformations with higher values of RMSD as
well as of Rg. This behavior is also apparent in traces of all CVs (see panels B to E in Figure 3.3).
I also observe that in each run the peptide samples fully folded as well as unfolded states multiple



































t=0 ns t=~110 ns
Figure 3.3: (A) Snapshots of folding of insulin-B-chain from a typical metadynamics
trajectory are shown as black cartoons. The conformations shown in a box are from an
NMR structure of insulin B-chain (PDB code 2JV1). The side-chains of seven common
residues between the insulin B-chain and S371, and of two C-terminal residues of
insulin B-chain (PheB24 and PheB25) are shown in black and red sticks, respectively.
(B, C, D, E) Two-dimensional PMFs corresponding to each of the four metadynamics
trajectories and the traces of evolution of both CVs are shown. The range of free-
energy values in PMF maps are from 0 kcal/mol to 25 kcal/mol with green indicating
lower values and light blue indicating higher values. The horizontal lines on CVs-
traces correspond to simulation time (ns) with divisions marked at every 20 ns, while
the vertical lines show the values of bounds of each CVs (0 to 9.5 A˚ for RMSD and
8.7 to 18.7 A˚ for Rg). A few selected snapshots of peptide conformations sampled
from lower free-energy (metastable) basins in PMF maps are also depicted as black
cartoons.
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In Figure 3.3A, I show snapshots from a typical metadynamics trajectory (run1 in Table 3.1)
of the insulin B-chain. In this trajectory, the peptide samples unfolded and semi-folded states
during the first ∼60 ns, often with short helical turns, thereafter it largely explores folded states
until 100 ns. This is followed by two sharp transitions, one to a semi-folded state at 100 ns
and the other to a fully folded state at ∼110 ns before reverting to a semi-folded state again
toward the end of the trajectory. The traces of CVs from three other trajectories (Figure 3.3C, D,
and E) show similar behavior albeit the time-scales at which transitions occur between unfolded
and folded states are different for each trajectory demonstrating that independent trajectories are
microscopically distinct. Because the metadynamics algorithm maintains the history and thereby
statistics on the exploration of CVs, it provides on-the-fly estimates on the relative free-energies of
conformations explored. These are shown in Figure 3.3B-E as two-dimensional contour maps with
dark-green regions indicating the lower values of the free-energy and light-blue regions indicating
the higher values of the free-energy. Analyzing dark-green regions in these PMF maps, I observe
that conformations with the lowest free-energy values correspond to lower values of both CVs
(RMSD, Rg), which also means that the peptide is significantly folded in these states. The solution
structure of the human insulin monomer is now known (PDB code 2JV1) and shows that (inset in
Figure 3.3A) the 18-residue peptide I studied forms a long α-helix in the first 13 residues, which is
followed by a sharp 5-residue turn containing two key phenylalanine residues (shown as red sticks
in Figure 3.3A). Comparing metastable conformations sampled from the PMFs (Figure 3.3B-E), I
find that metadynamics accurately reproduces the structural features observed in the solution NMR
structure of the human insulin B-chain including rotamers of both phenylalanines, and therefore
validates its usefulness as a method to explore the conformational space accessible to the mimetic
peptide S371 using the same set of CVs.
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3.4.2 Free Energy Profiles and Conformational Ensembles of the Mimetic Pep-
tide S371
Similar to the insulin B-chain, starting with a fully unfolded conformation of S371, I carried out
four independent metadynamics runs (see Table 3.1), two of which (run1 and run3) were carried
out with the Gaussian width (δ) and frequency (τG) parameters similar to the B-chain runs and
the other two runs (run2 and run4) with decreased values of δ and τG. In Figure 3.4A, I show
snapshots from various time-points of run1 depicting the progress of conformational sampling of
S371. In this run, the peptide adopts unfolded conformations ranging from extended to collapsed
states for the first ∼50 ns, followed by significantly folded states until ∼81 ns, after which the
peptide unfolds again at about 90 ns. The first transition to a significantly folded state occurs
around ∼30 ns in run2, ∼65 ns in run3, and ∼40 ns in run4, and the traces of CVs from all four
runs (Figure 3.4B-E) indicate multiple structural transitions in S371 between fully folded, semi-
folded, and unfolded states. I sampled 200 metastable/stable conformations from the free-energy
regions below 1 kcal/mol in PMFs (green areas) and overlayed all such conformations (red box in
Figure 3.4A). These data show that S371 adopts an α-helical structure throughout its 18 residue
sequence although the first residue (Gly) and the last helical turn that includes two charged residues
(Lys17 and Lys18) remain significantly flexible. I also find that the side-chains of three aromatic
residues (Phe7, Tyr8, and Phe11) are found in two different rotameric states, and the side-chains of
nearly all residues common between S371 and αCT (see sequence alignment in Figure 3.1C) remain
solvent-exposed and therefore accessible.






































Figure 3.4: Same format as in Figure 3.3 (such as peptide conformations, PMF
maps, and CVs-traces) are shown for the folding of the mimetic peptide S371. The
side-chains of seven common residues between S371 and αCT are shown as red sticks,
while the side-chain of a Tyr residue of S371 (common with insulin B-chain residue
TyrB16) is shown in a black stick representation. The overlay of 200 metastable/stable
conformations of S371 (sampled using metadynamics) with free-energy values below 1
kcal/mol are shown in red cartoons along with side-chain rotamers (red box in panel
A).
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3.4.3 Free Energy Profiles of the Truncated Mimetic Peptide S371
I carried out a ∼100 ns long metadynamics simulation of the truncated (lacking two C-terminal Lys
residues) 16-residue mimetic peptide S371 with the CHARMM force-field as well as a ∼200 ns long
metadynamics simulation of the full-length (18 residues) S371 peptide with the AMBER force-field.
The results from these trajectories are reported in Figure 3.6 and Figure 3.8, respectively.
3.4.4 Simulation of L1 Domain in Complex with the S519C16
I conducted a ∼570 ns classical MD equilibration of the human insulin receptor L1 domain
in complex with the S519C16 peptide (same sequence as the first 16 residues of S371) and report
results from this simulation in the Figure 3.2 E, F and Figure 3.7. I also carried out 20 SMD runs
of the dissociation of S519C16 from the L1 domain. The results from these runs are reported in
Figure 3.5. All simulations were conducted/analyzed with the NAMD/VMD software suite.
A B C
Figure 3.5: SMD simulations for the dissociation of the peptide from the L1 domain.
(A and B) The unbinding force as well as work values are plotted along the distance
reaction coordinate from 20 independent SMD runs: the average of all force profiles
is shown as a black trace and the gray shaded area indicates the standard deviation
based upon all runs, while work profiles (B) are plotted from low (blue) to high (red)
work values. (C) The PMF trace computed using Jarzynski’s Equality is shown as a
function of the dissociation reaction coordinate.
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3.5 Discussion
Insulin is known to bind to its receptor via two binding epitopes, Site 1 and Site 2, where the
primary hormone-binding site (Site 1) is formed by residues located in receptor’s α-subunit domains
L1 and αCT. Although αCT has a relatively low-affinity (∼3 µM) for the L1 domain [154, 169], it
is a critical hormone-binding element [138, 181–184] and has been revealed to form an α-helix and
bind in tandem with the hormone (Figure 3.1B). Therefore, routes to design mimetic peptides with
agonistic or antagonistic properties toward IR have been explored through highly diverse peptide
display libraries which have led to the identification of several synthetic peptides that bind to IR
with micromolar or sub-micromolar affinity [159, 160, 162]. Because of sequence similarities with
the insulin B-chain and αCT (Figure 3.1C), these peptides have been speculated to form helical
structures [29].
In this work, I have presented all-atom structural models of a Site 1 insulin mimetic peptide S371
that forms a high-affinity receptor agonist S519 when added to the C-terminus of a Site 2 mimetic
sequence [160] but forms a potent antagonist S661 when added to the N-terminus of a related
Site 2 mimetic sequence [162]. The all-atom models of S371 were generated in explicit-solvent
environment using MD simulations combined with metadynamics, an enhanced conformational
sampling algorithm, that allows extensive and uniform sampling of peptide conformations in a
pre-defined set of CVs. Moreover, metadynamics algorithm gathers statistics on states visited in
the CVs-space via a history-dependent potential function that provides on-the-fly estimates of the
relative free-energy between such states. While both RMSD and Rg have been previously used
as promising CVs in several folding studies [185–192], I first validated the CVs by predicting the
conformation of the B-chain helix of the native hormone and found that metadynamics is able
to reproduce structural features observed in the solution NMR structural ensemble of the human
insulin (Figure 3.3).
Using the same set of CVs, I then embarked upon predicting the structure of the mimetic peptide
S371 using metadynamics simulations and found that the peptide indeed forms a stable α-helix with
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significant flexibility in its two C-terminal Lys residues (Figure 3.4). This observation suggests that
removing these two residues could lead to a more stable 16-residue helical peptide, as was required
in the design of agonist S519 and antagonist S661 [160, 162]. To further test this, I have carried
out a ∼100 ns long metadynamics simulation of the S371 peptide lacking two terminal Lys residues
(see Figure 3.6) that shows metastable conformations corresponding to a stable helical structure
in the C-terminus in comparison to conformations sampled from metadynamics simulations of the
18-residue S371 peptide. The flexibility in the first Gly residue of S371 is likely tolerated as it
provides a pivot between the Site 2 sequence followed by the Site 1 sequence in agonist S519 or
is a free N-terminal residue in antagonist S661. In the predicted structural ensemble for S371, I
also find two different rotameric states for residues Phe7, Tyr8, and Phe11. The access to such
side-chain rotamers can facilitate better positioning of S371 helix on the surface of the L1 domain
because the FXXXF sequence is also a part of αCT where both Phe-residues in αCT interact with
the L1 domain (Figure 3.1B), while the Tyr-residue in S371 is also present in the insulin B-chain
and anchors the B-chain helix at Site 1 via direct interactions with L1 (see the panel labeled as
liganded in Figure 3.1B). Considering sequence similarities of S371 with the insulin B-chain and
αCT (Figure 3.1C) as well as structural constraints mentioned above, I proposed models of S371
binding on the L1 surface in Figure 3.2. In the first model (Figure 3.2A), I show positioning of
S371 on the apo L1 domain that was obtained by aligning on αCT all predicted S371 conformers
based upon seven common residues between S371 and αCT that are also resolved in the apo IR
crystal structure. I observe that S371 conformations in this model align very well with the apo
αCT position (albeit the last two Lys-residues remain flexible) including two Phe-residues in the
FXXXF motif. This model helps explain the observation from isothermal titration calorimetry
(ITC) experiments of Menting et al. [169] that show a direct competition between αCT and S371
for binding to L1 because the nanomolar binding affinity of the Site 1 mimetic peptide decreases
5-fold in the presence of αCT. Because the crystal structures reveal that αCT is displaced on insulin
binding (see the panel labeled as liganded in Figure 3.1B), I constructed the second S371-bound
model (Figure 3.2B) by aligning predicted S371 conformations on the displaced αCT conformation
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which is resolved between Phe705 and Val715 (PDB code 3W11). This model shows that S371
can be positioned in the place of the displaced αCT leaving enough space for the hormone to
bind, an observation suggesting that αCT will be further perturbed from its already displaced
position (relative to the apo αCT structure). Given that αCT is a part of the α-chain of IR
and hence physically linked on both termini, further displacement in its position is unlikely to
be accommodated due to steric constraints and also because it may lead to an unstable receptor
structure or the loss of critical interactions with the C-terminus of the insulin B-chain (if the










Figure 3.6: Metadynamics folding simulation of the truncated S371 peptide lacking
two terminal Lys residues.
The PMF map as well as the trace of each CVs is shown similar to Figures ??, 3.4
B-E. Two metastable helical conformations of the truncated peptide are highlighted
in red cartoon representations.
This led me to the third model (Figure 3.2C) which shows the way in which S371 could take
3.5. Discussion 59
the position of the insulin B-chain helix without significantly interfering with the displaced αCT
position. Although this model is plausible, it does not suggest a competing mechanism for the
binding of S371 and αCT to the L1 domain, as observed in ITC experiments [169]. Given steric
constraints on αCT and its displacement on insulin binding, my models outlined above collectively
suggest that in the IR ectodomain S371 binds to L1 in a conformation similar to that of αCT in
its apo or displaced positions. These conclusions are consistent with a recently reported crystal-
lographic structure of the mimetic peptide S519C16 (the C-terminal 16-residue Site 1 component
of S519 that is identical to S371) in complex with a fragment of the IR ectodomain that contains
the L1 domain [193]. I show a snapshot of the S519C16/L1 complex in Figure 3.2D in which the
disposition of the mimetic peptide is highly similar to my model in Figure 3.2A. To further under-
stand the stability of this complex as well as the conformational variability of the mimetic peptide
on the surface of the L1 domain, I carried out a ∼570 ns long MD equilibration of this complex.
From this simulation, in Figure 3.7 I report the RMSD of the backbone atoms of the peptide, the
angle of rotation of the principal axis of the peptide on the L1 domain, and non-bonded interaction
energies between all-atoms of the peptide and of the L1 domain. These data show that during this
simulation, the peptide maintains its helical fold with an average RMSD of ∼1.5 A˚ (the red trace
in Figure 3.7 A), has strong electrostatic interactions with residues of the L1 domain (the red trace
in Figure 3.7 C), and can rotate up to 20◦ (Figure 3.7B and snapshots in Figure 3.2E) with respect
to its position in the crystal structure. From each frame of this trajectory, the overlay of positions
of all atoms of the peptide on the surface of the L1 domain (Figure 3.2F) reveals a large area
overlapping with the apo or liganded conformations of αCT. Furthermore, using a combination of
SMD simulations and Jarzynski’s non-equilibrium equality [124, 194], I computed the unbinding
force, work, and the PMF along a distance reaction coordinate for the dissociation of S519C16 from
the L1 domain (see Figure 3.5). These data reveal a net positive free energy change for the peptide
unbinding reaction indicating that the peptide prefers to be in the bound state at equilibrium, as
also observed during the ∼570 ns MD equilibration.
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Figure 3.7: MD equilibration (∼570 ns) of the L1-S519C16 complex (PDB: 5J3H)
shown in Figure 3.2D.
(A) RMSD vs. simulation time trace for the backbone atoms of the 16-residue mimetic
peptide. RMSD was calculated after aligning each trajectory frame based upon the
L1 domain. The average trace is shown in red while the fluctuations are plotted in
blue. (B) Angle of rotation of the principal axis of the peptide vs. simulation time
is shown corresponding to the Figure 3.2E. Alignment and color schemes are same as
in panel A. (C) Non-bonded interaction energy vs. simulation time traces are shown
for the interaction between all atoms of the peptide and the L1 domain: total non-
bonded energy (black trace), van der Waals energy (yellow trace), and electrostatic
energy (red trace).
while I have not studied here other peptides in which S371 can be incorporated in various
ways, I surmise the following. As S371 is added to the C-terminus of the affinity-optimized agonist
S519, I speculate that the Site 2 part of S519 likely folds into short helical motifs similar to the
A-chain of insulin, particularly given that the Site 2 sequence also contains a disulfide bond [159].
Some tentative modeling of the Site 2 sequence in a recent study supports this suggestion [193].
On the other hand, S371 is added at the N-terminus of antagonist S661 and in case it occupies
the position of the insulin B-chain (as shown in Figure 3.2C), the folding of the Site 2 sequence
(that follows S371) may further lead to subtle rearrangements (due to steric constraints) in the C-
terminus of αCT or in the loops of two fibronectin domains (F1 and F2) that harbor Site 2 residues
of the receptor. Taken together, my predicted structures of S371 (Figure 3.4) and its receptor-
bound models on the L1 surface (Figure 3.2) provide structural bases to rationalize a number of
experimental observations about the interaction of Site 1 insulin mimetic peptides with IR and to
explain the molecular origins of their agonistic or antagonistic properties. Although it was not an
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aim of this work to compare various force-fields, I have carried out a ∼200 ns long metadynamics
simulation of S371 using the AMBER force-field [195] (Figure 3.8). This simulation shows that
on a ∼200-ns timescale metadynamics can generate structural transitions to semi-folded states of









Figure 3.8: Metadynamics folding simulation of S371 with the AMBER force-field.
The PMF map as well as the trace of each CVs is shown similar to Figures ??, 3.4
B-E. Two metastable conformations with significant helical content are highlighted in
red cartoon representations.
3.6 Conclusions
Using MD simulations assisted by metadynamics, an enhanced conformational sampling algo-
rithm, I have presented all-atom structural models of a Site 1 insulin mimetic peptide S371 which
can be combined with different Site 2 mimetic peptides to form potent agonists or antagonists for
IR [160, 162]. I find that S371 adopts an α-helical structure with flexible termini, particularly in
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helical turns corresponding to the last two Lys-residues. Using sequence similarities between S371,
the insulin B-chain, and αCT as guides, I also proposed structural models of S371 binding on the
L1 surface of IR that provide insights into competing binding properties of S371 and αCT as well
as their positioning on the L1 surface in apo and liganded forms of IR. The results also demonstrate






In this chapter, the dynamics of structures of transmembrane and juxtamembrane regions of IR
and IGF1R in a membrane environment have been investigated by MD simulation. The receptor
tyrosine kinase superfamily comprises many cell-surface receptors including the insulin receptor
(IR) and type 1 insulin-like growth factor receptor (IGF1R) that are constitutively homodimeric1
transmembrane2 glycoproteins.3. Therefore, these receptors require ligand-triggered domain rear-
rangements rather than receptor dimerization for activation. Specifically, binding of peptide ligands
to receptor ectodomains transduces signals across the TMDs for trans-autophosphorylation4 in cy-
toplasmic kinase domains. The molecular details of these processes are poorly understood in part
due to the absence of structures of full-length receptors. Using MD simulations and enhanced
conformational sampling algorithms, I present all-atom structural models of peptides containing 51
1A dimer is a large molecular complex that is comprised of two proteins. A homodimer is formed by two identical
protein chains.
2 Transmembrane is referred to a part of a protein or entirety of a protein that is permanently located within the
biological membrane
3Proteins that have carbohydrate groups linked to the their chains; insulin receptor has many glycosylation
sites [196]
4 This is defined as the phosphorylation of the kinax by itself when a phosphate group is added to serine, threonine
or tyrosine residues within kinases domain. This process regulates the catalytic activity [197].
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residues from the transmembrane and juxtamembrane regions of IR and IGF1R. In my models, the
transmembrane regions of both receptors adopt helical conformations with kinks at Pro961 (IR) and
Pro941 (IGF1R), but the C-terminal residues corresponding to the juxtamembrane region of each
receptor adopt unfolded and flexible conformations in IR as opposed to a helix in IGF1R. I also
observe that the N-terminal residues in IR form a kinked-helix sitting at the membrane-solvent
interface, while homologous residues in IGF1R are unfolded and flexible. These conformational
differences result in a larger tilt-angle of the membrane-embedded helix in IGF1R in comparison
to IR to compensate for interactions with water molecules at the membrane-solvent interfaces.
The metastable/stable states for the transmembrane domain of IR, observed in a lipid bilayer,
are consistent with a known NMR structure of this domain determined in detergent micelles, and
similar states in IGF1R are consistent with a previously reported model of the dimerized trans-
membrane domains of IGF1R. My all-atom structural models suggest potentially unique structural
organization of kinase domains in each receptor.
4.2 Background
IR and IGF1R are homologous, ligand-activated, and constitutively homo-dimeric transmem-
brane glycoproteins of the Receptor Tyrosine Kinase (RTK) superfamily [140]. Both IR and IGF1R
have similarities in primary sequences, structural topologies, functions, and binding affinities for
peptide ligands such as insulin and insulin-like growth factors (IGFs) [29, 31, 144–146, 174, 198–
203]. Structurally, each subunit in receptors is composed of three large protein fragments: the
extracellular part (also known as the ectodomain) (see Figure 5.1), the intracellular part (contain-
ing kinase domains), and a single-pass transmembrane domain (TMD) that connects extracellular
and intracellular fragments (see Figure 4.1). Specifically, the TMD as well as the catalytic kinase
domain are located in the β-chains of each subunit of receptor homodimers. TMD potentially plays
a critical role in mediating signaling via IR and IGF1R because ligand binding to extracellular
subunits leads to conformational changes that are conveyed (via TMD) to kinase domains, thereby
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triggering trans-autophosphorylation and downstream signaling cascades [130–132, 141, 204–206].
Initially, the TMD appeared to play a passive role in insulin signaling [207] but other studies in-
dicate that modifications in TMDs of IR or IGF1R alter receptor internalization as well as affect
kinase activation and negative cooperativity5 [209–212], while replacing IR-TMD with that of gly-
cophorin A inhibits insulin action [213]. The mechanistic details of these processes remain poorly
understood at the molecular scale, but simple mechanical models for signal transduction via TMD
suggest that a lateral shift or a rotational motion of TMD is energetically more favorable than the
vertical motion in the phospholipid bilayer, as it would suggest dimerization of TMDs that could
bring kinase domains in proximity [210, 214–216]. However, recent studies propose different mech-
anisms for IR and IGF1R activation [202, 217]: Lee et al. [166] have suggested that TMDs of IR
in the nonactivated basal state are constitutively dimerized and dissociate on ligand binding, while
Kavran et al. [218] have suggested that ligand binding leads to dimerization of TMDs in IGF1R.
Previously, a different “yo-yo” model of receptor activation was proposed by Ward et al. [201] in
which the ligand-induced conformational change releases kinase domains (for transphosphorylation)
from an initially constrained position near the membrane. These studies do not directly support a
common mechanism of activation of transmembrane cell-surface receptors [216].
Therefore, the exact mechanism of signal transduction in IR and IGF1R remains elusive in part
due to the lack of knowledge of intact structures of full-length receptors (in apo or ligand-bound
forms) although several structures of excised extracellular and intracellular domains have been
solved [148–155, 219–226]. The solution structure of IR-TMD has been determined in detergent
micelles [227], but the deviation of the hydrophobic thickness of micelles from lipid bilayers can
potentially cause changes in protein conformations [228]. Nonetheless, this study suggested that
the excised IR-TMD sequence remains largely monomeric in solution and forms an α-helix with a
kink at residues Gly960 and Pro961, but the possibility of dimer formation was not excluded de-
pending upon the detergent/protein ratio. It was also speculated that the presence of one SXXXG
5 When an enzyme or a receptor has multiple ligand binding sites, the affinity of one ligand can be increased or
decreased by another ligand. This phenomenon is known as positive or negative cooperativity [208].
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sequence motif in IR-TMD could play a role in dimerization similar to the GXXXG motif [59, 60].
Currently, no experimental data on the structure of IGF1R-TMD are available. I have previously
conducted MD simulations in explicit solvent with all-atom structural models and enhanced sam-
pling algorithms [229] which are highly promising tools to understand conformational flexibility of
receptor structures and their ligand binding mechanisms [54, 170–174]. In this work, I aimed to
study the structure, orientation, and conformational variability of TMDs of IR and IGF1R in an
explicit lipid bilayer environment. In particular, I have studied the folding/unfolding behavior and
stability of membrane-embedded peptide sequences of IR and IGF1R using enhanced sampling sim-
ulations conducted with metadynamics algorithm [120] because classical MD simulations are likely
insufficient for sampling of all relevant peptide conformations in the lipid bilayer. In particular,
my predicted structural ensembles are consistent with recent NMR data [227] and reveal that the
presence of Gly960 and Pro961 in IR-TMD indeed results in increased flexibility in comparison to
IGF1R-TMD, while metastable structural ensembles of both peptides show significant differences
in their orientation in the membrane and in conformations of the N- and C-termini. I also observe
different patterns of water distribution near peptide residues at the membrane-solvent interface
and find that changes in backbone conformations of peptides correlate with certain angle variables
measured relative to the membrane-normal.
4.3 Materials and Methods
4.3.1 System Preparation and Initial Equilibration
All MD trajectories in this chapter were generated with NAMD [176] using the TIP3P wa-
ter model and the CHARMM force-field with the CMAP correction [177, 178]. VMD was used
for system creation, protein rendering and analyses [180]. All simulations were carried out in the
NPT ensemble using the Langevin thermostat at 310 K and the Nose´-Hoover barostat. I modeled 51
residues for IR (939−FYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLG−989)
and IGF1R (918−DPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLG−968)
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that included the predicted TMD sequence (underlined; 957-979 for IR and 936-959 for IGF1R)
for each receptor (Sequence numbering is based upon protein knowledgebase www.uniprot.org




Figure 4.1: (A) Initial configurations of IR-TMD and IGF1R-TMD in membrane
and solvent environments. Lipid and water molecules are shown in black and cyan
wireframe representations, respectively. Peptides are shown as gray cartoons with the
predicted TMD sequence rendered in blue. Two proline residues at the N-terminus of
each peptide are shown in red space-filling representations. (B) Peptide configurations
at the end of MD equilibration step 3.
For each sequence, I generated an ideal α-helix as a starting structure using VMD’s psfgen tool
and generated a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) membrane patch of
∼80 A˚ × 80 A˚ in size using VMD’s membrane builder tool. Each peptide was then embedded in
the POPC bilayer by aligning the centers of mass and the principal axis of each helix along the
z-direction. Thereafter, overlapping lipid molecules within 2 A˚ of each peptide were deleted. Each
system was solvated with ∼17700 water molecules, neutralized with KCl, and brought to an ionic
strength of 0.2 M. The final simulation domains measured ∼83 A˚ × 80 A˚ × 140 A˚ and contained
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74168 (IR) and 74144 (IGF1R) atoms, respectively. Each system was then equilibrated in three
consecutive steps. In the first step, initially a conjugate-gradient minimization was carried out for
1000 cycles which was followed by a short MD equilibration (0.5 ns long with a 2-fs time step)
by keeping all atoms fixed except those in lipid tails. In the second step, MD equilibration was
continued for 5 ns in the NPT ensemble by fixing only peptide atoms. In the third step, no atoms
were fixed or constrained in a 50 ns MD equilibration in the NPT ensemble. The final atomic
coordinates after the equilibration in the third step were used to setup enhanced exploration of
peptide conformations in lipids using metadynamics, as described below. Initial and equilibrated
configurations of IR-TMD and IGF1R-TMD are shown in Figure 4.1.
4.3.2 Metadynamics Simulations
Metadynamics has been successfully applied to study many biophysical problems [110–116] in-
cluding prediction of peptide conformations in lipid membranes [117, 118]. In this work, I have
used as CV the root-mean-squared-deviation (RMSD) of the backbone Cα atoms with respect to a
perfect α-helix. The RMSD CV was bounded between 0 A˚ and 15 A˚, and therefore, low values of
RMSD indicate helical conformations and higher values indicate kinks and/or unfolded states. For
all metadynamics simulations, a 1-fs integration time step was used, and the Gaussian height (W ),
width (δ), and frequency (τG) of 0.1 kcal/mol, 0.2 A˚, and 1 ps, respectively, were used. Metady-
namics simulations converged in 160 ns (IR-TMD) and 145 ns (IGF1R-TMD), respectively, after
which each trajectory sampled the CV range diffusively. The converged free-energy profiles from
the last 10 ns of each metadynamics trajectory were used for analyzing metastable conformations
and for carrying out other analyses reported in this work. I note that I have not studied the effect
of including multiple CVs in my simulations.
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4.4 Results
4.4.1 Orientation of IR-TMD and IGF1R-TMD in the Membrane
In metadynamics simulations, the change in RMSD of peptides relative to a perfect helix could
be due to several different types of structural features such as tilting, bending, or unfolding. There-
fore, to understand the orientation of peptides in the lipid bilayer, I computed three angle variables
and analyzed their correlation with the RMSD change (Figure 4.5). For IR-TMD, α and β char-
acterize the orientation (relative to the membrane-normal) of the helix preceding Pro961 and the
helix corresponding to the transmembrane sequence (962-979), and γ characterizes the interhelical
angle, while in IGF1R-TMD, α and β characterize the orientation of helices between 934-948 and
951-966 relative to the membrane-normal and γ is the interhelical angle.
These data (Figure 4.5 B, D) indicate that several conformations in the RMSD range (0-15
A˚) can take a wide variety of angle values suggesting multiple orientations of peptides due to
enhanced conformational sampling via metadynamics. For IR-TMD, I find that angles α and γ are
correlated with RMSD such that an increase in RMSD results in an increase in α but a decrease
in γ. Structurally, this means that the N-terminal helix in IR-TMD kinks toward the membrane,
thereby becoming parallel to the membrane-solvent interface, while the membrane-embedded helix
straightens to align along the membrane-normal, as also indicated by a sharp decrease in β. For
the metastable/stable conformations of IR (Figure 4.2 C), I observe α values between ∼70◦ and
90◦, γ values slightly smaller than ∼110◦, and β values between ∼5◦ and 25◦. For IGF1R-TMD, I
observe no significant correlation between the angle α and RMSD as α remains near 30◦ on average,
suggesting that the helix between residues 934-948 remains tilted relative to the membrane-normal.
However, an increase in RMSD is correlated with a decrease in β and γ that leads to a kink at
Gly950. This kink is unstable and not observed in metastable/stable conformations of IGF1R-
TMD (Figure 4.2 D) where γ values near 180◦ are observed. In these IGF1R-TMD conformations,
a significant contribution to change in RMSD is due to the unfolding of the N-terminus (residues
918-932) and a minor contribution is due to a kink at Pro941.




Figure 4.2: (A, B) Averaged potentials of mean force from the last 10 ns of meta-
dynamics simulations for IR-TMD (top) and IGF1R-TMD (bottom) in a lipid mem-
brane. Free energy profiles show relatively small energetic differences (∼2-3 kcal/mol)
in a wide range (5-11 A˚) of RMSD, as indicated by magnified profiles (inset). Shaded
regions on PMF traces indicate computed statistical variation in free energy profiles.
(C, D) Overlay of all metastable/stable conformations for IR-TMD and IGF1R-TMD
in gray cartoon representations except the transmembrane sequence which is displayed
in blue cartoons. All depicted conformations are aligned on the initial configuration
of each peptide (shown in Figure 4.1 A) with alignment based upon residues in the
predicted transmembrane sequence (blue cartoon). Pro961 (IR-TMD) and Pro941
(IGF1R-TMD) are shown in red, and Gly960 (IR) in green space-filling representa-
tions, respectively. Horizontal lines indicate the approximate location of the lipid
bilayer.
4.4.2 Interactions of IR-TMD and IGF1R-TMD Peptides with the Solvent
In each 51-residue long peptide studied here, several charged amino acids are present in the
sequence preceding as well as following the predicted TMD sequence (957-979 for IR and 936-959
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for IGF1R). Because I observed kinked or unstructured configurations in the termini of each peptide,
I analyzed all metastable conformations for interactions with water molecules at the membrane-
solvent interface. Specifically, I present average number of water molecules within 4.5 A˚ of each
protein residue in Figure 4.3. These data show that no water molecules are observed in the vicinity
of helix-forming hydrophobic residues buried in the membrane (for example, 965-977 for IR-TMD








Figure 4.3: (A, B) The average number of water molecules per residue within ∼4.5
A˚ of metastable/stable conformations of IR-TMD and IGF1R-TMD. ( C, D) Selected
snapshots from metastable/stable conformations of IR-TMD (C) and IGF1R-TMD
(D) are shown to highlight interactions with water molecules (red licorice representa-
tions). Several charged residues in the termini of each peptide and a proline residue
(961 for IR and 941 for IGF1R) are shown in brown and red space-filling representa-
tions, respectively. Each peptide is rendered as a cartoon in the same coloring scheme
as in Figures 4.1 and 4.2.
Both IR-TMD and IGF1R-TMD have an “Arg-Lys-Arg” motif immediately following the TMD
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sequence that is exposed to solvent as indicated by the increasing number of water molecules for
residues in this motif of each peptide. Importantly, this motif is part of the unfolded C-terminus in
IR-TMD but is fully folded in IGF1R-TMD. The exposure of this motif to solvent is compensated
by a larger tilt angle in IGF1R-TMD in comparison to homologous sequence in IR-TMD. Several
other residues in the C-terminus of each peptide have over 10 water molecules in their vicinity. A
significant difference in water distribution is observed in the N-terminus of each peptide largely
because residues 918-932 in IGF1R-TMD are highly flexible, unfolded, and located outside the
membrane, while the homologous residues in IR-TMD form an α-helix resting at the membrane-
solvent interface, such that a charged residue Lys956 has over 25 water molecules in its vicinity.
The kink-forming residue Pro961 in IR-TMD is also significantly exposed to the solvent, but the
corresponding residue Pro941 in IGF1R-TMD is completely shielded from the solvent. The highest
water density is observed for Arg966 in IGF1R-TMD, and for Lys956 or Arg982 in IR-TMD.
4.4.3 Free Energy Profiles and Conformational Ensembles of IR-TMD and
IGF1R-TMD
Starting with a perfectly α-helical conformation of each peptide (Figure 4.1 A), I carried out
independent ∼55 ns long MD equilibrations in explicit membrane and solvent environments before
launching enhanced sampling simulations using metadynamics. The final conformations of peptides
sampled from these MD trajectories (Figure 4.1 B) show that even at these short-timescales, pep-
tides deviate from their initial conformations and adopt tilted conformational states with respect
to the membrane-normal. Specifically, IR-TMD largely maintains an α-helical structure but with
a sharp kink at Pro961 such that residues 939 to 958 in the N-terminal helix interact strongly
with lipids than the water molecules. IGF1R-TMD also remains α-helical with a minor kink at
Pro941 but the first 10 residues in the N-terminus spontaneously unfold and interact with the water
molecules. The Cα-RMSDs relative to a perfect helix for the final peptide conformations are 6.35
A˚ (IR-TMD) and 3.75 A˚ (IGF1R-TMD), respectively.
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To uniformly explore peptide conformations between 0-15 A˚ RMSD and to obtain estimates
on the free energy, I carried out 160 ns (IR-TMD) and 145 ns (IGF1R-TMD) long metadynamics
simulations. Consistent with enhanced conformational sampling, each peptide visited both helical
and non-helical states multiple times during these simulations. The averaged free energy profiles
(potentials of mean force; PMFs) from the last 10 ns of each metadynamics trajectory (Figure 4.2
A, B) indicate that peptide conformations below an RMSD of ∼3.5 A˚ and above ∼11.5 A˚ are
significantly higher in free energy relative to other states. This suggests that peptides prefer neither
a fully helical structure (which occurs at 0 A˚ RMSD) nor a significantly unfolded configuration
(which occurs beyond 12 A˚ RMSD), but instead metastable/stable configurations likely contain
both helical and partially-unfolded structural motifs. Moreover, the stable conformations with the
lowest free-energy relative to other states occur at ∼6 A˚ RMSD for IR-TMD and ∼8 A˚ RMSD for
IGF1R-TMD (inset in Figure 4.2 A, B).
From the last 10 ns of each metadynamics trajectory, I harvested several metastable/stable
configurations for each peptide (17 for IR and 11 for IGF1R) with a ∼2-3 kcal/mol free-energy
difference. These conformations for IR-TMD and IGF1R-TMD are distinct (Figure 4.2 C, D)
and have the following features: (1) in IR-TMD, α-helical structures are observed for residues
939-958 in the N-terminus and residues 962-980 (part of the predicted transmembrane domain
sequence, 957-980, of IR). These two helices are stably held together by a sharp kink at Gly960 and
Pro961. The remaining residues in the C-terminus (981-989) are highly flexible and adopt unfolded
conformations; and (2) in IGF1R-TMD, the N-terminal residues 918-932 are significantly flexible
and unfolded, a small α-helix kinked at Pro941 is observed between 933-941, while a full α-helix
is observed for residues 942-968. To quantify these observations, I further carried out secondary
structure analysis on all metastable/stable configurations and computed average helicity on a per
residue basis. These results (Figure 4.4) show that the α-helical content for IR-TMD is reduced
between residues 939-942 and no helical content is observed between residues 959-961 and 982-989,
while for IGF1R-TMD, no helical content is present between residues 918 to 931 and a minor
decrease in helicity is observed at residue Gly950. I note that an unstable kink at Gly950 mostly
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Figure 4.4: Averaged percentage helicity per residue for all metastable/stable con-
formations of IR-TMD (A) and IGF1R-TMD (B).
4.5 Discussion
In this work, I have presented all-atom structural models of 51-residue long peptides containing
the transmembrane domain sequence of IR and IGF1R (957-979 for IR and 936-959 for IGF1R).
These models have been generated in explicit membrane and solvent environments using MD simu-
lations assisted by enhanced conformational sampling algorithms that facilitate extensive sampling
of conformational space and provide information on key thermodynamic properties such as the free
energy. For both receptors, I observe that the residues corresponding to the transmembrane domain
sequence are fully membrane-embedded and form α-helices with a major kink at Pro961 in IR and
a minor kink at Pro941 in IGF1R. A kink in IGF1R-TMD at Gly950 is unstable and recovers to an
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α-helical conformation. Based upon angle collective variables characterizing the orientation of each
peptide in the membrane (Figure 4.5), I observe that the membrane-embedded α-helix in IGF1R-
TMD is significantly more tilted (relative to the membrane-normal) than in IR-TMD (Figure 4.3
C,D). However, it is important to point out that these angles were not explicitly included as CVs
in my metadynamics calculations and therefore were not extensively sampled. The values of angles
reported in Figure 4.5 are those that correspond to extensive sampling along RMSD CV, as also
indicated by multiple values of a specific angle corresponding to a single value of RMSD. I also
notice major differences in conformations of peptide termini: a short α-helix is observed for the
N-terminal residues (939-958) of IR-TMD, but significantly unfolded and flexible conformations are
observed for the N-terminal residues (918-932) of IGF1R-TMD, while an α-helix is observed for
the C-terminal residues (960-968) of IGF1R, but unfolded and flexible conformations are observed
for the C-terminal residues (981-989) of IR. Importantly, irrespective of different conformations in
the C-terminus of each peptide, an ”Arg-Lys-Arg” motif is solvent exposed, albeit at the expense
of a larger tilt angle in IGF1R-TMD than in IR-TMD. However, I observe that all N-terminal
residues (918-932) in IGF1R-TMD are solvent exposed, but only a few N-terminal residues (Lys956
and Pro961) in IR-TMD are significantly solvated. This difference is primarily due to the fact
that a short α-helix in the N-terminus of IR-TMD is partially membrane-embedded such that
the positively-charged residues are oriented toward the membrane-solvent interface, while the N-
terminal residues in many metastable conformations of IGF1R-TMD reside outside the membrane.
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Figure 4.5: Two angle collective variables relative to the membrane-normal and one
between the helices are shown to quantify peptide orientations in a lipid bilayer: (A,
B) IR-TMD and (C, D) IGF1R-TMD. Correlations of angles with RMSD are shown
in panels (B) and (D). Scattered blue dots indicate all values of angles explored via
metadynamics trajectories and red lines are the best fit curves. Black dots are angles
corresponding to metastable/stables conformations shown in Figure 4.2 C, D.
Li et al. [227] have recently determined a solution structure of the transmembrane domain of
IR (PDB code 2MFR) using NMR spectroscopy in dodecylphosphocholine (DPC) micelles. The
following features observed in the NMR conformational ensemble are consistent with my IR-TMD
structural models: (i) a well-defined α-helix (between residues Leu962 and Tyr976) buried in the
DPC micelles with a kink at Gly960 and Pro961; (ii) a flexible and solvent-exposed C-terminal
region (between residues Gln983 and Leu988); and (iii) a short α-helix (between residues Phe939
and Tyr944) partially-buried in the DPC micelles with weak solvent interactions for Thr942 and
Asp943. On comparing my models with the NMR structure, I observe that the kink angle at
Pro961 in my IR-TMD models is larger than what is observed in the NMR structure, which results
in increased interactions of Pro961 with the solvent in my models. I therefore analyzed the spherical
micellar region encasing IR-TMD reported in Li et al.’s work [227] and found that it is at least ∼3-4
A˚ thicker than the equilibrium thickness of a POPC membrane. I speculate that the difference in
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the hydrophobic thickness of a bilayer and a micelle could have contributed to a difference in the
kink-angle near Gly960 and Pro961. However, the observation of a kink at these residues in my
models and the NMR structure is consistent with the observation of enhanced helicity in IR-TMD
on individual or simultaneous mutations of Gly960 and Pro961 to Ala [230] as well as with the
role of Gly and Pro residues as helix breakers [231, 232]. Currently, no experimental structure of
IGF1R-TMD is known, but consistent with my all-atom structural models of IGF1R-TMD, classical
MD simulations reported in Kavran et al.’s work [218] indicate a kink at Pro941, interactions of
His935 with the solvent, and a significantly-tilted α-helical conformation of the transmembrane
sequence.
A major unresolved question is related to the dimerization of IR-TMD and IGF1R-TMD in
the basal or activated states of receptors in part because no experimental structures of these do-
mains in a dimeric configuration have been reported so far. However, different models have been
proposed [202, 217] by Ward et al. [201], Lee et al. [166], and Kavran et al. [218], as outlined in
the introduction. For the isolated IR-TMD, Li et al. [227] primarily observed a monomeric con-
formation in the DPC micelles but suggested the possibility of a dimer with weak binding affinity
because replacing IR-TMD with a strong dimer-forming TMD of glycophorin A [233] inhibits in-
sulin signaling [213]. For IGF1R-TMD, Kavran et al.’s work [218] has suggested that IGF1R-TMD
can form stable dimers by associating near kink-inducing residue Pro941 such that His935 residues
in helices can interact with each other and the solvent. The conformations of helices reported in
this dimer are consistent with my IGF1R-TMD structural models. Importantly, Cabail et al. [226]
have provided crystallographic, biochemical, and biophysical evidence showing that the phospho-
rylated kinase domains of IR and IGF1R dimerize through exchanged juxtamembrane regions, but
∼20 residues of unknown structure in the N-terminus of the juxtamembrane sequence preclude
conclusive support for dimerized or dissociated transmembrane helices. While I have not directly
studied the dimerization of IR-TMD or IGF1R-TMD in this work, the C-terminal sequences in my
51-residue long peptides include several residues from the N-terminal juxtamembrane regions of
receptors (10 residues of IR and 9 residues for IGF1R). As described above, in both receptors these
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residues are significantly exposed to the solvent, but adopt distinct conformations (in IR-TMD, com-
pletely unstructured and flexible conformations are observed as opposed to IGF1R-TMD, where
these residues participate in an α-helix). I speculate that these conformational differences could
contribute to different structural organization of kinase domains in the basal or activated states of
receptors.
4.6 Conclusions
Using MD simulations combined with enhanced sampling algorithms, I have presented all-atom
structural models of IR-TMD and IGF1R-TMD in explicit membrane and solvent environments. I
found intact α-helical conformations for the membrane-embedded residues of each peptide with a
larger tilt-angle (relative to the membrane-normal) in IGF1R-TMD in comparison to IR-TMD. I
also observe kinks in membrane-spanning helices at Pro961 (IR) and Pro941 (IGF1R). The major
differences in peptide conformations are in the terminal sequences where a kinked α-helix is observed
for the N-terminus of IR-TMD as opposed to unfolded conformations in IGF1R, and an α-helix
is observed in the C-terminus of IGF1R-TMD as opposed to unfolded conformations in IR-TMD.
These differences in conformations lead to increased solvation of the N-terminal residues in IGF1R-
TMD in comparison to IR-TMD, but similar solvation patterns are observed in the C-terminal
residues containing an “Arg-Lys-Arg” motif.
79
Chapter 5
STUDIES ON DIMERIZATION OF
IR TMDs
5.1 Introduction
In chapter 4, I described studies on isolated TMDs of IR and IGF1R. The studies described
in this chapter are aimed at understanding the dimerization propensity of TMDs by taking IR-
TMDs as a model system. The main hypothesis is motivated by the conflicting experimental
evidence suggesting that IR-TMDs are pre-dimerized in apo-IR, an observation contrary to the
only known structural data on the IR-ectodomain (PDB code 4ZXB; see Figure 5.1) that shows
a dramatic separation of the membrane-proximal domains by ∼100 A˚ as well as the evidence of
primarily monomeric states of isolated IR-TMDs in Dodecyl-phosphocholine (DPC) micelles [227].
To understand the likelihood of dimerization of IR-TMDs, I designed three different constructs
that were studied in a lipid bilayer environment: (1) isolated TMDs, (2) TMDs anchored to the
ectodomain, and (3) TMDs anchored to the kinase domains (see Figure 1.5).
5.2 Methods
All MD trajectories were generated with Anton [107], a special-purpose supercomputer, using
the TIP3P water model and the CHARMM force-field with the CMAP correction [177, 178]. VMD
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was used for system creation, protein rendering, and analyses [180]. All simulations were carried
out in the NPT ensemble using the Langevin thermostat at 310 K and the Nose´-Hoover barostat.
Figure 5.1: This figure is adopted from the article [174]. It shows the reorganization
of the full-length IR on ligand binding (A), and (B) the architecture of the full-length
IR created by combining known crystal structures of the IR-ectodomain and the
kinase domain, whereas dashed lines indicate the missing juxtamembrane residues.
Construct 1: I used the solution NMR structure of the IR-TMD in micelles (PDB: 2MFR)
as a starting structure for MD simulations. I modeled 51 residues for IR (939−PTYFYVTDYLD
VPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPL−988) that included the predicted TMD
sequence (underlined; 957-979 for IR). Sequence numbering is based upon protein knowledge-base
accession numbers P06213.1 I used CHARMM-GUI2 web-based interface to generate a palmitoy-
loleoylphosphatidylcholine (POPC) membrane patch of ∼100 A˚ × 100 A˚. Two replicates of the
TMD peptide were then embedded in the POPC bilayer, and were placed 50 A˚ apart by aligning
the center of mass and the principal axis of each helix along the z-direction. Thereafter, overlapping
lipid molecules within 2 A˚ of each TMD peptide were deleted. The system was solvated with ∼20750




was then equilibrated in four consecutive steps. In the first step, initially a conjugate-gradient min-
imization was carried out for 1000 cycles which was followed by a short MD equilibration (0.5 ns
long with a 2-fs time step) by keeping all atoms fixed except those in lipid tails. In the second step,
MD equilibration was continued for 1 ns in the NPT ensemble by fixing only peptide atoms. In the
third step, no atoms were fixed or constrained in a 10 ns MD equilibration in the NPT ensemble.
In the fourth step, the final atomic coordinates after the equilibration in the third step were used
to setup the MD simulation of IR TMDs in lipids using Anton, as described in the section 2.6.3,
for 3 µs.
Construct 2: In this construct, TMDs are anchored to the IR ectodomain. I used the crystal
structure of the IR ectodomain by Croll et al. [155]. This model contains the atomic coordinates
of the IR homodimer, and modeled coordinates of residues that were omitted from the corre-
sponding crystal structure (PDB: 4ZXB). The principal axis for two replicates of TMDs were
aligned along the z-direction, separated, and anchored to the C-terminal fibronectin domains of
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VAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDE
ELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIA
KIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLG−988). Note that the modeled structure is the
IR isoform A which has 12 resides less than the isoform B. The residues 719 to 747 were missing
in the crystal structure and I used MODELLER to refine coordinates for those residues. I used
CHARMM-GUI web-based graphical user interface to generate a 85% POPC/15% 1-palmitoyl-2-
oleoyl-glycero-3-phosphoserine (POPS) membrane patch of ∼180 A˚ × 180 A˚. The lipid composi-
tion was chosen to be consistent with anionic lipids in the mammalian plasma membrane [234].
Thereafter, overlapping lipid molecules within 2 A˚ of TMDs were deleted. The system was sol-
vated with ∼158000 water molecules, neutralized with NaCl, and brought to an ionic strength of
0.15 M. The system was then equilibrated in four consecutive steps. In the first step, initially a
conjugate-gradient minimization was carried out for 1000 cycles which was followed by a short MD
equilibration (0.5 ns long with a 2-fs time step) by keeping all atoms fixed except those in lipid tails.
In the second step, MD equilibration was continued for 1 ns in the NPT ensemble by fixing only
peptide atoms. In the third step, no atoms were fixed or constrained in a 10 ns MD equilibration
in the NPT ensemble. In the fourth step, the final atomic coordinates after the equilibration in
the third step were used to setup an MD simulation of this construct using Anton, as described in
section 2.6.3, for 2 µs.
Construct 3: I used the most recent crystal structure of the activated IR kinase dimer
(PDB: 4XLV) and retained Mg+2 ion, the Phosphomethylphosphonic-acid Adenylate Ester (ACP)
molecule, and water molecules from the crystal structure for carrying out simulations. The prin-
cipal axis for the whole kinase domain was aligned along the z-direction and the membrane and
TMD (residue numbers: 939 to 989) regions in this construct were used to build a system of both
TMDs anchored to the kinase dimer. The juxtamembrane regions (residue numbers 988 to 1002)
were missing in the crystal structure and I used MOELLER to refine coordinates for those residues.
Each TMD-kinase domain in this dimeric construct totally contained 372 residues: (939−PTYF
YVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFP






SEENK−1310). I used the CHARMM-GUI web-based graphical user interface to generate a 85%
POPC/15% POPS membrane patch of ∼160 A˚ × 160 A˚. The system was solvated with ∼103000
water molecules, neutralized with NaCl, and brought to an ionic strength of 0.15 M. The system
was then equilibrated in four consecutive steps, as described for constructs 1 and 2. The final
atomic coordinates after the equilibration in the third step were used to setup an MD simulation
of this construct in a lipid environment using Anton for 3 µs.
5.3 Results and Discussion
I used two metrics for TMDs to characterize the relative orientation and the position of each
TMD in the lipid membrane. The first metric was distances between the C-terminal residues (976
to 979), the N-terminal residues (957 to 960) and the central residues (966 to 969) of each TMD.
For example, to calculate the N-terminal distances between two TMDs, the center of mass of four
residues in N-terminus (IIIG) was calculated and the length of connecting vector of the two centers
of masses was computed. The second metric was the deviation angle of the principal axis of each
TMD (IIIGPLIFVFLFSVVIGSIYLFL, 957-979) with respect to the membrane normal. These two
metrics for construct 1 are shown in Figures 5.2 and 5.3.
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Figure 5.2: Distances of three parts of TMDs during the MD simulation of construct
1.
Figure 5.3: Deviation angle of each with respect to the membrane normal is shown
for construct 1.
As we see from distance traces in the Figure 5.2, two TMDs were parallel to each other at
the beginning of the simulation. The N-termini of TMDs approach each other in the first µs and
remain close to each other until 2 µs, while the C-termini and the central regions remain separated.
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However, in the final 1 µs of this MD simulation, I observe that the distances between the N-
terminal, C-terminal, and the central regions of TMDs converge due to fluctuations in their tilt
angles with respect to the membrane normal, that are shown in Figure 5.3. Figure 5.4 shows three
snapshots at t= 0, 0.5 and 2.5 µs that correspond to three observable regions in Figure 5.2.
Figure 5.4: Snapshots of TMD interactions.
Figure 5.5: Distances between TMD motifs are shown for construct 2.
The distances between TMDs in construct 2 where they are connected to the ectodomain vary
between 120 to 40 A˚ (Figure 5.5), and all three distances show relatively similar values. The
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corresponding angle traces are shown in Figure 5.6 which show that each TMD adopted a different
tilt angle (∼50◦ and ∼30◦).
Figure 5.6: Deviation angle of each with respect to the membrane normal is shown
for construct 2.
Figure 5.7: Distances between TMD motifs are shown for construct 3.
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Figure 5.8: Deviation angle of each with respect to the membrane normal is shown
for construct 3.
Figure 5.7 shows an overall decrease in distances between the terminal and central motifs in each
TMD for the first 2 µs of simulation, but the N-terminal regions move away and the C-terminal
regions move closer in the final 1 µs of simulation. The tilt angles fluctuate around ∼40◦±10.
Although the C-terminal regions of TMDs are anchored to kinase domains, the flexibility is provided
by the juxtamembrane regions that do not fold into a specific tertiary structure and remain unfolded
and flexible during the simulation.
5.4 Conclusion
Overall, these preliminary data show that in the membrane environment, IR TMDs can po-
tentially dimerize in isolated and kinase-anchored states (constructs 1 and 3), but not in the
ectodomain-anchored state (construct 2). This means for the full-length receptor, significant con-
formational changes have to occur in the ectodomain to facilitate dimerization of TMDs, as I did
not observe any dimerization of TMDs in construct 2 although distances between TMD motifs can
decrease from 120 A˚ to 40 A˚. This hypothesis needs to be investigated in future studies.
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Chapter 6
STUDIES ON DYNAMICS IN
APO-RGS PROTEINS
6.1 Abstract
Although many homologous proteins have highly conserved structural motifs as well as overall
structural folds, the functional characteristics of such proteins are strikingly different in solution,
indicating a role of dynamic motions. The differences in dynamics of closely-related proteins present
significant hurdles for structure-based design of small molecules targeting such proteins. In this
chapter, I describe studies of the interplay of protein dynamics and small-molecule inhibition in a
set of signaling proteins, known as Regulators of G-protein Signaling (RGS) proteins, that modulate
signaling in G-protein coupled receptors by binding to active Gα-subunits of heterotrimeric G pro-
teins and accelerating hydrolysis of Guanosine Triphosphate (GTP), thereby terminating activity.
While structures of several known RGS proteins largely contain α-helical motifs, some Thiadia-
zolidinone (TDZD) compounds that inhibit the RGS-Gα interaction by covalent modification of
cysteine residues have shown different levels of specificities and potencies for closely related RGS
proteins, thereby indicating intrinsic differences in their dynamics. However, key cysteines in RGS
proteins inhibited by TDZDs are not exposed on the protein surface. I hypothesize that transient
allosteric binding pockets expose cysteine residues differentially between RGS protein isoforms. I
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have characterized such differences in three different apo RGS proteins (RGS4, RGS8, and RGS19)
using microsecond-scale classical MD simulations with CHARMM and AMBER force-fields. Anal-
yses of these trajectories reveal high fluctuations in α5 and α6 helices and in the loops connecting
them that facilitate differential mechanisms of transient exposure of deeply buried cysteine residues
to allosteric inhibitors. Hydrogen-deuterium Exchange (HDX) studies were used to probe the dy-
namics of RGS4, RGS8, and RGS19, three RGS proteins inhibited at a range of potencies by
TDZDs. HDX experiment revealed differences in α6 helix flexibility among RGS isoforms, which
could cause differences in cysteine exposure and lead to differences in potency of TDZD inhibition.
I further validated MD simulation findings using HDX-Mass Spectrometry (MS) analysis of all
three proteins and provide details on exchange rates for hydrogen atoms at the resolution of single
residues.
6.2 Introduction
Protein-protein interactions (PPIs) remain a poorly tapped pool of potential targets for small-
molecule inhibitors. Targeting PPIs has been challenging because many protein-protein interfaces
are flat and lack a dedicated small-molecule binding pocket [235–237]. However, it may be possible
to interrupt PPIs by binding to transiently exposed pockets [238, 239] either at the protein-protein
interface [240] or at allosteric sites [241, 242]. Targeting of allosteric sites, as they are less evolution-
arily conserved, may confer better specificity than directly targeting interfaces [243]. In addition,
there may be a variation in dynamic exposure of allosteric pockets among members of a protein fam-
ily. Such differences in protein dynamics could drive inhibitor specificity [244]. G-protein signaling
is critical in pharmacology. Approximately ∼30% of marketed drugs target GPCRs, and more tar-
get related pathways [245]. RGS proteins control GPCR signaling by binding to active, GTP-bound
Gα subunits and accelerating GTP hydrolysis. This terminates G-protein signaling. By inhibiting
an RGS protein, signaling through a GPCR may be amplified. The Neubig lab, our collaborator
at the Michigan State University, previously identified thiadiazolidinone (TDZD) inhibitors of the
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RGS-Gα interaction in a high-throughput screen [246]. They allosterically inhibit RGS proteins by
covalent modification of cysteine residues at sites distant from the RGS-Gα interface. The TDZD
inhibitor CCG-50014 is most potent against RGS4, followed by RGS19 and distantly by RGS8
[247]. RGS4 inhibitors may be valuable as therapeutics for Parkinson’s disease. RGS4 is highly
expressed in the striatum [248, 249] where it regulates synaptic plasticity in response to dopamine
signaling [250, 251]. A TDZD inhibitor with enhanced specificity for RGS4, CCG-203769, reduces
brady-kinesia in a raclopride model of certain Parkinson’s-like motor deficits in mice [252]. The
RGS homology domain, which is responsible for the GTP-ase accelerating activity of RGS proteins,
is a 120-amino acid domain consisting of nine α-helices. Differences in TDZD potency may be due
to different locations or numbers of cysteines among RGS isoforms, or due to differential transient
cysteine exposure. RGS4, RGS8, and RGS19 all share an α4 helix cysteine, while RGS4 and RGS8
share one on the α6-α7 interhelical loop (Figure 6.1). Notably, these cysteines are buried beneath
the protein surface in crystal structures [253, 254]. Therefore, it may be necessary for dynamic
pockets to open to expose these cysteines for TDZD interaction. Understanding of dynamic pock-
ets will be beneficial, as such a pocket may be exploited in rational design of novel non-covalent
inhibitors using a docking based virtual screen. Vashisth et al. previously showed that the α5-α6
helical pair is flexible using enhanced sampling MD simulations and NMR experiments [58]. Co-
valent modification by TDZD inhibitors could lock the α5-α6 interhelical loop in a position that
prevents RGS interaction with Gα proteins. I hypothesize that differential transient exposure of
buried cysteine residues drives TDZD selectivity. Here, I used HDX-MS and long time-scale clas-
sical unbiased MD studies to examine differences in dynamics between RGS4, RGS8, and RGS19.
HDX-MS and MD studies make a powerful combined experimental and computational approach
for evaluating protein dynamics [255, 256].
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Figure 6.1: Cartoon representation of three RGS proteins, A. RGS4 which includes
4 cysteine residues (PDB: 1AGR, Method: X-ray diffraction), B. RGS8 has 2 cysteine
residues (PDB: 2ODE, Method: X-ray diffraction), C. RGS19 has only one cysteine
residue (PDB: 1CMZ, Method: solution NMR).
6.2.1 Importance of Studying RGS Proteins
According to major regulatory health agencies in US, depression, the most common mental
disorder in US, Parkinson’s and Alzheimer’s disease, common causes for losing cognitive functioning,
have engaged tens of millions of adults [7]. The costs of caring for a patient with Alzheimer’s
disease, for example, is very costly for Medicare, insurances, government and Americans families.
The number of Americans who reach 80s and beyond is growing dramatically because of advances
in technology, social welfare, and more importantly, baby boom generation who turned 60s in 2016
[257]. In these ages the risk for Alzheimer’s and other dementias is elevated substantially. The
number of people who will have Alzheimer’s dementia in 2030 and 2050 are 35 and 110 percent more
than in 2010 respectively which will substantially increase the cost of care [258]. These statistical
predictions and numbers urge comprehensive investigations for remedies to cure cognitive diseases
specifically Alzheimer’s and Parkinson’s disease. These diseases are linked to proteins that have a
role in transduction of signals from the outside to inside of cells and across the cellular membrane,
a fatty lipid-based envelope holding cells together which are described in Sec. 6.2.2.
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6.2.2 Physiological Roles of RGS Proteins
The complex signaling process starts with the binding of a small molecule, named as a lig-
and, to a membrane-embedded protein called a receptor through which the information is con-
veyed to intracellular machinery. This signal transduction process is the basic biological process
of converting extracellular information into intracellular functions. Pharmaceutical industry de-
ploys chemical molecules to intervene in signal transduction particularly at the extracellular part
which mostly target a GPCR. GPCRs are one of the most important receptor families in cells.
Heterotrimeric guanine-nucleotide-binding proteins (G proteins) are important intermediaries for
signal-transduction pathways to the intracellular portion of a cell. The signaling of GPCRs is
regulated through a cell by a group of proteins know as Regulator of G-protein Signaling (RGS)
proteins, which terminate G-protein signaling activity by binding to the Gα subunit and acceler-
ating hydrolysis of bound GTP [34]. As one can see in the Figure 6.2 the binding of agonists1
to GPCRs enhances the activity of a protein called Guanine Nucleotide-exchange Factor (GEF).
GEFs is a group of proteins that activate monomeric GTPases by dissociation of GTPases from
Guanosine Diphosphate (GDP) and consequently binding to (GTP) [259]. GEF leads to constant
ratio of inactive to active G protein [260]. Conformational changes of Gα and dissociation of the
Gα-Gβγ complex allows each subunit to propagate signals though cells. Signaling through the cell
is continued for a long time if there is no inhibition for the process. However, RGS protein, at this
stage, forms a barrier for GPCR signaling by catalyzing reassociation of Gα-Gβ. RGS proteins
form a complex with Gα.GTP (Figure 6.3) and enhance the rate of GTP hydrolysis to GDP by
the G-protein α-subunit, which leads to Gα-Gβγ reassociation and completes the GPCR activa-
tion cycle. With considering the role of RGS proteins in negative regulation of G-proteins, one
can think of a strategy for prolonged dissociated G-protein subunits in cell which causes enhanced
receptor-stimulated responses. Inhibiting the binding of the RGS protein to Gα.GTP is the key
for this strategy.
1An agonist is a chemical substance that binds to a receptor and activates the receptor to transduce biological
signals into a cell.
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There are 20 human RGS proteins. Results from several research groups show that these RGS
proteins differ in targeting Gα substrate and also in their tissue expression profiles. However,
experiments have revealed that the messenger RNAs of many RGS proteins are present in neuronal
tissues. For example, RGS4 proteins are expressed in the central nervous system regions such as
cortex, amygdala, and thalamus [34]. All RGS proteins have a conserved 120-amino acid sequence
in their RGS domains [37]. RGS8 accelerates GPCR downstream signals in addition to negative
regulation of G-proteins which is crucial for rapid regulation of neuronal excitability [35]. In vitro
and in vivo experiments show that RGS19 influenced cardiac development [36].
Figure 6.2: The whole process of GPCR signaling. This picture illustrates how an
RGS protein changes the processes through a cell. This process begins with a ligand
(step 1) and causes cascade phenomena and signaling through the cell (step 2 to 5).
RGS protein terminates G protein signaling by accelerating hydrolysis of GTP to
GDP and reassociation of G protein subunits (step 6 to 8).
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Figure 6.3: Gα.GDP.AlF 4 and RGS Complex, Gray: Gα, blue: GDP, red: RGS,
(PDB: 1AGR). This cartoon shows the relative position of RGS protein and Gα
protein when they are interacting.
Figure 6.4: (A) General structure of TDZD compounds, (B) Structure of the lead
compound, CCG50014.
In particular, targeting of RGS4 may be therapeutically beneficial in treatment of Parkinson’s
disease. TDZDs are a series of compounds that inhibit RGS4, RGS8, and RGS19 by covalent
modification of cysteine residues (Figure 6.4). However, cysteines in the crystal structures of RGS
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proteins (RGS4, RGS8, RGS19) which are shared by inhibited RGS proteins are not exposed to
the protein surface so the cysteines are not accessible to inhibitors for covalent modification. The
questions I was trying to address using MD simulations in this chapter are: Do RGS proteins evolve
conformationally to the extent that the common buried cysteine is exposed to the solvent? If the
common cysteine remained buried, what is the mechanism of inhibition by TDZDs? Do three RGS
protein isoforms show the same mechanism of cysteine exposure? What does the binding pocket
in RGS proteins look like? How long lived are the transient binding pockets?
6.2.3 Molecular Dynamics as a Tool for Studies of RGS Protein Dynamics
RGS proteins are excellent model systems for studying their molecular scale dynamics because
(i) their functional role in negative regulation of GPCR proteins is well established, (ii) the ex-
perimental structure of RGS proteins (specifically RGS4, RGS8, and RGS19) in apo forms have
been resolved using crystallographic or NMR techniques (Figure 6.1), and (iii) they are amenable
to inhibition by small molecules such as TDZD analogue compounds through cysteine covalent
modification.
In this chapter, the proposed theoretical framework for studies included the development and
application of classical MD methods in combination with thermodynamic calculations on all-atom
models of three RGS proteins (RGS4, RGS8, and RGS19). These three were chosen because
they represent a range of potencies of inhibition by the TDZD inhibitors discovered in the Neubig
lab [261–263] and analysis of their dynamics should help define the inhibitory mechanism (Figure 6.4
represents general structure of TDZD compounds and their lead inhibitor structure). RGS4 and
RGS19 are inhibited in a relatively potent manner (∼30 and ∼150 nM, respectively) by CCG-50014.
In contrast, RGS8 is much less potently inhibited (11 µM). The experimental work that Vince
Shaw in Neubig lab has conducted including performing HDX experiments and measuring melting
temperatures of these three RGS proteins along with my computational work on RGS proteins
including MD simulations of RGS proteins, and modeling of HDX data using MD simulations to
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not only reveal dynamics in RGS protein but also provide mechanistic explanations for the binding
of inhibitory compounds.
6.3 Materials and Methods
6.3.1 MD Simulations of RGS Proteins
System setup and simulation details: Computations were performed on Trillian, a Cray
XE6m-200 Supercomputer and using Premise, an in-house GPU based cluster. In addition, this
work used the Extreme Science and Engineering Discovery Environment (XSEDE) [264]. I carried
out all MD simulation trajectories and their analyses using the NAMD/VMD software suite [62,
63], and the CHARMM force-field with the CMAP correction [84, 265]. The initial coordinates
for RGS4, RGS8, and RGS19, respectively, were taken from the protein data bank entries 1AGR,
1EZT, 2IHD, 2ODE, and 1CMZ. Each protein was initially modeled using the psfgen tool in VMD,
and then further solvated in a simulation box (∼65 A˚ × ∼70 A˚ × ∼65 A˚) of TIP3P water molecules
and charge-neutralized with NaCl. The final solvated and ionized simulation domains contained
28160 atoms (RGS4), 30731 atoms (RGS4), and 29560 atoms (RGS19), respectively. The box
volume was then optimized in the NPT ensemble by initially applying 500 cycles of a conjugate-
gradient minimization scheme followed by a short 40-ps MD run with a 2-fs time step in which
the temperature was controlled using the Langevin thermostat and the pressure was controlled by
the Nose-Hoover barostat. I carried out all simulations using periodic boundary conditions. These
briefly equilibrated systems of all RGS proteins were further subjected to long time-scale (2 µs for
each protein) MD simulations in the NVT ensemble.
RMSD, RMSF, and SASA measurements: I carried out the analyses on per-residue RMSF
and RMSD, as reported in Figures 6.7, 6.8, and 6.9, by aligning each frame of MD trajectories to
the initial frame based upon all Cα atoms of each protein. The SASA of sulfur atoms in cysteines
(Figure 6.10, 6.11) were calculated using a probe radius of 1.4 A˚.
6.3. Materials and Methods 97
6.3.2 Protocols of HDX Experiments
Protein expression and purification: N-terminally truncated (∆51) rat RGS4 with 6xHis
tag in pET23d vector, RGS homology domain of human RGS8 (42-173) with 6xHis tag in pQE80
vector, and RGS homology domain of human RGS19 (89-206) with 6xHis tag in pET15b vector
were individually transformed into BL21(DE3) E. coli. Protein expression was induced by addi-
tion of 200 µM IPTG. Expression was carried out overnight at 25◦C and cells were harvested by
centrifugation. Pellets were resuspended in 50 mM HEPES 100 mM NaCl pH 7.4 and lysed by
sonication. Lysate was centrifged, supernatants were applied to nickel affinity column, and protein
was eluted with 300 mM imidazole. RGS4 was further purified by SP sepharose column. Column
was equilibrated with 50 mM Na Acetate, 40 mM NaCl, 1 mM DTT, 1 mM EDTA, and 1mM
EGTA (pH 5.5) and protein eluted by linear gradient to buffer including 1M NaCl. RGS8 and
RGS19 were purifed by Q sepharose column. Column was equilibrated with 20 mM NaCl, 50 mM
Tris, and 1 mM DTT (pH 8.0), and protein eluted with linear gradient to buffer including 1M
NaCl.
Hydrogen/deuterium exchange: HDX-MS was performed as essentially as described in Cho-
davarapu et al. [266]. Proteins were incubated on ice for desired time in 90% D2O containing 100
mM NaCl and 5 mM HEPES, pH 7.4. All columns and valves were kept on ice to reduce back
exchange. Exchange was quenched by 1:1 addition of ice cold 1% (v/v) formic acid in H2O, bring-
ing the pH to 2.5. 100 µl samples were immediately loaded at 0.1 ml/min, using external pump
(LC-20AD; Shimadzu), to an Enzymate pepsin column (2.1 x 30 mm, Waters) equilibrated with
cold 0.1% formic acid in H2O. After 1 min, the pump was stopped and proteins were digested
on-column for 1 min. Following digestion, the resulting peptides were eluted at 0.5 ml/min onto an
Xbridge BEH C18 VanGuard trap column (2.1 x 5 mm, Waters). The peptides were then eluted
from the trap column by valve switching of liquid flow, using a Waters 2777c autosampler, onto
an Ascentis Express Peptide ES-C18 column (2.1 x 50 mm, Supelco). Flow through the 2777c
autosampler valve and the Peptide ES-C18 column was controlled by a Waters Acquity Binary
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Solvent Manager. The peptides were initially washed for 1 min at 0.3 ml/min with 99% solvent
A (0.1% formic acid in H2O) and 1% solvent B (acetonitrile). Peptides were then separated by
elution with a gradient from 1% B to 30% B at 3 min, then to 99% B at 6 min and held at 99% for
1 min. Eluted peptides were analyzed using a Xevo G2-XS QToF mass spectrometer (Waters) by
electrospray ionization operating in positive-ion mode. Mass spectra were acquired in continuum
mode over m/z 100-2000. Deuterium incorporation was determined by the increase in centroid mass
of each peptide’s isotope distribution compared to undeuterated control. Data were analyzed using
Microsoft Excel, HX Express,[267] and Graphpad Prism software. The RGS protein expression
and experimental HDX studies were performed by Vincent Shaw, Department of Pharmacology
and Toxicology, Michigan State University, East Lansing, MI.
6.4 Results
We performed HDX-MS to compare solvent exposure kinetics of RGS4, RGS8, and RGS19
apo-proteins. These RGS protein isoforms represent a range of potencies of inhibition by TDZD
inhibitors (RGS4>RGS19>>RGS8). I hypothesized that all proteins exhibited EX2 kinetics, in
which hydrogen exchange occurs at a much slower rate than the frequency of partial unfolding events
[268]. Thus, deuterium incorporation can be observed on slow time scales, and be representative of
the total time spent in short-lived alternate conformational states. The α4 helix contains the only
cysteine shared by all three proteins. Fragments of the same length and position were observed
in the α4 helix of RGS4 and RGS8. The cysteine-containing fragment from α4 (residues 92-97)
in RGS4 shows significantly higher exchange than that from RGS8 (residues 86-91). After a 1000
minute incubation in D2O, the 92-97 fragment of RGS4 had 35% deuterium incorporation, while
the analogous fragment in RGS8 had only 8% deuterium incorporation. Surprisingly, RGS19 had
much faster exchange than RGS4 or RGS8 in the α4 helix. It reached 48% deuterium incorporation
by only 100 minutes, while RGS4 and RGS8 had 9% and 1% respectively (Figure 6.5 B).
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Figure 6.5: (A) Locations of cysteines in RGS4, RGS8, and RGS19. (B-F) Kinetics
of deuterium exchange in selected protein fragments from (A) α4, (B) α5, (C) α5-α6
interhelical region, (D) α6 and (E) α7. Sequences of observed fragments are aligned
and residue numbers of each fragment indicated. n=3. Data provided by Vincent
Shaw.
A similar trend was observed in the α5 helix. RGS8 had the least exchange after 1000 minutes
100 Chapter 6. STUDIES ON DYNAMICS IN APO-RGS PROTEINS
(24% deuterium incorporation), followed by RGS4 and RGS19 (38% and 49% deuterium incorpora-
tion, respectively, (Figure 6.5 C). One pattern consistent among all three isoforms is high exchange
in the α5-α6 interhelical loop, indicating that RGS proteins are flexible in this region. Those
fragments in all three proteins exceeded 50% deuterium incorporation by 100 minutes (Figure 6.5
D). This was not surprising, as the α5-α6 loop is the longest unstructured region within the RGS
domain. In the α6 helix, RGS19 again had higher exchange than RGS8 and RGS4. RGS8 was par-
ticularly protected in the residue 126-136 fragment, reaching only 7% deuterium incorporation after
1000 minutes. However, higher exchange was observed in the residue 130-140 fragment of RGS8,
likely because this fragment also contains residues that are a part of the α6-α7 loop (Figure 6.5 E).
A similar effect was seen in RGS4 near the α7 helix, in which a fragment wholly within α7 (residues
150-159) had much slower exchange than a fragment partially overlapping the α6-α7 loop (residues
143-151) (Figure 6.5 F). According to these results, RGS8 had low deuterium exchange relative to
other RGS proteins throughout the helices surrounding its cysteines. This is indicative of rigidity
of these helices in RGS8, which likely prevents exposure of cysteines to solvent. This observation
may also explain the low potency of TDZDs against RGS8 relative to other RGS isoforms.
The α6 helix of RGS4 has more deuterium exchange than the α4, α5, and α7 helices (Figure
6.6 A and B). Rapid exchange in the α6 helix may be due to movement away from neighboring
helices or unfolding of the helix itself. Such a movement could increase solvent exposure of the
otherwise buried cysteine 148 on the α6-α7 loop. This would allow access by TDZD inhibitors.
Because the higher exchange on α6 compared to other nearby helices is unique to RGS4, this
potentially explains the increased potency of TDZDs against RGS4 versus RGS8. In the α4, α5,
and α6 helices, RGS19 shows higher deuterium exchange than RGS4 or RGS8, indicating that
RGS19 is highly dynamic. For example, in a fragment of the α5 helix, RGS19 had 51% deuterium
incorporation after 30 minutes, while similar fragments in RGS4 and RGS8 had 15% and 17%
incorporation, respectively (Figure 6.6 B). Surprisingly, despite higher flexibility, RGS19 is not
more potently inhibited by TDZDs than RGS4. Notably, RGS19 lacks cysteines on the α6 helix
and α6-α7 loop which may contribute to potency of inhibition by TDZDs (Cys132 and Cys148 in
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RGS4). For RGS19, a more pronounced movement of the α4, α5, and α7 helices may be needed
to allow TDZDs to access its single cysteine on the α4 helix. To probe the molecular details
of dynamic motions in RGS4, RGS8, and RGS19 that underlie flexibility differences observed in
HDX-MS as well as possible routes of access to cysteines by TDZDs, I performed long time-scale
classical MD simulations in explicit-solvent (see Sec. 6.3.1). Previous short time-scale classical
MD simulations of RGS proteins did not show any major conformational changes; but enhanced
sampling simulations did show changes [58]. Here, I conducted microsecond time-scale classical
MD simulations, through which the flexibility in key helices became apparent. All three proteins
had regions of pronounced movement.
Figure 6.6: (A) Global kinetics of deuterium exchange. Deuterium incorporation
is expressed as a percent of exchangeable amide hydrogen positions. (B) Degree of
deuterium incorporation at 300 minutes in 90% D2O is mapped onto protein structure
of RGS4, RGS8, and RGS19. n=3 (This figure is provided by Vincent Shaw).
RGS4 showed unique motions within the α6 helix (Figure 6.7 A), while in RGS8 and RGS19,
movement was primarily within the α6-α7 interhelical loop (Figure 6.7 B and C). In RGS8 and
RGS19, pronounced movements also occurred in N- and C-terminal residues. This is likely an
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effect of free terminal ends; residues outside of the RGS homology domains were not included in
the simulations.
Figure 6.7: Root mean squared fluctuations across protein sequence during 2-µs
MD simulations of (A) RGS4 (PDB: 1AGR, 1EZT), (B) RGS8 (PDB: 2IHD, 2ODE),
and (C) RGS19 (PDB: 1CMZ). Color bars indicate helical regions.
Figure 6.8 shows the fluctuations of helices and the connecting loops surrounding the key
cysteine residues. The simulations with the CHARMM force-field show significant fluctuations
specifically within α6 in RGS4, and α6-α7 interhelical loop in both RGS8 and RGS19. However,
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simulation with the AMBER force-field show considerable movements within α4-α5 and α6-α7 in-
terhelical loop in RGS4, transient fluctuations within α4-α5 interhelical loop in RGS8, and α6 in
RGS19, and prolonged large deviation of α5-α6 interhelical loop in RGS19. Overall, simulations
with the CHARMM force-field reveal plausible exposure of buried cysteine residues compared to
the AMBER force-field.
Figure 6.8: Root mean squared deviation from the initial conformation during MD
simulations. RMSD of α4 helix (blue), α5 helix (gray), α6 helix (green), α7 helix
(yellow), α4-α5 loop (red), α5-α6 loop (cyan), and α6-α7 loop (purple) for (A) RGS4,
(B) RGS8, and (C) RGS19.
This can be observed in Figures 6.10 and 6.11. The conformations observed during movements
of the α6 helix and α6-α7 loop show distinct routes of cysteine exposure among three RGS pro-
teins. In the RGS4 crystal structure (PDB: 1AGR), Asn140 occludes Cys148 from exposure to the
104 Chapter 6. STUDIES ON DYNAMICS IN APO-RGS PROTEINS
protein surface (Figure 6.9 D). In the MD simulation using 1AGR as initial coordinates, a transient
movement of the α6 helix was observed, reaching a distance of 15.1 A˚ between α-carbons at 1.24
µs (Figure 6.9 G), versus 5.9 A˚ at baseline. This movement coincided with a high solvent exposure
of Cys 148, as measured by its SASA (Figure 6.11 A).
Figure 6.9: Conformational changes during MD simulations. Root mean squared
deviations of α6 helix and α6-α7 loop, starting conformation, and a snapshot confor-
mation during MD simulation are shown for (A, D, G) RGS4, (B, E, H) RGS8, and
(C, F, I) RGS19. Protein regions plotted in MD trajectories are depicted in color
in protein structures. Arrows indicate locations of notable solvent exposure during
simulation.
In MD simulations of RGS8 (using PDB code 2ODE as initial coordinates), helices α4, α5,
α6, and α7 were stable relative to the same helices in other proteins tested. However, the α6-α7
interhelical region, which includes cysteine 160, underwent a pronounced movement (Figure 6.9
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B). Cys160 rotated toward the protein surface at 1 µs, and remained exposed to solvent for the
remainder of the trajectory (Figure 6.9 H and 6.11 B). RGS19 lacks the cysteine in the α6-α7
interhelical loop, having only Cys123 on α4. MD simulation of RGS19 (starting with the PDB
code 1CMZ) revealed a movement of the α6-α7 interhelical loop away from the α4 and α5 helices,
resulting in an open groove in the protein surface (arrow in Figure 6.9 I). This observation likely
explains the higher observed deuterium incorporation of α4 and α5 helices in RGS19 compared to
RGS4 and RGS8, but additional changes, perhaps induced by compound binding, may be required
for full exposure of Cys123.
Figure 6.10: SASA of sulfur atoms are shown for shared cysteines on α4 helix over
2 µs trajectory in (A) RGS4, (B) RGS8, and (C) RGS19.
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The metrics of RMSD or RMSF do not distinguish transient exposure of cysteine in the α4
helix. However, SASA of sulfur atom, as a sensitive metric, shows very transient peaks for cys-α4
exposure in different RGS proteins, particularly in CHARMM force-field simulation (Figure 6.11).
The corresponding conformations for these peaks are shown in Figure 6.12 in which the sulfur atom
of cys-α4 is exposed from the notch between α4 and α7. In Figure 6.13, the structures of RGS
proteins at these time points are overlaid on the corresponding PDB structure to investigate the
mechanism of cys-α4 exposure. The rotation of the cysteine residue about the α4 axis is the major
cause of exposure, however a small opening of the notch between α4 and α7 helices is also playing
a role in solvent exposure of this cysteine.
Figure 6.11: SASA of sulfur atoms are shown for shared cysteines on α6-α7 inter-
helical loop over 2 µs trajectory in (A) RGS4, and (B) RGS8.
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Figure 6.12: Conformational changes during MD simulations expose Cys in the
α4 helix. The snapshot conformation during MD simulation are shown for (A.1
(PDB:1AGR) ,A.2 (PDB:1EZT) RGS4), (B.1 (PDB:2IHD), B.2 (PDB:2ODE) RGS8),
and (C (PDB:1CMZ) RGS19). The yellow spheres indicate the solvent exposure of
sulfur atom during simulation. The time under each snapshot corresponds to peaks
of SASA in Figure 6.10 (CHARMM force-field).
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Figure 6.13: Conformational changes during MD simulations (blue) are compared
with PDB structures (gray). The snapshot conformations that are presented in Fig-
ure 6.12 are overlaid on PDB structures here for (A.1 (PDB:1AGR), A.2 (PDB:1EZT)
RGS4), (B.1 (PDB:2IHD), B.2 (PDB:2ODE) RGS8), and (C (PDB:1CMZ) RGS19).
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6.5 Discussion
There was good concordance between regional protein flexibility in the HDX-MS studies and
in MD simulations. In RGS8, helices α4, α5, α6, and α7 were protected from deuterium exchange
and were also stable during MD simulations. The dramatic movement of the RGS4 α6 helix in
simulation mirrors its high solvent exposure in HDX studies. This suggests that the movement of
the α6 helix is likely responsible for solvent exposure of Cys148 in RGS4, providing a plausible
route of access by TDZD inhibitors. Indeed, cysteine 148 was the most important single cysteine
for inhibition of RGS4 by the other cys-linking inhibitor, CCG-4986 [269]. Deuterium exchange was
measured on a much longer time-scale than MD simulations. In order for an exchange to occur,
amide hydrogens must be in a conformation amenable to exchange, requiring both interruption
of H-bonds and proximity of solvent waters. These exchange-competent states are short lived,
often existing on a 10-100 picosecond timescale [256]. They are frequent enough to be readily
observed in microsecond timescale simulations; however, the rate of intrinsic hydrogen exchange is
much slower than the rate of hydrogen solvent exposure. This is termed EX2 kinetics, in which
an amide hydrogen may make multiple visits to a solvent-exposed state before an exchange event
occurs [268]. While exchange is still representative of the time spent in an open state, this allows
observation of exchange on much longer timescales than those of dynamic motions. Interestingly, the
structured basis of dynamic cysteine exposure varied among protein isoforms. In RGS4, movement
of helix 6 exposed the α6-α7 cysteine, while in RGS8, helix 6 was stable and that cysteine rotated
toward solvent during a movement of the α6-α7 loop. RGS19 lacks a cysteine on the α6-α7 loop,
but opens a cleft toward a deeply buried α4 helix cysteine. Despite sharing many of the same
cysteines, these results suggest that the route of modification by covalent inhibitors varies among
RGS isoforms. These differences in dynamic motions among RGS isoforms may contribute to
differences in potency of TDZD inhibition in two ways. First, differences in the rate of covalent
modification or the magnitude of effect on Gα binding may be driven by differences between RGS
isoforms in the direction of cysteine solvent exposure. Second, distinct transient conformations
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occurring more frequently in certain RGS isoforms may permit unique non-covalent docking to
drive covalent modification. In such a scenario, the open state may be taken advantage of in
a docking-based virtual screen, permitting the discovery of non-covalent RGS inhibitors. These
possibilities remain an object of future investigations.
6.6 Conclusion
The application of HDX-MS and MD methods reveals that RGS isoforms differ in their mech-
anism of transient cysteine exposure, suggesting distinct routes of access by covalent inhibitors.
These differences are potentially responsible for the selective potency of TDZD inhibitors among
RGS isoforms. Importantly, the conformations of RGS proteins in which cysteine residues are




HDX MODELING USING MD
SIMULATIONS
7.1 Abstract
In the previous chapter (chapter 6), HDX experiments were used to probe the dynamics of
RGS4, RGS8, and RGS19, three RGS proteins inhibited at a range of potencies by TDZDs. In
this chapter, I have studied different HDX models to predict HDX rates for three RGS protein
isoforms (RGS4, RGS8, and RGS19) using microsecond MD simulations with CHARMM and AM-
BER force-fields. HDX experiments were carried out at a fragment resolution for the RGS proteins
and were used to evaluate the accuracy of HDX models. To carry out HDX modeling and pre-
dict hydrogen deuterium incorporation by MD simulations, I used different published criteria and
models providing a comprehensive comparison of existing models. Furthermore, I developed new
HDX models with optimized parameters which had comparable accuracy and more computational
efficiency compared to other models. Even though the suggested novel models and one of the
preexisting models show strong correlations with the HDX experiment, the results show different
trends and values for distinct HDX models.
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7.2 Introduction
HDX is a chemical reaction where a covalently bonded hydrogen atom is exchanged with a
deuterium atom. In proteins, HDX refers to a process in which amide hydrogen atoms in the
backbone are replaced by deuterium atoms. HDX-MS has been widely used in the literature as
an excellent technique for understanding protein dynamics. The number of publications that use
HDX methods has been growing substantially during recent decades ago as shown in Figure 7.1.
Figure 7.1: The number of articles returned when searching for “Hydrogen deu-
terium exchange” in PUBMED.
This method was discovered by Linderstrom-Lang when he tried to understand detailed deuter-
ation of hormone insulin. He published his article in 1955 [270] in which he described that HDX
kinetics did not behave linearly and showed complexities in folded proteins. HDX has been used as
a tool for understanding of protein-protein interactions [271] as well as protein-ligand interactions
[272]. Furthermore, it has been used to reveal protein dynamics and folding which are challenging
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to study with NMR or X-Ray methods [273]. The fundamental concept of HDX is illustrated in
Figure 7.2. The protein (gray color) undergoes a conformational change by which some amide
hydrogens (red color) are exposed. This short period of time (I will show it is between 10 to 100 ps
for buried amide hydrogens) provides the necessary condition for an HDX reaction and the amide
hydrogens are immediately replaced by deuterium. This mechanism indicates that HDX is some-
how correlated with solvent accessibility of amide hydrogens therefore HDX provides an analytical
means for studying protein conformational dynamics.
Figure 7.2: Conformational change in the protein structure exposes amide hydro-
gens to D2O and leads to hydrogen-deuterium exchange
HDX is a unique method for understanding the structural dynamics and folding of proteins
because it provides residue-level resolution and insights about the protein structure, protein inter-
actions, folding and conformational dynamics [274–276]. Even though the HDX rate correlations
for unstructured small peptide chains were quantitatively established [277], in folded proteins, the
HDX rate is significantly reduced and hard to predict [278]. This complexity originates from: (i)
hydrogen atoms are unresolved in refined experimental protein structures, (ii) H-bonded structures
protect amide hydrogens from exchanging with deuterium [278], and (iii) transient fluctuations
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of local structure that are a determinant for the HDX rate [279, 280]. The major determinants
for HDX rates have been a controversial subject in the literature which has resulted in defining
different criteria, cutoffs, and metrics for precisely predicting HDX experimental data by HDX
modeling [281, 282]. HDX can be used to compare solvent exposure of distinct protein regions.
Flexible protein regions will undergo more frequent interruptions of secondary structure, allowing
more frequent solvent exposure of backbone amide hydrogens and faster incorporation of solvent
deuterium. In a particular case, I used HDX for studying RGS protein isoforms in chapter 6.
I hypothesized that RGS proteins would have high flexibility in the α4 − α7 helices, the region
containing the buried α4 and α7 cysteines. The Neubig lab has conducted HDX experiments to
compare regional deuterium incorporation over time in RGS4, RGS8, and RGS19, and the results
are given in Sec. 6.4.
To investigate and study HDX modeling, I used microsecond time-scale MD simulations for
three isoforms of RGS proteins (RGS4, RGS8, RGS19) using CHARMM and AMBER force-fields.
RGS isoforms (see Figure 7.3) are good candidates for this study because (i) RGS isoforms have
conserved spatial structures with nine α-helices and several connecting loops (Figure 7.3, panel
B), (ii) despite structural similarities, RGS isoforms lack many homologous sequences (Figure 7.3,
panel A), (iii) HDX experiments have been carried out for three RGS isoforms at the level of
peptide fragments, and (iv) all-atom MD simulations at a microsecond time-scale were done using
two different force-fields. Below, I present a brief literature review on important HDX models that
have been proposed in the past two decades. I used these models to quantify HDX rates for RGS
protein isoforms. I will present the accuracy and performance of these models for RGS protein
isoforms in the results section of this chapter.
1. Resing et al. [283] conducted early studies to predict HDX from protein structures by fitting
protection factors to an equation in the form of log(Pi) = log(kint/khdx) = u∗(SAi)+v/(HBi),
where khdx is the experimental exchange rate of an amide hydrogen, kint is the intrinsic













Figure 7.3: (A) Sequence alignment of RGS proteins, (B) Structural alignment of
crystal structure of RGS proteins (PDBs: 1AGR, 2ODE, 1CMZ).
hydrogen from the surface of protein in A˚, and HBi is the hydrogen-bond length of backbone
amide nitrogens to an acceptor. They used deuterium exchange rates measured by Milne et
al. [284] for horse heart cytochrome c.
2. Vendruscolo et al. [285] proposed a model for HDX based on the exploration of conformations
using Monte Carlo sampling biased by experimental data. They speculated that the protection
of amide hydrogens comes from the buried part of the amide group and also from the hydrogen
bonding in the secondary structure which resulted in a phenomenological expression including
the number of contacts of residue i with other residues (N ci ) and the number of hydrogen
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bonds formed by the amide hydrogens of residues (N hi ), respectively. According to their
definition, hydrogen bonds are present if the angle between the NH vector and the OH vector
is below 0.7 rad and the OH distance is below 2.4 A˚. Also, two residues are in contact if any
pair of their atoms are closer than 8.5 A˚.
3. Best et al. [286] used the same phenomenological approximation that Vendruscolo et al.
had proposed but with minor changes in definition of (N ci ) and (N hi ). The contribution
of burial in the model is the number of heavy atoms within a distance of 6.5 A˚ from the
amide nitrogen. A cutoff of 2.4 A˚ between the donor hydrogen and the acceptor was used for
identifying a hydrogen bond without an angle criterion. They optimized the parameters of
their model using experimental protection factors and the corresponding protection factors
from a 1 ns conventional MD simulation of seven different proteins. They acknowledge that
major protein fluctuations were elusive from short MD simulations. That motivated them to
conduct a biased simulation of basic pancreatic trypsin inhibitor by using hydrogen-exchange
restraints with varying values of the parameters.
4. Kieseritzky et al. [281] used MD simulations as a complement for hydrogen exchange experi-
ments. They simulated oxidized c-type cytochrome under native conditions (PDB code 1K3H)
with the CHARMM22 force-field using explicit water molecules modeled using the TIP3P wa-
ter model. The simulation was 3 ns long. They proposed different protection factors based
on a linear function of protection factors log(Pi) = log(kint/khdx) = β1PFE1 + β2PFE2 .
They optimized parameters β1 and β2 to arrive at an agreement between computed (based on
MD simulation data) and measured hydrogen exchange protection factors. The nine different
protection factor correlations in their paper show varieties of error and Pearson’s correlation
coefficient out of which PFE1= [the number of residues which are in contact with correspond-
ing residue] and PFE2=[the inverse of the backbone atom RMSF] show the least error and
the best correlation.
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5. A model was suggested by Ma et al. [287] where NH βi is the average number of hydrogen
bonds between the NH atom of residue i and C=O backbone oxygen within 2.6 A˚ distance,
and NH soli is the average number of hydrogen bonds between NH and water oxygen within
3.0 A˚ distance of residue i. In the original model, NH β is measured in β-sheets and the
correlation is moderate Pi = (NH soli + NH
β
i )/C.NH soli . They used CHARMM27 force-field to
do MD simulations of different β-sheet conformations, each of which was for 60 ns.
6. Park et al. [288] recently developed a novel model based on a comprehensive HDX-MS
experimental data using Amber 11 ff99SB force-field and a 100 ns long simulation. Their
logistics growth function HDX model consist of one fitting parameter called “base”. NHstati
is defined as ([the number of snapshots showing H-bonding of amide hydrogen to protein]-
[the number of snapshots showing H-bonding amide hydrogen to water ])/[the total number
of snapshots]. They provided three amide hydrogen bond models out of which model HB2 has
been compared with other models in their paper. I also deployed HB2 amide hydrogen bond
model in my RGS dynamics work in which H-bonding of amide hydrogen to the side-chain as
well as C=O group in the backbone are counted as H-bonding of amide hydrogen to protein.
The fraction of deuterium incorporation for each amide hydrogen was computed by the first
order reaction kinetics DIresi = 1− exp(−kint,it/Pi).
7. Persson et al. [256] used a significantly long MD simulation of protein BPTI (0.262 ms long)
implemented in Amber ff99SB-I/TIP4P-Ew force-field. They start with a description of the
standard model in which each amide can be exposed to solvent in an open state or buried
within the protein by a closed state and show that (N −H)c kc←→
ko
(N −H)o kint−→ (N −D)o in
which HDX rate is governed by khdx = kokint/(ko+kc+kint). The assumption of kint  kc+ko,
which is an applicable assumption for HDX experiments, results in a simple and practical
phenomenological model khdx = kint/(P + 1). The protection factor here is the key for the
calculation of hydrogen-deuterium exchange rate and it is defined as the ratio of residence time
in the closed state to residence time in the open-state which is applicable to MD simulations.
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The criteria for the open state and the closed state play an important role in computing
protection factors. They speculate that direct access to external solvent and disruption of
any intramolecular H-bond with the N-H group are key factors in defining the open-state. A
residue is in an open state when the amide hydrogen has at least two water oxygens within
2.6 A˚ and that the amide hydrogen has no other polar protein atom (except in neighboring
residues) within 2.6 A˚.
7.3 Materials and Methods
The reader is referred to the methods section of the previous chapter (Sec. 6.3.1 and Sec 6.3.2)
for MD simulation methods and the HDX experimental protocols for RGS proteins which are used in
this chapter to carry out HDX modeling. To study HDX modeling, I used all-atom MD simulations
for three RGS protein isoforms that were performed with five different protein structures using the
two widely used force-fields (CHARMM and AMBER) and explicit water molecules on a time-scale
of 2 µs. The HDX experiments were carried out at 273 K (Sec. 6.3.2) which differs from the
MD simulation temperature. The temperature setting in MD simulations was 310 K to mimic
biological conditions and study folded states of RGS proteins. Even with this discrepancy, it is
possible to deploy MD simulations for HDX modeling since variation of the temperature does not
change deuterium incorporation results significantly [281]. In all models, the intrinsic HDX kinetic
rates are calculated at 273 K to comply with HDX experiments.
To predict HDX experimental rates using MD simulations, the first step is to model the HDX
process mathematically and understand its mechanism. More than ten computational models for
HDX exist in the literature which differ in criteria and definitions of the mechanism. I have used
the most recent HDX modeling (seven models) as well as developing two novel models based on the
SASA and the hydrogen bonds in amide hydrogens. A summary of all MD simulations for RGS
proteins is listed in Table 7.1 which shows 10 different simulations of apo-RGS proteins using both
CHARMM and AMBER force-fields that occupied ∼360 GB of data on the hard drive. Analyzing
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these big data and using them for more than seven HDX models was challenging because of the
size of trajectories and the time required for computations. However, I used two approaches to deal
with this challenge. At first, I developed a bash code to analyze large trajectories using parallel
computations to generate raw data and for the measurement of different metrics. The second
technique was to use python for analyzing raw data and converting them to meaningful plots and
figures. Analyzing these big data was primarily done by MATLAB; even though I used parallel
computations toolbox in MATLAB, the computational time was considerably longer than python.
The bash code for parallel VMD calculations is provided in Appendix E.1 and the related tcl codes
are in Appendix F.2. The python codes for HDX modeling are provided in Appendix C.2.
The seven models from the literature as well as my two novel models are listed in Table 7.2.
Models that originate from previous publications have their own parameters (parameters with no
superscripts in Table 7.2). I optimized parameters of seven models as well as novel models by
minimizing the objective function (Equation 7.1) which incorporates HDX experiments and MD
simulations of all apo-RGS proteins. It should be noted here that optimization of parameters was
determined separately for each force-field due to the fact that CHARMM and AMBER force-fields







∣∣∣DIfragexp −DIfragsim ∣∣∣)SY S (7.1)
where OF is the objective function, DI is deuterium incorporation, SY S is the number of simula-
tions for RGS protein using same force-field, and frag is the fragment number.
The HDX experiment determined deuterium incorporation values for RGS4, RGS8 and RGS19
measured at seven discrete times 1, 3, 10, 30, 100, 300, and 1000 minutes according to the HDX
protocol (Sec. 6.3.2). The HDX experiment provided fragment-based Deuterium Incorporation
(DI) where MD simulation, as a detailed atomic-resolution computational method, generated DI
at a residue resolution. Figure 7.4 shows the residues that are incorporated in the definition
of each fragment for three RGS proteins. To have comparable DI from both experiments and
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simulations, DI of residues (except Prolines that do not have amide hydrogens) were averaged over





, m is the number of residues in the fragment. (7.2)
Table 7.1: Details of apo-RGS MD simulations.
Protein PDB #atoms force−field (Length)
RGS4
1AGR 28160 CHARMM36 (2 µs), AMBER (2 µs)
1EZT 29275 CHARMM36 (2 µs), AMBER (2 µs)
RGS8
2IHD 27490 CHARMM36 (2 µs), AMBER (2 µs)
2ODE 30731 CHARMM36 (2 µs), AMBER (2 µs)
RGS19 1CMZ 29560 CHARMM36 (2 µs), AMBER (2 µs)
The concepts and related correlations for literature models were introduced in Sec. 7.2 above.
The description and philosophy of the two new models that were developed in this work are provided
in the following section. There are two general approaches for calculating deuterium incorporation
using conformational sampling tools such as MD and MC. The first approach, and also the oldest
one, correlates protection factor from metrics of the protein structure such as the length and number
of hydrogen bonds, distances from the molecular surface, RMSF, and the number of heavy atoms
within a certain distance cutoff of an amide nitrogen [281, 283, 286, 288, 289]. In this approach, the
protection factor is a ratio of the intrinsic kinetic rate to the observed kinetic rate (such as model
M8). In the second and more recent approach, there is no empirical correlation for the protection
factor, instead the protection factor is defined as a fractional population of the closed state to open
state for each amide hydrogen.
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Table 7.2: Different models and optimized values of their parameters based on
CHARMM and AMBER force-field simulations using HDX data (optimized values of







M1 [283] log(Pi) = u ∗ (SAi) + v/(HBi)
(1999−resing) u = 0.76, v = 8.2
uch = 6.15, vch = 5.32
uam = 5.18, vam = 4.92
M2 [285] ln(Pi) = (βcN ci + βhNhi )
( 2003−Vendruscolo) βc = 1, βh = 5
βchc = 0.49, βchh = 0.85
βamc = 0.5, βamh = 0.9
M3 [286] ln(Pi) = (βcN ci + βhNhi )
(2006−Best) βc = 0.35, βh = 2
βchc = 0.23, βchh = 5.40
βamc = 0.23, βamh = 4.00
M4 [281] ln(Pi) = (βcN ci + βr(N ri )−1)
(2006−Kieseritzky) βc = 0.5, βr = 0.9
βchc = 0.45, βchr = 1.31
βamc = 0.19, βamr = 6.45
M5 [287] Pi = (CoNH soli + CcNH
β
i )/CoNH soli
(2011−Ma) Ccho = 8.48× 10−6, Cchc = 2.50
Camo = 0.15, Camc = 1.47× 104
M6 [288] Pi = base/(1 + (
√
base)1−NHstati)
(2015−Park) base = 108
basech = 1.3× 108
baseam = 0.4× 108
M7 [256] Pi = τC/τO
(2015−Persson) dw = 2.6A˚, dp = 2.6A˚
dchw = 2.43A˚, dchp = 2.73A˚






M8 ln(Pi) = (βsSASA−γsi + βpD
−γp
i )
βchs = 0.72, βchp = 2.60× 101
γchs = 0.53, γchp = 0.99
βams = 1.30× 10−3, βamp = 3.65× 101
γams = 2.64, γamp = 1.27
M9 Pi = τC/τO
dchsasa = 9.15A˚2, dchp = 3.00 A˚
damsasa = 8.02A˚2, damp = 2.99 A˚
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Fragment Fragment Fragment 
Number Number Number
1 67 to 73 INHECGL 1 84 to 87 VQSW 1 51 to 57 TRWADSF
2 74 to 80 AAFKAFL 2 87 to 91 WAQSF 2 58 to 68 DVLLSHKYGVA
3 76 to 80 FKAFL 3 88 to 104 AQSFDKLMHSPAGRSVF 3 58 to 69 DVLLSHKYGVAA
4 81 to 87 KSEYSEE 4 92 to 104 DKLMHSPAGRSVF 4 61 to 68 LSHKYGVA
5 88 to 91 NIDF 5 95 to 104 MHSPAGRSVF 5 61 to 69 LSHKYGVAA
6 92 to 97 WISCEE 6 105 to 108 RAFL 6 61 to 70 LSHKYGVAAF
7 92 to 118 WISCEEYKKIKSPSKLSPKAKKIYNEF 7 105 to 112 RAFLRTEY 7 62 to 69 SHKYGVAA
8 97 to 117 EYKKIKSPSKLSPKAKKIYNE 8 108 to 115 LRTEYSEE 8 66 to 72 GVAAFRA
9 98 to 118 YKKIKSPSKLSPKAKKIYNEF 9 109 to 115 RTEYSEE 9 69 to 77 AFRAFLKTE
10 116 to 123 NEFISVQA 10 109 to 117 RTEYSEENM 10 70 to 74 FRAFL
11 118 to 129 FISVQATKEVNL 11 119 to 122 FWLA 11 71 to 74 RAFL
12 119 to 129 ISVQATKEVNL 12 119 to 125 FWLACEE 12 75 to 81 KTEFSEE
13 123 to 129 ATKEVNL 13 126 to 132 LKAEANQ 13 79 to 83 SEENL
14 130 to 143 DSCTREETSRNMLE 14 127 to 137 KAEANQHVVDE 14 82 to 85 NLEF
15 130 to 149 DSCTREETSRNMLEPTITCF 15 129 to 141 EANQHVVDEKARL 15 86 to 90 WLACE
16 136 to 149 ETSRNMLEPTITCF 16 130 to 139 ANQHVVDEKA 16 86 to 91 WLACEE
17 143 to 151 EPTITCFDE 17 133 to 141 HVVDEKARL 17 91 to 101 EFKKTRSTAKL
18 144 to 149 PTITCF 18 142 to 145 IYED 18 91 to 105 EFKKTRSTAKLVSKA
19 150 to 159 DEAQKKIFNL 19 145 to 154 DYVSILSPKE 19 92 to 101 FKKTRSTAKL
20 150 to 173 DEAQKKIFNLMEKDSYRRFLKSRF 20 147 to 154 VSILSPKE 20 92 to 105 FKKTRSTAKLVSKA
21 158 to 173 NLMEKDSYRRFLKSRF 21 147 to 157 VSILSPKEVSL 21 93 to 111 KKTRSTAKLVSKAHRIFEE
22 160 to 165 MEKDSY 22 151 to 157 SPKEVSL 22 102 to 111 VSKAHRIFEE
23 160 to 173 MEKDSYRRFLKSRF 23 158 to 174 DSRVREGINKKMQEPSA 23 102 to 112 VSKAHRIFEEF
24 166 to 173 RRFLKSRF 24 175 to 182 HTFDDAQL 24 106 to 111 HRIFEE
25 183 to 196 QIYTLMHRDSYPRF 25 106 to 112 HRIFEEF
26 188 to 196 MHRDSYPRF 26 112 to 125 FVDVQAPREVNIDF
27 113 to 120 VDVQAPRE
28 113 to 125 VDVQAPREVNIDF
29 118 to 125 PREVNIDF
30 118 to 129 PREVNIDFQTRE
31 126 to 136 QTREATRKNLQ
32 130 to 140 ATRKNLQEPSL
33 141 to 153 TCFDQAQGKVHSL
34 144 to 155 DQAQGKVHSLME
35 146 to 153 AQGKVHSL
36 154 to 162 MEKDSYPRF
37 154 to 169 MEKDSYPRFLRSKMYL
38 160 to 168 PRFLRSKMY
RGS8
Residue ID SequencesPDB : 2ODE
RGS4
Residue ID SequencesPDB : 1AGR
RGS19
Residue ID SequencesPDB : 1CMZ
Figure 7.4: Fragment definition for each RGS protein. Each fragment comprises
residues whose color determines different parts of the proteins. Connecting loops have
black color in fragment and white color on the protein structure.
This phenomenological model is expressed as (N −H)C kC←→
kO
(N −H)O kint−→ (N −D)O by which
the overall HDX rate is defined as khdx = kint/(P + 1) and the protection factor is Pi = τC/τO
where τC and τO are mean residence times in the closes and open states, respectively. The common
practical assumption to conclude these formulas is: kint  kC + kO [256]. In this context, specific
criteria are used to distinguish the open state from the closed state and then compute mean residence
time in open and closed states (such as model M9). I have optimized different correlations that link
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protection factors to MD simulations and interestingly I found that a correlation that incorporates
by solvent accessible surface area (SASAi) of amide hydrogens and distances of amide hydrogens to
the first polar atom (except in the neighboring residues) (Di) could predict experimental deuterium
incorporation with a good accuracy compared to other models. In this model, M8, ln(Pi) is a power
function of (SASAi) and (Di). To justify the practical application of (SASAi) and (Di) in an HDX
calculation, I used a second approach in model M9 where the same metrics, SASAi and Di, were
used for distinguishing between the open state and the closed state. The open state in model M9
happens for each amide hydrogen whenever its SASA crosses a threshold (dsasa) and that the amide
hydrogen has no other polar protein atom (except in neighboring residues) within a threshold of dp.
The values of thresholds in model M9 and four correlation coefficients in model M8 are obtained by
minimizing an objective function (Equation 7.1) using the python optimization module [290]. The
intrinsic exchange rate in new models was calculated according to Bai et al. [277]. The results that
show accuracy and comparison of both the literature and the novel models are provided in Sec 7.4.
7.3.1 Details of New Models (M8, M9)
Petruk et al. have shown that averaged SASA with or without the number of waters in the
first solvation shell (#WFSS) of each amide hydrogen in all-atom explicit water MD simulations
were able to reasonably predict the number of exchanged hydrogens in peptides [291]. McAllister
et al. speculated from their HDX experiments and MD simulations that SASA is a better indicator
for being protected from the solvent rather than a hydrogen bond criterion [292]. On the other
hand, Persson et al. could not find an accurate agreement between HDX experiments and MD
simulations based on SASA [256]. Park et al. showed that there are anticorrelations between the
SASA of amide hydrogens and the experimental residue resolution protection factors. Even with
the existence of reasonable SASA and Protection Factor (Pi) functionality, they chose hydrogen
bonding as a metric for HDX modeling because of the following reasons: (i) lack of an absolute
reference value for SASA due to a variety of algorithms [293, 294], (ii) all buried amide hydrogens
have zero SASA which prevents discrimination among them, (iii) energy function is very sensitive
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to SASA, and(iv) SASA of amide hydrogens as a sole metric cannot be used to predict the folded
states of residues, even when hydrogen amides are fully exposed to the solvent [288]. Argument
(i) is not a solid reason since even though different algorithms compute distinct SASA values, the
relative and qualitative values of SASA are a determinant for the Pi function. In addition, all
amide hydrogens which are completely buried have zero SASA and those which are partially buried
have a value of SASA close to zero. In Pi calculations there is no need to discriminate between
amide hydrogens which are buried and have zero SASA, argument (ii) is addressed. Besides, high
sensitivity of the energy function to small changes of SASA does not have any contradiction with
using SASA as a metric for the Pi. Also, HDX depends on the exposure of amide hydrogens and
not on being folded or unfolded according to the rational phenomenological mechanism of the HDX
reaction. It is well accepted that having two metrics, instead of one, improves the performance
of HDX prediction [256, 288]. My studies show that a combination of SASA and distance to
nearby polar atoms could successfully predict HDX whereas a threshold was determined for SASA
(see models M8 and M9). The argument (iv) is addressed. Considering these contradictory views
toward using SASA as a metric for HDX, I was eager to evaluate SASA of amide hydrogens as a
metric in the HDX calculation. I used the distances of amide hydrogens from the first polar atom
as an alternative metric along with SASA of each amide hydrogen to comply with the theory of
HDX in which a residue may be protected by polar atoms despite having large enough SASA [256].
This assertion comes from the fact that surface exposed hydrogens (high value of SASA) can be
significantly protected from hydrogen-deuterium exchange [283]. Surprisingly, these two metrics in
combination have resulted in trends and values consistent with experiments.
7.4 Results and Discussion
I used multiple HDX models to predict results of HDX experiments using MD simulations.
This illuminated weaknesses and strengths of different models and also provided new optimized
parameters for each model. It also provided two novel HDX models. Figures 7.6, 7.5 and 7.7
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illustrate the performance of each model at different time-points in terms of quantitative comparison
(error, in panel A and correlation coefficient, in panel B) of models with experiment. Each model
was analyzed both with the available published parameters as well as with parameters optimized for
our RGS HDX dataset and 2 µs MD simulations. Panel A represents the error that was calculated




|xi − yi| (7.3)
r(x, y) = Σ(xi − x¯)(yi − y¯)√




PDB: 1AGR 1EZT 2IHD 2ODE 1CMZ 1AGR 1EZT 2IHD 2ODE 1CMZ
M1 0.24 0.23 0.27 0.23 0.19 0.60 0.58 0.67 0.65 0.58
M2 0.15 0.28 0.19 0.17 0.38 0.41 -0.16 0.31 0.33 0.39
M3 0.21 0.22 0.13 0.13 0.24 0.48 0.47 0.61 0.62 0.49
M4 0.19 0.20 0.13 0.13 0.29 0.32 0.29 0.51 0.50 0.43
M6 0.15 0.15 0.11 0.10 0.25 0.41 0.49 0.58 0.59 0.41
M7 0.17 0.14 0.13 0.12 0.15 0.65 0.68 0.75 0.79 0.76
M1* 0.13 0.13 0.10 0.10 0.19 0.56 0.60 0.77 0.65 0.61
M2* 0.15 0.15 0.12 0.10 0.21 0.37 0.35 0.61 0.62 0.49
M3* 0.25 0.15 0.10 0.09 0.24 -0.03 0.49 0.62 0.63 0.55
M4* 0.15 0.16 0.12 0.10 0.20 0.41 0.34 0.58 0.62 0.54
M5* 0.18 0.16 0.14 0.14 0.20 0.02 0.23 0.51 0.36 0.09
M6* 0.15 0.14 0.11 0.10 0.25 0.40 0.49 0.58 0.58 0.40
M7* 0.13 0.12 0.10 0.09 0.17 0.60 0.63 0.74 0.76 0.74
M8 0.12 0.12 0.09 0.08 0.22 0.63 0.66 0.75 0.73 0.60
M9 0.14 0.14 0.09 0.09 0.16 0.61 0.65 0.83 0.76 0.78
RGS4 RGS8 RGS4 RGS8
Error CC
Figure 7.5: Performance of different models (using CHARMM force-field). (A) The
average error between DI of models and the experimental DI (error(x, y) =
∑ |xi −
yi|). (B) Pearson correlation coefficient between DI of models and the experimental
DI (pcc(x, y) = Σ(xi − x¯)(yi − y¯)/
√
Σ(xi − x¯)2Σ(yi − y¯)2). Models with superscript
of * indicate an optimization algorithm used to find new parameters. The shaded
areas show the relative magnitude of values.
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RGS19RGS4 RGS8
1 3 10 30 100 300 1000 1 3 10 30 100 300 1000 1 3 10 30 100 300 1000
M1 0.09 0.11 0.15 0.23 0.30 0.35 0.41 0.09 0.12 0.16 0.25 0.35 0.43 0.49 0.12 0.12 0.11 0.14 0.19 0.26 0.36
M2 0.13 0.17 0.25 0.29 0.35 0.39 0.39 0.07 0.11 0.17 0.20 0.23 0.25 0.30 0.20 0.27 0.34 0.43 0.47 0.51 0.48
M3 0.13 0.16 0.23 0.26 0.28 0.26 0.20 0.07 0.10 0.15 0.15 0.15 0.15 0.15 0.17 0.21 0.25 0.30 0.29 0.27 0.22
M4 0.12 0.15 0.22 0.23 0.24 0.23 0.19 0.07 0.10 0.14 0.14 0.16 0.17 0.17 0.20 0.26 0.31 0.36 0.35 0.32 0.24
M6 0.09 0.11 0.14 0.16 0.17 0.19 0.19 0.07 0.09 0.10 0.11 0.12 0.12 0.13 0.17 0.21 0.24 0.29 0.30 0.29 0.23
M7 0.11 0.14 0.15 0.17 0.16 0.17 0.17 0.11 0.12 0.12 0.13 0.14 0.15 0.14 0.07 0.10 0.12 0.16 0.18 0.21 0.20
M1* 0.08 0.08 0.11 0.13 0.15 0.17 0.19 0.08 0.08 0.08 0.09 0.11 0.13 0.15 0.13 0.16 0.18 0.23 0.23 0.23 0.17
M2* 0.10 0.12 0.16 0.16 0.16 0.16 0.21 0.05 0.07 0.10 0.12 0.13 0.14 0.17 0.18 0.21 0.23 0.24 0.21 0.19 0.18
M3* 0.10 0.12 0.15 0.14 0.15 0.17 0.20 0.04 0.07 0.10 0.11 0.12 0.13 0.15 0.19 0.24 0.27 0.29 0.25 0.22 0.19
M4* 0.10 0.12 0.16 0.16 0.16 0.17 0.21 0.05 0.07 0.10 0.12 0.13 0.15 0.18 0.17 0.21 0.22 0.23 0.20 0.18 0.18
M5* 0.13 0.15 0.18 0.19 0.19 0.17 0.15 0.13 0.14 0.14 0.14 0.14 0.14 0.13 0.17 0.19 0.21 0.24 0.22 0.22 0.17
M6* 0.09 0.11 0.15 0.16 0.17 0.19 0.19 0.06 0.08 0.10 0.11 0.12 0.12 0.13 0.17 0.21 0.25 0.30 0.30 0.30 0.24
M7* 0.08 0.09 0.11 0.13 0.15 0.16 0.17 0.07 0.08 0.09 0.10 0.11 0.11 0.12 0.11 0.12 0.14 0.18 0.20 0.22 0.20
M8 0.07 0.08 0.11 0.13 0.15 0.16 0.17 0.03 0.06 0.09 0.10 0.11 0.11 0.12 0.15 0.18 0.21 0.25 0.26 0.26 0.21
M9 0.08 0.09 0.10 0.12 0.16 0.19 0.21 0.08 0.08 0.08 0.09 0.10 0.11 0.13 0.08 0.10 0.13 0.18 0.20 0.22 0.20
1 3 10 30 100 300 1000 1 3 10 30 100 300 1000 1 3 10 30 100 300 1000
M1 0.31 0.59 0.73 0.72 0.65 0.59 0.52 0.64 0.69 0.73 0.68 0.64 0.65 0.56 0.67 0.79 0.77 0.66 0.55 0.38 0.25
M2 -0.25 -0.18 -0.10 -0.07 -0.05 -0.04 -0.07 0.58 0.47 0.38 0.31 0.23 0.16 0.09 0.50 0.48 0.47 0.41 0.35 0.28 0.27
M3 0.44 0.48 0.47 0.44 0.47 0.53 0.51 0.77 0.68 0.60 0.56 0.52 0.54 0.65 0.49 0.58 0.52 0.45 0.47 0.44 0.45
M4 0.03 0.12 0.24 0.34 0.46 0.51 0.43 0.64 0.55 0.49 0.47 0.45 0.43 0.49 0.44 0.43 0.45 0.46 0.48 0.40 0.37
M6 0.24 0.40 0.52 0.53 0.51 0.47 0.48 0.52 0.55 0.60 0.60 0.58 0.60 0.63 0.36 0.49 0.55 0.47 0.38 0.31 0.31
M7 0.59 0.72 0.73 0.72 0.69 0.64 0.59 0.72 0.74 0.80 0.79 0.78 0.78 0.78 0.83 0.83 0.80 0.78 0.75 0.68 0.65
M1* 0.45 0.68 0.70 0.67 0.62 0.53 0.41 0.71 0.74 0.80 0.76 0.71 0.66 0.62 0.50 0.61 0.70 0.67 0.63 0.57 0.60
M2* -0.05 0.15 0.40 0.51 0.55 0.53 0.44 0.62 0.56 0.56 0.59 0.65 0.67 0.64 0.48 0.49 0.57 0.59 0.52 0.39 0.38
M3* 0.20 0.34 0.55 0.61 0.57 0.52 0.50 0.68 0.58 0.53 0.60 0.64 0.68 0.67 0.54 0.55 0.63 0.64 0.59 0.47 0.41
M4* 0.04 0.20 0.40 0.50 0.52 0.51 0.43 0.63 0.57 0.55 0.57 0.63 0.65 0.62 0.51 0.54 0.64 0.65 0.59 0.47 0.41
M5* -0.07 -0.13 -0.10 0.04 0.27 0.41 0.45 0.09 0.23 0.39 0.46 0.55 0.64 0.67 -0.24 -0.15 -0.03 0.09 0.19 0.28 0.47
M6* 0.24 0.38 0.51 0.53 0.51 0.47 0.48 0.51 0.54 0.60 0.59 0.58 0.60 0.63 0.34 0.48 0.54 0.47 0.38 0.31 0.31
M7* 0.27 0.58 0.72 0.72 0.70 0.68 0.65 0.72 0.73 0.77 0.73 0.74 0.78 0.78 0.78 0.82 0.79 0.76 0.73 0.65 0.65
M8 0.58 0.71 0.69 0.66 0.64 0.61 0.59 0.77 0.73 0.75 0.72 0.72 0.74 0.73 0.53 0.64 0.69 0.65 0.59 0.54 0.56
M9 0.51 0.64 0.72 0.72 0.66 0.60 0.54 0.83 0.82 0.82 0.78 0.75 0.77 0.78 0.88 0.90 0.86 0.79 0.73 0.64 0.63
A
B
Less error or high pcc
Less pcc or high error
Figure 7.6: Performance of different models (using CHARMM force-field). (A) The
average error between DI of models and the experimental DI. (B) Pearson correlation
coefficient between DI of models and the experimental DI. Models with superscript of
* indicate that an optimization algorithm was used to find new parameters (optimized
parameters are shown in Table 7.2 with superscript of ch). The color scheme is based
on each column in which green color indicating that the model could predict with
a good accuracy (less error or high correlation coefficient), red color meaning less
accuracy, and white color intermediate accuracy.
Correlation coefficient is a dimensionless index that varies from -1 to +1 and determines the
strength of association between two input variables; more positive values mean highly correlated,
more negative values mean highly anti-correlated, and closeness to zero means no correlation. The
error is a dimensionless index of discrepancy between the predicted DI fraction and the correspond-
ing value of experimental exchange that was averaged over all fragments of each protein. Models
M1 to M6 show significant errors and poor correlations for simulation with both CHARMM and
AMBER force-fields. Even though model M1 could partially predict the trend and the values of
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DI for RGS19, the model is deficient for RGS4 and RGS8.
RGS19RGS4 RGS8
1 3 10 30 100 300 1000 1 3 10 30 100 300 1000 1 3 10 30 100 300 1000
M1 0.10 0.12 0.19 0.25 0.31 0.36 0.40 0.07 0.10 0.14 0.23 0.33 0.42 0.48 0.13 0.14 0.14 0.17 0.18 0.23 0.36
M2 0.12 0.14 0.21 0.23 0.26 0.28 0.30 0.07 0.11 0.17 0.20 0.23 0.25 0.30 0.20 0.27 0.34 0.43 0.47 0.51 0.48
M3 0.13 0.16 0.24 0.27 0.29 0.28 0.24 0.07 0.10 0.15 0.16 0.16 0.17 0.18 0.20 0.27 0.33 0.40 0.41 0.41 0.31
M4 0.10 0.13 0.17 0.16 0.16 0.15 0.19 0.05 0.07 0.11 0.13 0.14 0.14 0.16 0.18 0.21 0.22 0.24 0.22 0.20 0.18
M6 0.10 0.13 0.18 0.20 0.21 0.21 0.23 0.05 0.07 0.09 0.11 0.14 0.17 0.21 0.17 0.22 0.25 0.30 0.31 0.32 0.26
M7 0.10 0.11 0.13 0.14 0.16 0.18 0.20 0.10 0.11 0.13 0.17 0.20 0.20 0.18 0.09 0.11 0.14 0.17 0.18 0.20 0.20
M1* 0.09 0.10 0.14 0.16 0.16 0.16 0.16 0.08 0.08 0.10 0.11 0.13 0.14 0.15 0.11 0.14 0.17 0.21 0.21 0.21 0.16
M2* 0.09 0.11 0.16 0.18 0.21 0.21 0.21 0.05 0.07 0.10 0.12 0.14 0.15 0.18 0.18 0.21 0.22 0.23 0.22 0.20 0.18
M3* 0.09 0.11 0.16 0.17 0.19 0.20 0.20 0.04 0.08 0.11 0.12 0.13 0.15 0.18 0.19 0.23 0.25 0.28 0.24 0.22 0.19
M4* 0.09 0.12 0.14 0.15 0.16 0.18 0.20 0.05 0.08 0.12 0.13 0.13 0.13 0.16 0.16 0.19 0.21 0.22 0.20 0.20 0.19
M5* 0.07 0.09 0.11 0.13 0.14 0.16 0.17 0.09 0.09 0.10 0.12 0.13 0.14 0.17 0.14 0.16 0.19 0.22 0.20 0.19 0.14
M6* 0.08 0.10 0.14 0.17 0.19 0.20 0.22 0.05 0.07 0.09 0.12 0.14 0.18 0.22 0.17 0.21 0.25 0.29 0.30 0.30 0.23
M7* 0.07 0.07 0.10 0.12 0.14 0.16 0.17 0.06 0.07 0.08 0.10 0.14 0.16 0.17 0.14 0.17 0.19 0.23 0.24 0.25 0.23
M8 0.05 0.06 0.09 0.12 0.14 0.16 0.17 0.03 0.05 0.07 0.08 0.09 0.10 0.11 0.13 0.17 0.21 0.27 0.26 0.26 0.23
M9 0.07 0.08 0.12 0.14 0.17 0.19 0.20 0.08 0.08 0.09 0.09 0.11 0.12 0.14 0.10 0.15 0.19 0.25 0.25 0.26 0.22
1 3 10 30 100 300 1000 1 3 10 30 100 300 1000 1 3 10 30 100 300 1000
M1 0.03 0.19 0.23 0.24 0.24 0.24 0.22 0.56 0.56 0.56 0.59 0.63 0.64 0.53 0.56 0.67 0.66 0.53 0.45 0.35 0.27
M2 -0.11 0.02 0.16 0.22 0.26 0.24 0.18 0.55 0.44 0.35 0.28 0.20 0.13 0.07 0.35 0.33 0.31 0.28 0.24 0.19 0.19
M3 0.50 0.54 0.53 0.50 0.48 0.50 0.49 0.64 0.54 0.45 0.40 0.39 0.44 0.54 0.68 0.66 0.64 0.64 0.62 0.51 0.50
M4 0.09 0.28 0.51 0.59 0.58 0.55 0.49 0.60 0.52 0.48 0.50 0.57 0.61 0.60 0.56 0.57 0.64 0.63 0.55 0.39 0.35
M6 0.14 0.20 0.26 0.28 0.26 0.17 0.08 0.61 0.66 0.71 0.63 0.55 0.47 0.32 0.00 0.08 0.15 0.16 0.19 0.17 0.11
M7 0.60 0.71 0.74 0.72 0.69 0.65 0.59 0.82 0.78 0.75 0.72 0.69 0.67 0.66 0.85 0.83 0.78 0.75 0.75 0.67 0.65
M1* 0.17 0.23 0.35 0.46 0.55 0.54 0.48 0.71 0.64 0.61 0.64 0.65 0.65 0.65 0.66 0.70 0.68 0.64 0.61 0.53 0.52
M2* 0.37 0.47 0.51 0.42 0.30 0.19 0.07 0.59 0.51 0.48 0.52 0.60 0.60 0.57 0.56 0.57 0.63 0.60 0.51 0.34 0.32
M3* 0.48 0.56 0.56 0.46 0.31 0.18 0.09 0.59 0.49 0.45 0.52 0.59 0.63 0.69 0.65 0.71 0.69 0.62 0.53 0.38 0.38
M4* 0.50 0.64 0.72 0.73 0.70 0.65 0.57 0.61 0.53 0.49 0.52 0.62 0.67 0.66 0.50 0.55 0.69 0.72 0.67 0.53 0.45
M5* 0.44 0.49 0.57 0.63 0.67 0.65 0.59 0.34 0.55 0.57 0.55 0.61 0.66 0.67 0.11 0.21 0.21 0.24 0.34 0.43 0.56
M6* 0.40 0.45 0.42 0.37 0.30 0.23 0.19 0.63 0.66 0.70 0.62 0.54 0.45 0.29 0.04 0.11 0.15 0.13 0.16 0.13 0.08
M7* 0.66 0.76 0.77 0.74 0.70 0.65 0.61 0.76 0.74 0.74 0.72 0.67 0.64 0.62 0.64 0.76 0.75 0.69 0.64 0.55 0.53
M8 0.80 0.84 0.78 0.72 0.70 0.66 0.61 0.84 0.81 0.78 0.76 0.74 0.75 0.76 0.79 0.84 0.75 0.66 0.62 0.54 0.55
M9 0.70 0.74 0.71 0.68 0.67 0.64 0.60 0.83 0.78 0.71 0.72 0.72 0.72 0.73 0.82 0.81 0.77 0.73 0.69 0.64 0.65
A
B
Less error or high pcc
Less pcc or high error
Figure 7.7: Performance of different models (using AMBER force-field). (A) The
average error between DI of models and the experimental DI. (B) Pearson correlation
coefficient between DI of models and the experimental DI. Models with superscript of *
indicate that an optimization algorithm was used to find new parameters (optimized
parameters are shown in Table 7.2 with superscript of am). The color scheme is
based on each column in which green color indicating that the model could predict
with a good accuracy (less error or high correlation coefficient), red color meaning
less accuracy, and white color intermediate accuracy.
After optimizing parameters for these models, model M1∗ shows much improvement compared
to other models for CHARMM simulations while the errors and correlations for other models
(M2∗ to M6∗) only improved moderately. Model M7 shows a good correlation for all simulations
(CHARMM and AMBER) with both default and optimized open and closed state criteria. How-
ever, the error is much less when using optimized parameters. A Comparison of all models to
experimental HDX at a fragment level resolution is presented in Appendix H. The proposed models
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(M8 and M9), both of which are based on SASA of amide hydrogens and distances of hydrogens
to the first polar atom, show results comparable with the published model M7 including a version
with optimized parameters M7∗. Models M8 and M9 predict HDX trends with less error. These
two models consistently result in higher correlations and fewer errors in different simulations with
the same force-field. Even though my proposed models (M8 and M9) are based on the same met-
rics, each shows different deuterium incorporation for the same fragments. For example, in RGS4
(Figures H.26 and H.27) fragments 10 to 12, M9 over-computes deuterium incorporation while M8
under-computes, specifically at times 1 and 3 minutes. The discrepancies between M8 and M9
are distinguishable in RGS19 (see Figures H.30 and H.15). Both models show same deuterium
incorporation for 1000 minutes, however, at shorter times (t=1 or 3 minutes) M8 does not cap-
ture deuterium incorporation accurately. These differences reveal the performance of fractional
populations of open and closed states modeling compared to pure correlation-based modeling in
deuterium incorporation prediction using MD simulations. Figure 6.5 shows that amide hydrogens
were exchanged rapidly in RGS19 whereas amide hydrogens are slow in RGS4 and RGS8. This
phenomenon is directly linked to dynamics and flexibility in RGS19 and a 2 µs MD simulation did
not capture some dynamics of RGS19 which caused literature HDX models (M1 to M7) and also
new models (M8, M9) with optimized parameters to underestimate deuterium incorporation for
RGS19 (Figures H.25, H.10, H.15, H.15).
Different models show distinct predictions for long-time HDX (300 and 1000 minutes) and
short-time HDX (1 to 100 minutes). For example, the new models, specifically with the CHARMM
force-field, precisely predict HDX results for RGS8 in short and long time HDX studies (Figure
H.28, H.29 for CHARMM, and H.13, H.14 for AMBER). However, some models show less deu-
terium incorporation for short time HDX compared to long time HDX such as models M2∗ to M6∗.
Similarly M8 predictions for RGS4 using the CHARMM force-field do as well (see Figures H.22 and
H.27). This inconsistency between short time and long time HDX predictions may originate from
the optimization process, complexities in correlating HDX to protein dynamics, and averaging over
residue deuterium incorporations to drive fragment deuterium incorporation. As Figure H.16 or
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H.17 show, models (M3, M4, M6) with default parameter were deficient in the prediction of short
time HDX whereas long time HDX were reasonably well predicted. This provides an inference that
the optimization may not be the cause of discrepancy between predictions in short and long time
HDX. Figures 7.8 and 7.9 show deuterium incorporation maps on RGS protein structures for the
experimental data and for models M7, M8, and M9 using CHARMM and AMBER force-fields, re-
spectively. These two figures show differences from using two different force-fields. However, these
discrepancies are not significant; model M8 shows less deuterium incorporation in the α4 helix of
RGS4 using AMBER compared to the CHARMM force-field. Also, model M9 shows less deuterium
incorporation in the α4 helix of RGS8 using the CHARMM force-field. Deuterium incorporation
of α6 helix, α5-α6 connecting loop, and α6-α7 connecting loop in RGS proteins are predicted well
using these models with both force-fields. These regions of RGS isoforms showed large dynamic
motions and fluctuations in MD simulations (see Figure 6.7) which resulted in precise predictions
of HDX models. Helices α3 and α4 are the crucial regions of RGS proteins in which these models
were incapable of accurate predictions of deuterium incorporation and as one sees in Figure 6.7,
the RMSF of these regions are small which indicates high rigidity.
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Figure 7.8: Deuterium incorporation map of RGS proteins at a time of 1000 minutes.
HDX mapping for experiment, models M7, M8, and M9 (CHARMM force-field) are
presented.
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Figure 7.9: Deuterium incorporation map of RGS proteins at a time of 1000 minutes.
HDX mapping for experiment, models M7, M8, and M9 (AMBER force-field) are
presented.
In model M9, which is a phenomenological model, two criteria were evaluated simultaneously
(see sec. 7.3) to justify the open state or closed state in each frame of MD simulation trajectories.
Then the mean residence time (MRT) of the closed state and the open state is used to calculate
132 Chapter 7. HDX MODELING USING MD SIMULATIONS
Pi (see Equation 7.5). However, to calculate Pi for model M9, I divided the number of frames in
which an amide hydrogen is in a closed state (NCO) by the number of frames in which an amide
hydrogen is in an open state (NFO).
Pi = τC/τO (7.5)
where Pi is protection factor, τC and τO are the mean residence time in the closed and the open
state, respectively.
If NO and NC are the number of visits to the open state and the closed state during the MD
trajectory respectively, and TO and TC are total time that each amide is in open or closed state
respectively, I can write:
TO = NFO∆τ = NOτO (7.6)
TC = NFC∆τ = NCτC (7.7)
where ∆t is time-step (which is 2-fs in RGS protein MD simulations). I used the following equation
for all MD simulations:
NO = NC − 1 (7.8)
In addition, I assumed all amide hydrogens in the first and the last frame of MD simulations are
in the closed state and at least one frame is in the open state. These two assumptions are for
simplicity since without them, Pi goes to infinity (since τO become zero). Under these assumptions
a combination of Equations 7.8, 7.6, 7.7, and 7.5 results in the following equation that I used in
HDX modeling calculations:
Pi = TC/TO (7.9)
Which I used to calculate Pis.
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Figure 7.10: Mean residence time for amide hy-
drogens in the open state (open circles) and the
closed state (solid circles) based on model M9 and
CHARMM force-field.
Figure 7.11: Mean residence time for amide hydro-
gens in the open state (open circles) and the closed
state (solid circles), corrected for the binning error,
based on model M9 and CHARMM force-field.
Figures 7.11 and 7.13 show mean residence time of the closed and the open state for CHARMM
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Figure 7.12: Mean residence time for amide hydro-
gens in the open state (open circles) and the closed
state (solid circles) based on model M9 and AMBER
force-field.
Figure 7.13: Mean residence time for amide hy-
drogens in open state (open circles) and closed state
(solid circles), corrected for the binning error, based
on model M9 and AMBER force-field.
MD simulations have reported RGS protein dynamics every 2-fs which means there is no in-
formation for 2-fs about the state of the amide hydrogen. Many open states may occur shorter
than ∆t and cannot be captured by limited sampling resolution [256]. Persson et al. [256] modeled
(open state)(closed state) dynamics by using an alternating Poisson process and quantitatively
corrected mean residence time (τ cO for the Open state and τ cC for the closed state) for the sampling
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resolution systematic binning error (Equations 7.12 and 7.13).






Figures 7.10, 7.12 show τ cO and τ cC for model M9 in simulations with CHARMM and AMBER
force-fields, respectively. τO changes between 20 to 50 ps while τ cO changes between 5 to 50 ps. τC
changes between 170 ps to 2 µs while τ cC changes between 110 ps to 2 µs. These figures confirm
that the transient open states happen in a shorter period of time, on less than 100 ps time-scale.
7.5 Conclusion
In this chapter, I used MD simulations to study HDX phenomenon in RGS protein isoforms.
Different models show distinct capabilities for the prediction of HDX trends seen in experiments.
Older models with their default parameters, except model M7, were not able to predict HDX exper-
iments with good accuracy. However, models with optimized parameters show reasonable accuracy
for predicting trends and values of deuterium incorporation. My new HDX models have been de-
veloped based on the metrics of SASA of amide hydrogens and distances of amide hydrogens to the
first polar atom. The new models interestingly show significant improvement in accuracy compared
to other models. For new models, mere protein coordinates are enough for HDX calculations and
require less computational time and resources. The new model, M9, shows that the mean residence
time of amide hydrogens in the open state is in the range of 5 to 50 ps which indicates the very





8.1 Future Research Directions
The future work may consist of the following suggestions.
In Chapters 3 and 4, I studied the folding of an insulin mimetic peptide and TMDs of IR
and IGF1R in aqueous and lipid environment, respectively. To conduct these studies, I used an
enhanced sampling method (metadynamics) which was able to predict metastable conformations.
There are other known insulin mimetic peptides that can be used for further case studies using the
metadynamics method. For example, Schaffer et al. [160] provide a list of peptides that work as
high-affinity IR agonists and antagonists and the structures of those peptides are yet to be found.
Even though metadynamics could reveal the metastable conformations of TMD of IR as well as
TMD of IGF1R, the PMF map for the interaction of two TMDs in a lipid bilayer is yet to be
investigated by the metadynamics method.
In chapter 5, I studied IR dynamics in three different aims each of which pursued particular
goals. In this thesis, I reported general observations and findings of the simulations but the sim-
ulation trajectories have a great potential to be analyzed for further studies; the simulations that
include the binding pocket for hormone insulin can be analyzed by defining a docking simulation
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using software such as ICM.1 This work may result in finding the routes and mechanisms of binding
of insulin to its pocket on the IR structure. If HDX experiment be applied on the IR protein, it may
provide a valuable information on dynamics in different parts of the receptor and can be compared
with MD simulations using HDX modeling. The simulation of IR was performed without hormone
insulin, which excluded the effect of insulin binding on IR. One can search for the open binding
pocket in the current simulation trajectories, and dock hormone insulin in the binding pocket and
continue the simulation to capture the effect of the hormone on the dynamics of IR. One of the
aims considered in chapter 5 was to carry out the whole IR simulation in a lipid bilayer, which
included the ectodomain, the TMDs, and the kinase domains. However, the simulation time was
limited to 1 µs because of our computational resources. One can continue the simulation for a
longer time (e.g., a few µs) and also increase the size of the simulation box to reduce the effect of
self interaction.
In chapter 6, I studied the dynamic motions of apo-RGS proteins using µs long simulations and
HDX experiments. Inhibitor candidates can be added in the MD simulation box of RGS proteins
to investigate their interactions and the effect of inhibitors on the dynamics of RGS proteins, and
likely ways in which the inhibitors interact with cysteine residues. Another future work may be
covalent docking of inhibitor candidates to the exposed cysteine residues to understand structural
perturbations. The final goal of the inhibition of RGS proteins is to prevent the formation of the
RGS-Gα complex. One can conduct the simulation of the RGS-Gα complex, with and without
inhibitor molecules. Besides, one can use enhanced sampling methods to calculate the energy
of interaction between RGS and Gα proteins in different inhibition conditions. Simulations of
apo-RGS proteins show differences in dynamics in helices and loops. One hypothesis is that the
formation of salt-bridges has an important role in decreasing the protein flexibility. Therefore,
alteration of residues that are engaged in a salt-bridge may change the flexibility of RGS proteins.
To investigate the effects of a salt-bridge, one can mutate residues and carry out conventional or
biased MD on apo-RGS proteins. This study can be supported by HDX experiments on mutated
1Molsoft molecular modeling technology, Internal Coordinate Mechanics (ICM) https://www.molsoft.com
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RGS proteins.
In chapter 7, I optimized seven different models and developed two new models for the predic-
tion of HDX using MD simulations. The parameters used in these models were based on the MD
simulations of three RGS protein isoforms with two different force-fields (AMBER and CHARMM).
For future investigations, one can apply these nine models (with optimized parameters) on the HDX
data of various candidate proteins besides the RGS proteins. The HDX data for these candidate
proteins are either available in the literature, or can be obtained through independent HDX exper-
iments. The ideal and desired HDX model should not be tied to a particular type of protein or a
simulation. Instead, it should be applicable to a variety of proteins. In other words, an ideal model
yields an acceptable accuracy for a variety of proteins when the parameters of the particular model
are optimized using a limited HDX experiments. I used MD simulations to produce conformations
and predict deuterium incorporation which was also observed in experiments. There is no software
or tool to do inversely; receive HDX experiment data and produce corresponding conformational
sets for the protein. This idea can be put into practice by using biased MD simulation in which
proper collective variables, as well as specific algorithms, are applied in an MD simulation to bias
dynamics to account for experimentally observed trends.
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Appendix A
NAMD Input Files and Sample
Scripts
A.1 Sample NAMD configuration file
In this section, I provide a general script for running classical and unbiased MD simulation in
NAMD using the NPT ensemble. There is a description corresponding to each line of code in the
script. For NVT ensemble, remove pressure control section or simply change {1} to {0}.
1
2 set input ionized ;# First we specify the files that contain the molecule structure
↪→ and initial conditions. A coordinates PDB file is always required, even if the




6 set outputname npt ;# The outputName prefix will be used to create all of the
↪→ trajectory (.dcd, .xst), output (.coor, vel, .xsc), and restart (.restart.coor,
↪→ .restart.vel, .restart.xsc) files generated by this run. Be careful that this is
↪→ different from $input, or the job will overwrite its input files!
7
8
9 set temperature 310 ;# Setting the Tcl variable $temperature makes it easy to change
↪→ the target temperature for many options. Target temperature used several times
↪→ below
10 if {0} { ;# To read binary output files of the previous run and continue the
↪→ simulation change {0} to {1}. We use the Tcl variable $inputname to avoid errors
↪→ in typing the input file names, since we will end up copying and modifying this
↪→ file several times during the course of a long simulation. The extendedSystem
↪→ file holds the periodic cell dimensions that are needed to continue after a
↪→ constant pressure simulation. In order to start numbering timesteps with the
↪→ final step of the previous run, we use firsttimestep to specify the timestep on
↪→ which the input coordinates and velocities were written.
11 set inputname npt.restart ;# only need to edit this in one place!
12 binCoordinates $inputname.coor ;# coordinates from last run (binary)
13 extendedSystem $inputname.xsc ;# cell dimensions from last run
14 binVelocities $inputname.vel ;# velocities from last run (binary)





19 # Next are the parameter file itself and the options that control the nonbonded
↪→ potential functions. These are mostly specified by the CHARMM force field, but
↪→ the cutoff and other distances may be shortened when full electrostatics are
↪→ used; Just be sure that you adjust all of the distances together. The
↪→ pairlistdist can be made longer if you see warnings in the NAMD output, but
↪→ making it bigger than necessary will reduce performance.
20 paraTypeCharmm on
21 parameters par_all36_prot.prm ;# Force-Field Parameters
22 parameters toppar_water_ions_namd.str ;# Force-Field Parameters
23 temperature $temperature ;# If we are starting from scratch, use the coordinates from
↪→ the PDB file and take velocities randomly from a Boltzmann distribution, using
↪→ the $temperature variable.
24 COMmotion no
25 # Force-Field Parameters
26 exclude scaled1-4
27 1-4scaling 1.0




32 # Integrator Parameters : The integration timestep is normally limited to 1 fs. This
↪→ can be extended to 2 fs by fixing the length of all bonds in the molecule
↪→ involving hydrogen atoms via rigidBonds all, which also makes water molecules
↪→ completely rigid. To only make water rigid, use rigidBonds water and a 1 fs
↪→ timestep. For any simulations involving water molecules, one should make water
↪→ rigid since water molecules have been parametrized as rigid water. Nonbonded
↪→ forces must be calculated at least every 2 fs, which in this example is every
↪→ step. Full electrostatics forces (from particle mesh Ewald, discussed below) are
↪→ evaluated every other step in this example. nonbondedFreq and






38 # Periodic Boundary Conditions
39 if {1} { ;# If the simulation will use periodic boundary conditions, they are
↪→ specified as shown below. Like the temperature option, these should only be
↪→ given when starting a simulation from scratch, since the basis vectors will
↪→ fluctuate during constant pressure simulation and updated values need to be read
↪→ via extendedSystem from a .xsc file.
40 cellBasisVector1 68.18 0. 0.
41 cellBasisVector2 0. 70.20 0.
42 cellBasisVector3 0. 0. 66.73
43 cellOrigin 4.402883052825928 -3.4777019023895264 5.647762298583984
44 }
45 wrapAll on ;# With wrapping, some molecules will jump between sides of the cell in the
↪→ trajectory file to yield the periodic image nearest to the origin. Without
↪→ wrapping, molecules will have smooth trajectories, but water in the trajectory
↪→ may appear to explode as individual molecules diffuse. Wrapping only affects
↪→ output, not the correctness of the simulation.
46 #PME (for full-system periodic electrostatics): Particle mesh Ewald (PME) full
↪→ electrostatics are more accurate and less expensive than larger cutoffs, and are
↪→ recommended for most work. PME is only applicable to periodic simulations, and
↪→ the user must specify a grid corresponding to the size of the periodic cell. PME
↪→ grid dimensions should have small integer factors only and be greater than or
↪→ equal to length of the basis vector. To manually define the grid size instead of
↪→ letting NAMD choose the dimensions for you according to these guidelines,
↪→ replace the GridSpacing command with explicit GridSize commands instead.
47
48 PME yes




52 # Constant Temperature Control : Langevin dynamics balances friction with random noise
↪→ to drive each atom in the system towards a target temperature. The following
↪→ parameters are good for equilibration, but a langevinDamping as low as 1. would
↪→ be sufficient for simulation. Higher damping may be necessary if, for example,
↪→ work done on the system by steering forces is driving up the temperature.
53 langevin on ;# do langevin dynamics
54 langevinDamping 5 ;# damping coefficient (gamma) of 5/ps
55 langevinTemp $temperature
56 langevinHydrogen off ;# don’t couple langevin bath to hydrogens
57 # Constant Pressure Control
58 if {1} { ;# Constant pressure is recommended for periodic simulations. Using
↪→ groupbased pressure to control the periodic cell fluctuations is desirable
↪→ because the atom-based pressure has more high-frequency noise. useFlexibleCell
↪→ is useful for anisotropic systems such as membranes, allowing the height, length
↪→ , and width of the cell to vary independently, possibly even fixing the lipid
↪→ crosssectional (x-y plane) area with useConstantArea. For a protein surrounded
↪→ by water there is nothing to prevent the cell from becoming highly extended in
↪→ one dimension, so it is better to choose useFlexibleCell no in this case.
59
60 useGroupPressure yes ;# needed for 2fs steps
61 useFlexibleCell no ;# no for water box, yes for membrane
62 useConstantArea no ;# no for water box, yes for membrane
63 langevinPiston on





69 # Output ;# We will write restart files, coordinate trajectory .dcd files, and
↪→ extended system (periodic cell) trajectory .xst files at regular intervals.
70 outputName $outputname
71 restartfreq 10000 ;# 10000 steps = every 20 ps
72 dcdfreq 10000
73 outputEnergies 10000 ;#The default is to print energies every steps, but that makes
↪→ for a very long file, so we’ll cut it down to every 100 steps. We’ll also enable




77 minimize 500 ;# Now we minimize the system to eliminate bad initial contacts,
↪→ reinitialize the velocities to the desired target temperature (since
↪→ minimization sets velocities to zero), and run for 1 ps. We could accomplish the
↪→ same thing with two different NAMD runs using the numsteps and minimization
↪→ options.
78 reinitvels $temperature ;# since minimization zeros velocities
A.2 Sample NAMD configuration file for SMD Simulations
The following script implements an SMD simulation in the NAMD software. There are addi-
tional settings in this script compared to classical MD scripts (Appendix A.1).
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5 outputName npt_cv
6
7 set temperature 310
8
9 # Continuing a job from the restart files
10 if {1} {
11 set inputname ./NPT/Npt
12 binCoordinates $inputname.restart.coor











23 # NOTE: Do not set the initial velocity temperature if you
24 # have also specified a .vel restart file!
25 temperature $temperature
26
27 # Periodic Boundary conditions
28 # NOTE: Do not set the periodic cell basis if you have also
29 # specified an .xsc restart file!
30 if {0} {
31 cellBasisVector1 20.0 0 0
32 cellBasisVector2 0 20.0 0
33 cellBasisVector3 0 0 50.0













47 # Integrator Parameters
48 timestep 1.0 ;# 2fs/step





54 #PME (for full-system periodic electrostatics)





60 # Constant Temperature Control
61 langevin on ;# do langevin dynamics
62 langevinDamping 1 ;# damping coefficient (gamma) of 5/ps
63 langevinTemp $temperature
64 langevinHydrogen no ;# don’t couple langevin bath to hydrogens
65
66 # Constant Pressure Control (variable volume)
67 if {1} {
68 useGroupPressure yes ;# needed for 2fs steps
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69 useFlexibleCell no ;# no for water box, yes for membrane
70 useConstantArea no ;# no for water box, yes for membrane
71
72 langevinPiston on












85 # Fixed Atoms Constraint (set PDB beta-column to 1)






92 # IMD Settings (can view sim in VMD)
93 if {0} {
94 IMDon on
95 IMDport 3000 ;# port number (enter it in VMD)
96 IMDfreq 1 ;# send every 1 frame
97 IMDwait no ;# wait for VMD to connect before running?
98 }
99
100 ## EXTRA PARAMETERS
101
102 # Put here any custom parameters that are specific to










113 ## EXECUTION SCRIPT
114
115 # Minimization





121 run 5000000 ;# 10ns
A.3 Metadynamics method in NAMD
To submit a metadynamics MD simulation in NAMD, two scripts are required: a configuration
file “main.conf” and a collective variable (CV) definition file “colvar.in” that are shown below.
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A.3.1 Configuration file: main.conf
The configuration file holds MD simulation settings that are similar to conventional MD simu-
lation. Besides, there are commands in the script that invoke the metadynamics function in NAMD
and the corresponding CV file.
1
2 set outName aBF
3































35 cellBasisVector1 48.19 0. 0.
36 cellBasisVector2 0. 67.60 0.
37 cellBasisVector3 0. 0. 79.36
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56 # This is a constant-V simulation
57 LangevinPiston off
58




























A.3.2 Collective variable file: colvar.in
As you see below, the colvar file contains definitions of CVs (here there are RMSD, Rg) and
























































A.4 NAMD Script for AMBER Force-Field
In the following, I provide a script for carrying out MD simulations using the AMBER force-field
in NAMD. It lacks commands for force-fields because the *.top file includes AMBER force-field that
was generated by Ambertools (Appendix D).
1 ## OUTPUT/INPUT
2 # Amber/(t,s,x)leap generated parm and crd file
3
4 set outputname npt






11 if {0} {
















27 ## SIMULATION PARAMETERS
































60 # Constant Pressure Control if on








69 if {1} {
70 useGroupPressure yes ;# needed for 2fs steps
71 useFlexibleCell no ;# no for water box, yes for membrane
72 useConstantArea no ;# no for water box, yes for membrane
73 langevinPiston on






80 # PME settings
81 PME on
82 PMETolerance 1.0e-6







89 # periodic cell
90 if {1} {
91 cellBasisVector1 70 0.0 0.0
92 cellBasisVector2 0.0 74 0.0
93 cellBasisVector3 0.0 0.0 67










B.1 One-dimensional implementation of metadynamics using Langevin
equation
To understand the underlying details of the metadynamics method, I developed a MATLAB
code in which metadynamics method, along with one-dimensional Langevin equation, is used to
reconstruct a hypothetical free energy landscape Vg. In this example, Langevin equation is in the
form of md2ξ
dt2 = −γ dξdt + fr(t) −
dVg
dξ , Here γ is the friction coefficient, fr(t) is a random force, ξ is
the collective variable, and Vg is the free energy landscape [123]. The result of the computational




4 clear f2 xx delt s w xxx XXX









14 xx = linspace(xmin,xmax,101);
15 xxx=xx;
16 XXX=vx2(xxx);
17 %dvx=@(x) 6*p1*x.ˆ5 + 5*p2*x.ˆ4 + 4*p3*x.ˆ3 + 3*p4*x.ˆ2 + 2*p5*x.ˆ1 +p6;
18 lower = vx(xx);
19 scrsz = get(groot,'ScreenSize')





















































72 xlabel('\xi Collective variable')






79 xlabel('Number of Gussians')
80 ylabel('\xi ')
81 if mod(i,30)==0
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104 p1 = 0.01161;
105 p2 = 0.009921;
106 p3 = -0.3989;
107 p4 = -0.3234;
108 p5 = 3.035;
109 p6 = 1.885;
110 p7 = -8;
111 answ=(p1*x.ˆ6 + p2*x.ˆ5 + p3*x.ˆ4 + p4*x.ˆ3 + p5*x.ˆ2 +p6*x + p7);
B.2 MATLAB code to convert CVs-trajectory to a Potential of
Mean Force (PMF)
NAMD generates profiles of PMF, based on the user-defined frequency, but, there is no tool for
producing PMFs out of CV-trajectories and using metadynamics parameters. To resolve this issue,
I programmed a code by which the reconstruction of the PMF is carried out using Equation 2.6.
This code was developed for obtaining a PMF profile using two dimensional collective variables
(RMSD and radius of gyration) in a metadynamics simulation. The reader may change it for one















15 global delt s1 s2 w
16 delt=.1;
17 %2*delt=width*hillwidth




21 fid = fopen('aBFo.colvars.traj','r')
















38 [XX,YY] = meshgrid(rm,rg);
39 V1=reshape(V',[size(rm,2)*size(rg,2) 1]);
40 end
41 % fileID = fopen(['PMF_',num2str(step),'.pmf'],'w');











53 global s1 s2


















71 global delt s w
72 answ=(vx2(x+1e-6)-vx2(x))/1e-6;
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B.3 MATLAB code for plotting PMF files
This script reads a PMF file in which the first column contains PMF values and the second and
third column are the values of CVs, in this case, RMSD and the radius of gyration, and makes a












12 %link='3rgyr_rmsd_meta_run4'; %used in paper
13 %link='3rgyr_rmsd_meta_run2'; %used in paper
14
15 cd(['../',link])
16 if 1 % 0 for TrajtoPMF
17 fid = fopen('aBFo.pmf', 'r')
18 else
19 fid = fopen('PMF_end.pmf', 'r')
20 end
21













35 xlin = linspace(min(x),max(x),1000);
36 ylin = linspace(min(y),max(y),1000);
37
38 [X,Y] = meshgrid(xlin,ylin);
39 F = scatteredInterpolant(x,y,z,'linear','linear');%'nearest' 'linear' 'natural'
40 Z = F(X,Y);
41
42 % axis tight; hold on
43 %plot3(x,y,z,'.','MarkerSize',15) %nonuniform
44 convmatri = [.05 .1 .05; .1 .4 .1; .05 .1 .05];
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56 if 0 % 1 for boundary effect correction













70 hcb = colorbar('location','EastOutside');
71 hcb.Label.String = 'kcal/mol';
72 hcb.Label.FontSize = 14;
73 hcb.Label.HorizontalAlignment='left';






80 scrsz = get(groot,'ScreenSize')
81 fig.Units='inches'
82 fig.Position=[1 1 6 4];
83 ax = gca;
84 ax.LineWidth=2
85 ax.FontSize=14;
86 ax.FontName='Times New Roman'
87 ax.FontWeight='Bold'
88 ax.Box='off'
89 axis([min(min(X)) max(max(X)) min(min(Y)) max(max(Y))])
B.4 MATLAB code for calculating the PMF using SMD
This script reads a force file (that is the output of a tcl script in Appendix F.1) and calculates







7 fid = fopen('ft.dat','r')







15 fid = fopen('ft.dat','r')
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20





























50 axis([0 25 0 70])
51
52 cmp=jet(20);






























The main philosophy of the development of this language is briefly described in aphorisms:
beautiful is better than ugly; explicit is better than implicit; simple is better than complex; complex
is better than complicated; readability counts [295]. Based on my experience, python is more
efficient in performance compared to MATLAB. It has a lot of libraries for bioinformatics, MD
simulation analysis, numerical and statistical analysis, and plotting tools which are available freely
on webs. In this appendix, I present the python codes that have been used in this thesis.
C.1 Python code for converting NAMD files to the DMS format
files
Convert an NAMD equilibrated trajectory to the DMS format by using “convertNAMDtoDMS.py”
file that is shown below. All MD simulations were initially equilibrated using NAMD software for
5 to 10 ns. The NAMD input and output files (including PSF file, as well as binary coordinate
(.coor), binary velocity (.vel), and extended system file (.xsc)) were used to generate a DMS file
for further simulation in Anton.
1 #!/usr/bin/env python
2 # -*- coding: utf-8 -*-
3 ########################################################
4 #
5 # this script converts a snapshot from a namd trajectory
6 # to a Desmond dms input file for use on Anton. Please
7 # note that the script requires VMD version 1.9 or higher.
8 #
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9 # (C) 2010-2012 Markus Dittrich, NRBSC, PSC, CMU
10 #
11 # call with:
12 #
13 # vmd -dispdev text -python -e convertNAMDtoDMS.py \
14 # -args -p ubq_wb.psf \
15 # -c ubq_wb_eq.restart.coor -v ubq_wb_eq.restart.vel \
16 # -x ubq_wb_eq.xsc -o outfile -s -S "protein"
17 #
18 # This program is distributed in the hope that it will be useful,
19 # but WITHOUT ANY WARRANTY; without even the implied warranty of






26 from atomsel import *
27 from AtomSel import AtomSel
28 from Molecule import Molecule





34 This function initializes the command line parser.
35 """
36
37 parser = optparse.OptionParser("Usage: vmdt -python -e "
38 "readVelocities.py -args [options]")
39
40 parser.add_option("-p", "--psffile", action="store", dest="psfFile")
41 parser.add_option("-c", "--coorfile", action="store", dest="coorFile")
42 parser.add_option("-v", "--velfile", action="store", dest="velFile")
43 parser.add_option("-x", "--xscfile", action="store", dest="xscFile")
44 parser.add_option("-o", "--outputfile", action="store", dest="outFile")
45 parser.add_option("-s", "--centerSystem", action="store_true", dest="doCenter")
46 parser.add_option("-S", "--centerSelection", action="store", dest="centerSel")
47
48 parser.set_defaults(doCenter = False, centerSel = "all")
49
50 opts, args = parser.parse_args(cmdlineArgs)
51 psfFile = opts.psfFile
52 coorFile = opts.coorFile
53 velFile = opts.velFile
54 xscFile = opts.xscFile
55 outFile = opts.outFile
56 doCenter = opts.doCenter
57 centerSel = opts.centerSel
58
59 # all filenames are required
60 if (psfFile == None) or (coorFile == None) or (velFile == None) \











72 def load_velocities(psfFile, velFile):
73 """
186 Appendix C. Python Scripts
74 Load the binary velocity file and extract velocities.
75 """
76




81 allVelocities = atomsel(’all’)
82 xVel = allVelocities.get(’x’)
83 yVel = allVelocities.get(’y’)
84 zVel = allVelocities.get(’z’)
85
86 # conversion from binvel units to A/ps
87 convFactor = 20.4582651391
88 xVel = [v * convFactor for v in xVel]
89 yVel = [v * convFactor for v in yVel]
90 zVel = [v * convFactor for v in zVel]
91
92 mol.delete()




97 def load_system(psfFile, coorFile):
98 """
99 Load the main system.
100 """
101







109 def set_velocities(mol, xVel, yVel, zVel):
110 """
111 Add the molecule velocities to the system.
112 """
113







121 def save_mol_as_dms(mol, fileName):
122 """
123 Save the current molecule as dms file.
124 """
125






132 Sets the systems periodic boundaries."
133 """
134 xscFile = open(xscFile,"r")
135
136 for line in xscFile:
137 continue
138
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139 items = line.split()
140 xDim = items[1]
141 yDim = items[5]
142 zDim = items[9]
143
144 #set pbd
145 pbcCommand = ("package require pbctools; pbc set { %s %s %s }"









155 Center the system around the selection.
156 """
157
158 centerSel = atomsel(selection)
159 center = centerSel.center()
160 negCenter = [-1.0 * item for item in center]
161







169 This removes the bond between hydrogen atoms in
170 TIP3P water if present since viparr will introduce
171 the proper constraint.
172 """
173
174 # it looks like atomsel doesn’t support set/getbonds
175 # so we have to use the deprecated AtomSel for now
176 oh2Sel = AtomSel("resname TIP3 and name OH2", 1)
177 h1Sel = AtomSel("resname TIP3 and name H1", 1)
178
179 oh2Indices = oh2Sel.get("index")
180 bondlist = []







188 # main routine
189 #####################################################
190 if __name__ == "__main__":
191
192 # parse the command line
193 psfFile, coorFile, velFile, xscFile, outfile, doCenter, \
194 centerSel = parse_cmdline(sys.argv[1:])
195
196 # transform NAMD to dms
197 vx, vy, vz = load_velocities(psfFile, velFile)





203 set_velocities(mol, vx, vy, vz)






C.2 Python codes for HDX modeling
The TCL code in Sec. F.2 was used to analyze the trajectory of MD simulations and extract
particular data from the trajectories (e.g. hydrogen bonds, distance to the first polar atoms,
SASA values and etc.). The data were saved in different files to be used by python code that are
shown in the current section. Each python code reads corresponding data file to carry out further
calculations and analysis. Below the python code for different models are shown in which command
“np.loadtext” reads the corresponding data file.
C.2.1 Model M1
Below is the python code for plotting the results for HDX model M1 (1999 Resing) [283].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os









16 self.name = []
17 self.par_name = []
18 self.par_val = []
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34 for i in range(0,np.size(hbond2,axis=0)):














49 sa = np.loadtxt( os.path.join(path,’1999_Rasing_SA_all.dat’) , skiprows=0)




53 HB = np.loadtxt( os.path.join(path,’1999_rasing_HB_ave.dat’), skiprows=0)




58 def calc_DI_MD(u, saa, v, HB):
59 PF = 10**( u*saa + v/HB)
60 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
61 PF[indexofnan] = np.nanmax(PF)
62 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
63 kint = np.array(sequence_kint(pr.seq))
64 # PF=PF[1:]# remove the N-terminous residue from PF
65 ind = [] # finding index of Prolins
66 for k, l in enumerate(list(pr.seq)):
67 if l == ’P’:
68 ind = k
69 PF = np.insert(PF, ind, ’NAN’)
70
71 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
72 for k, t in np.ndenumerate(t):
73 DI[k[1], :] = (1 - np.exp(-kint / (PF) * t))
74 return DI
75 u=0.76 # 28 #
76 v=8.2 # 11 #
77 # u=6.15
78 # v=5.32
79 DI_MD = calc_DI_MD(u, saa, v, HB)
80 plotandsavedata.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of HDX model M1 (1999 Resing) [283].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint
9 from scipy.optimize import minimize








17 self.name = []
18 self.par_name = []
19 self.par_val = []













32 for i in range(0,np.size(hbond2,axis=0)):














47 sa = np.loadtxt( os.path.join(path,’1999_Rasing_SA_all.dat’) , skiprows=0)




51 HB = np.loadtxt( os.path.join(path,’1999_rasing_HB_ave.dat’), skiprows=0)
52 saa = np.loadtxt( os.path.join(path,’1999_rasing_Sa_ave.dat’), skiprows=0)
53
54 def calc_DI_MD(u, saa, v, HB):
55 PF = 10**( u*saa + v/HB )
56 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
57 PF[indexofnan] = np.nanmax(PF)
58 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
59 kint = np.array(sequence_kint(pr.seq))
60 # PF=PF[1:]# remove the N-terminous residue from PF
61 ind = [] # finding index of Prolins
62 for k, l in enumerate(list(pr.seq)):
63 if l == ’P’:
64 ind = k
65 PF = np.insert(PF, ind, ’NAN’)
66
67 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
68 for k, t in np.ndenumerate(t):
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73 v=x[1]
74 DI_MD = calc_DI_MD(u, saa, v, HB)
75 DI_MD_2frag = []
76 DI_exp = []
77 idxs = []
78 leng = []
79 for i in range(0, len(pr.frag) - 1):
80 idx = pr.seq.find(pr.frag[i][2])




85 for k, i in enumerate(idxs):




89 print(’function is =’,answ)
90 return answ
91
92 x0 = np.array([.1,10])
93 bnds=((0, 5000), (0, 5000))
94
95 res = minimize(optim_fun, x0, args=(saa,HB) ,method=’SLSQP’,bounds=bnds,options={’xtol
↪→ ’: 1e-8, ’disp’: True})
96 print(res.x)
C.2.2 Model M2
Below is the python code for plotting the results for HDX model M2 (2003 V endruscolo) [285].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt









17 self.name = []
18 self.par_name = []
19 self.par_val = []
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31 hbond1 = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_all.dat’),
↪→ skiprows=0)
32 nic = np.loadtxt( os.path.join(path,’2003_Vendroscolo_number_of_contacts_all.dat’)
↪→ , skiprows=0)
33 hbond2=hbond1[:,1:] # averaging over all frames
34 nih=np.zeros(nic[:,1:].shape)
35 for i in range(0,np.size(hbond2,axis=0)):
36 for j in range(0,int(np.size(hbond2,axis=1)/8)):
37 indexofdist=np.array([0,2,4,6])
38 indexofangl=np.array([1,3,5,7])
39 nih[i,j]=np.sum((hbond2[i,indexofdist+j*8]<2.4)*1 * (np.arccos(hbond2[i,
↪→ indexofangl+j*8])>(3.14-0.7))*1)#
40
41 niha=np.mean(nih[:,:], axis=0) # averaging over all frames






46 niha = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_ave.dat’),
↪→ skiprows=0)




50 def calc_DI_MD(bc, nica, bh, niha):
51 PF = np.exp( bc*nica + bh*niha )
52 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
53 PF[indexofnan] = np.nanmax(PF)
54 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
55 kint = np.array(sequence_kint(pr.seq))
56 # PF=PF[1:]# remove the N-terminous residue from PF
57 ind = [] # finding index of Prolins
58 for k, l in enumerate(list(pr.seq)):
59 if l == ’P’:
60 ind = k
61 PF = np.insert(PF, ind, ’NAN’)
62
63 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
64 for k, t in np.ndenumerate(t):







72 DI_MD = calc_DI_MD(bc, nica, bh, niha)
73 plotandsavedata.func(DI_MD,pr,mod)




3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint
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17 self.name = []
18 self.par_name = []
19 self.par_val = []










30 hbond1 = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_all.dat’),
↪→ skiprows=0)
31 nic = np.loadtxt( os.path.join(path,’2003_Vendroscolo_number_of_contacts_all.dat’)
↪→ , skiprows=0)
32 hbond2=hbond1[:,1:] # averaging over all frames
33 nih=np.zeros(nic[:,1:].shape)
34 for i in range(0,np.size(hbond2,axis=0)):
35 for j in range(0,int(np.size(hbond2,axis=1)/8)):
36 indexofdist=np.array([0,2,4,6])
37 indexofangl=np.array([1,3,5,7])
38 nih[i,j]=np.sum((hbond2[i,indexofdist+j*8]<2.4)*1 * (np.arccos(hbond2[i,
↪→ indexofangl+j*8])>(3.14-0.7))*1)
39
40 niha=np.mean(nih[:,:], axis=0) # averaging over all frames






45 niha = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_ave.dat’),
↪→ skiprows=0)
46 nica = np.loadtxt( os.path.join(path,’2003_Vendroscolo_number_of_contacts_ave.dat’)
↪→ , skiprows=0)
47
48 def calc_DI_MD(bc, nica, bh, niha):
49 PF = np.exp( bc*nica + bh*niha )
50 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
51 PF[indexofnan] = np.nanmax(PF)
52 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
53 kint = np.array(sequence_kint(pr.seq))
54 # PF=PF[1:]# remove the N-terminous residue from PF
55 ind = [] # finding index of Prolins
56 for k, l in enumerate(list(pr.seq)):
57 if l == ’P’:
58 ind = k
59 PF = np.insert(PF, ind, ’NAN’)
60
61 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
62 for k, t in np.ndenumerate(t):
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67 bc=x[0]
68 bh=x[1]
69 DI_MD = calc_DI_MD(bc, nica, bh, niha)
70 DI_MD_2frag = []
71 DI_exp = []
72 idxs = []
73 leng = []
74 for i in range(0, len(pr.frag) - 1):
75 idx = pr.seq.find(pr.frag[i][2])





81 for k, i in enumerate(idxs):








89 x0 = np.array([.1,10])
90 bnds=((0, 5000), (0, 5000))
91
92 res = minimize(optim_fun, x0, args=(nica,niha),method=’SLSQP’,bounds=bnds,options={’
↪→ xtol’: 1e-8, ’disp’: True})
93 print(res.x)
C.2.3 Model M3
Below is the python code for plotting the results for HDX model M3 (2006 Best) [286].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt









17 self.name = []
18 self.par_name = []
19 self.par_val = []












31 hbond1 = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_all.dat’),
↪→ skiprows=0)
32 nic = np.loadtxt(os.path.join(path,’2006_Best_Nc_all.dat’) , skiprows=0)
33 hbond2=hbond1[:,1:] # averaging over all frames
34 nih=np.zeros(nic[:,1:].shape)
35 for i in range(0,np.size(hbond2,axis=0)):





41 niha=np.mean(nih[:,:], axis=0) # averaging over all frames






46 niha = np.loadtxt( os.path.join(path,’2006_best_hydrogen_bonds_ave.dat’), skiprows
↪→ =0)
47 nica = np.loadtxt( os.path.join(path,’2006_best_number_of_contacts_ave.dat’) ,
↪→ skiprows=0)
48
49 def calc_DI_MD(bc, nica, bh, niha):
50 PF = np.exp( bc*nica + bh*niha )
51 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
52 PF[indexofnan] = np.nanmax(PF)
53 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
54 kint = np.array(sequence_kint(pr.seq))
55 # PF=PF[1:]# remove the N-terminous residue from PF
56 ind = [] # finding index of Prolins
57 for k, l in enumerate(list(pr.seq)):
58 if l == ’P’:
59 ind = k
60 PF = np.insert(PF, ind, ’NAN’)
61
62 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
63 for k, t in np.ndenumerate(t):






70 DI_MD = calc_DI_MD(bc, nica, bh, niha)
71 plotandsavedata.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of HDX model M3 (2006 Best) [286].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint









17 self.name = []
18 self.par_name = []
19 self.par_val = []









29 hbond1 = np.loadtxt( os.path.join(path,’2003_Vendroscolo_hydrogen_bonds_all.dat’),
↪→ skiprows=0)
30 nic = np.loadtxt(os.path.join(path,’2006_Best_Nc_all.dat’) , skiprows=0)
31 hbond2=hbond1[:,1:] # averaging over all frames
32 nih=np.zeros(nic[:,1:].shape)
33 for i in range(0,np.size(hbond2,axis=0)):





39 niha=np.mean(nih[:,:], axis=0) # averaging over all frames






44 niha = np.loadtxt( os.path.join(path,’2006_best_hydrogen_bonds_ave.dat’), skiprows
↪→ =0)
45 nica = np.loadtxt( os.path.join(path,’2006_best_number_of_contacts_ave.dat’) ,
↪→ skiprows=0)
46
47 def calc_DI_MD(bc, nica, bh, niha):
48 PF = np.exp( bc*nica + bh*niha )
49 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
50 PF[indexofnan] = np.nanmax(PF)
51 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
52 kint = np.array(sequence_kint(pr.seq))
53 # PF=PF[1:]# remove the N-terminous residue from PF
54 ind = [] # finding index of Prolins
55 for k, l in enumerate(list(pr.seq)):
56 if l == ’P’:
57 ind = k
58 PF = np.insert(PF, ind, ’NAN’)
59
60 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
61 for k, t in np.ndenumerate(t):





67 DI_MD = calc_DI_MD(bc, nica, bh, niha)
68 DI_MD_2frag = []
69 DI_exp = []
70 idxs = []
71 leng = []
72 for i in range(0, len(pr.frag) - 1):
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73 idx = pr.seq.find(pr.frag[i][2])





79 for k, i in enumerate(idxs):








87 x0 = np.array([.1,10])
88 bnds=((0, 5000), (0, 5000))
89
90 res = minimize(optim_fun, x0, args=(nica,niha),method=’SLSQP’,bounds=bnds,options={’
↪→ xtol’: 1e-8, ’disp’: True})
91 print(res.x)
C.2.4 Model M4
Below is the python code for plotting the results for HDX model M4 (2006 Kieseritzky) [281].
1 # -*- coding: utf-8 -*-
2 """





8 from math import *
9 import numpy as np
10 import itertools as it
11 import os
12 import matplotlib.pyplot as plt









22 self.name = []
23 self.par_name = []
24 self.par_val = []









34 water = np.loadtxt( os.path.join(path,’final_water.dat’), skiprows=0)
35 closedwater=water[:,1::3]
198 Appendix C. Python Scripts
36 meanNOdist=np.mean(closedwater,axis=0)
37 rmsf=np.zeros(meanNOdist.shape)





41 nic = np.loadtxt( os.path.join(path,’2003_Vendroscolo_number_of_contacts_all.dat’)
↪→ , skiprows=0)




45 nica = np.loadtxt( os.path.join(path,’2006_Kieseri_number_of_contacts_ave.dat’),
↪→ skiprows=0)




50 def calc_DI_MD(bc, nica, bh, rmsf):
51 ind = [] # finding index of Prolins
52 for k, l in enumerate(list(pr.seq)):
53 if l == ’P’ or k==0:
54 ind.append(k)
55 rmsf=np.delete(rmsf,ind)
56 PF = np.exp( bc*nica + bh/rmsf )
57 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
58 PF[indexofnan] = np.nanmax(PF)
59 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
60 kint = np.array(sequence_kint(pr.seq))
61 # PF=PF[1:]# remove the N-terminous residue from PF
62 ind = [] # finding index of Prolins
63 for k, l in enumerate(list(pr.seq)):
64 if l == ’P’:
65 ind = k
66 PF = np.insert(PF, ind, ’NAN’)
67
68 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
69 for k, t in np.ndenumerate(t):







77 DI_MD = calc_DI_MD(bc, nica, bh, rmsf)
78 plotandsavedata.func(DI_MD,pr,mod)




3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint
9 from scipy.optimize import minimize
10 import protein_info







17 self.name = []
18 self.par_name = []
19 self.par_val = []


















36 nic = np.loadtxt( os.path.join(path,’2003_Vendroscolo_number_of_contacts_all.dat’)
↪→ , skiprows=0)




40 nica = np.loadtxt( os.path.join(path,’2006_Kieseri_number_of_contacts_ave.dat’),
↪→ skiprows=0)
41 rmsf = np.loadtxt( os.path.join(path,’2006_Kieseri_RMSF_NO.dat’), skiprows=0)
42
43
44 def calc_DI_MD(bc, nica, bh, rmsf):
45 PF = np.exp( bc*nica + bh/rmsf )
46 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
47 PF[indexofnan] = np.nanmax(PF)
48 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
49 kint = np.array(sequence_kint(pr.seq))
50 # PF=PF[1:]# remove the N-terminous residue from PF
51 ind = [] # finding index of Prolins
52 for k, l in enumerate(list(pr.seq)):
53 if l == ’P’:
54 ind = k
55 PF = np.insert(PF, ind, ’NAN’)
56
57 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
58 for k, t in np.ndenumerate(t):






65 DI_MD = calc_DI_MD(bc, nica, bh, rmsf)
66 DI_MD_2frag = []
67 DI_exp = []
68 idxs = []
69 leng = []
70 for i in range(0, len(pr.frag) - 1):
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71 idx = pr.seq.find(pr.frag[i][2])





77 for k, i in enumerate(idxs):




81 print(’function is =’,answ)
82 return answ
83
84 x0 = np.array([1,1])
85 bnds=((-10, 5000), (-10, 5000))
86
87 res = minimize(optim_fun, x0, args=(nica,rmsf) ,method=’SLSQP’,bounds=bnds,options={’
↪→ xtol’: 1e-8, ’disp’: True})
88 print(res.x)
C.2.5 Model M5
Below is the python code for plotting the results for HDX model M5 (2011 Ma) [287].
1 # -*- coding: utf-8 -*-
2 """





8 from math import *
9 import numpy as np
10 import itertools as it
11 import os
12 import matplotlib.pyplot as plt









22 self.name = []
23 self.par_name = []
24 self.par_val = []









34 water = np.loadtxt( os.path.join(path,’final_water.dat’), skiprows=0)
35 polar = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
36
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37 def calc_DI_MD(Co,Cc,water, polar):
38 water_tf=(water[:,1:]<3) * 1
39 polar_tf = (polar[:,1:] < 2.6) * 1
40 resnumber=int(((np.size(water, 1) - 1) / 3))
41 NHsol=np.zeros(resnumber)
42 NHB=np.zeros(resnumber)




47 indexofnan=[index for index, value in enumerate(PF) if np.isnan(value)]
48 PF[indexofnan]=np.nanmax(PF)
49 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
50 kint=np.array(sequence_kint(pr.seq))
51 # PF=PF[1:]# remove the N-terminous residue from PF
52 ind=[] # finding index of Prolins
53 for k,l in enumerate(list(pr.seq)):
54 if l==’P’:
55 ind=k
56 PF = np.insert(PF, ind, ’NAN’)
57
58 DI=np.zeros((7,pr.Cter_resid-pr.Nter_resid))





64 DI_MD = calc_DI_MD(Co,Cc,water, polar)
65 plotandsavedata.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of HDX model M5 (2011 Ma) [287].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint








17 self.name = []
18 self.par_name = []
19 self.par_val = []










30 self.a1 = []
31 self.a2 = []
32 self.a3 = []
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33 self.a4 = []
34 self.b0=[]
35 self.b1 = []
36 self.b2 = []
37 self.b3 = []









47 for pp in range(0,5):
48 path=os.getcwd()+’/’+rgs[str(pp)]+’_charm/models’
49 water1 = np.loadtxt( os.path.join(path,’final_water.dat’), skiprows=0)
50 polar11 = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
51 exec(’md.a’ + str(pp) + ’=water1’)
52 exec(’md.b’ + str(pp) + ’=polar1’)
53
54 def calc_DI_MD(Co,Cc,water, polar):
55 water_tf=(water[:,1:]<3) * 1
56 polar_tf = (polar[:,1:] < 2.6) * 1
57 resnumber=int(((np.size(water, 1) - 1) / 3))
58 NHsol=np.zeros(resnumber)
59 NHB=np.zeros(resnumber)




64 indexofnan=[index for index, value in enumerate(PF) if np.isnan(value)]
65 PF[indexofnan]=np.nanmax(PF)
66 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
67 kint=np.array(sequence_kint(pr.seq))
68 # PF=PF[1:]# remove the N-terminous residue from PF
69 ind=[] # finding index of Prolins
70 for k,l in enumerate(list(pr.seq)):
71 if l==’P’ and k!=0:
72 ind=k
73 PF = np.insert(PF, ind, ’NAN’)
74
75 DI=np.zeros((7,pr.Cter_resid-pr.Nter_resid))







83 err = np.zeros(5)




88 exec(’global pr; pr=pr_’ + rgs[str(pp)], globals(), locals())
89 exec(’global water; water=md.a’ + str(pp))
90 exec(’global polar; polar=md.b’ + str(pp))
91
92 DI_MD = calc_DI_MD(Co,Cc,water,polar)
93 DI_MD_2frag = []
94 DI_exp = []
95 idxs = []
96 leng = []
97 for i in range(0, len(pr.frag) - 1):
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98 idx = pr.seq.find(pr.frag[i][2])





104 for k, i in enumerate(idxs):





109 print(’function is =’,answ, err)
110 return answ
111
112 x0 = np.array([1,2])
113 bnds=((0, 5000), (0, 5000))
114
115 res = minimize(optim_fun, x0, args=(md) ,method=’SLSQP’,bounds=bnds,options={’xtol’: 1
↪→ e-8, ’disp’: True})
116 print(res.x)
C.2.6 Model M6
Below is the python code for plotting the results for HDX model M6 (2015 Park) [288].
1 # -*- coding: utf-8 -*-
2 """





8 from math import *
9 import numpy as np
10 import itertools as it
11 import os
12 import matplotlib.pyplot as plt









22 self.name = []
23 self.par_name = []
24 self.par_val = []








33 path=os.getcwd() + ’/hbond/’
34 fpdba = open(os.path.join(path,’pdba_bondH.dat’),’r’)
35 fpdsa = open(os.path.join(path,’pdsa_bondH.dat’),’r’)
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42 all_data=[x.split() for x in f.readlines()]
43 hb = np.zeros((int(1e5), pr.Cter_resid-pr.Nter_resid+1))
44 for row in range(0, len(all_data), 2):
45 x = np.array(all_data[row][1:], dtype=’|S4’)



















65 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
66 kint=np.array(sequence_kint(pr.seq))
67 ind=[] # finding index of Prolins




72 PF=PF[1:]# remove the N-terminous residue from PF
73 DI=np.zeros((7,pr.Cter_resid-pr.Nter_resid))
74 for k, t in np.ndenumerate(t):
75 DI[k[1],:]=(1-np.exp(-kint/PF*t))






Below is the python code for optimization of parameters of HDX model M6 (2015 Park) [288].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint
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16 self.year=[]
17 self.name = []
18 self.par_name = []
19 self.par_val = []







27 fpdba = open(os.path.join(path,’pdba_bondH.dat’),’r’)
28 fpdsa = open(os.path.join(path,’pdsa_bondH.dat’),’r’)




33 all_data=[x.split() for x in f.readlines()]
34 hb = np.zeros((int(1e5), pr.Cter_resid-pr.Nter_resid+1))
35 for row in range(0, len(all_data), 2):
36 x = np.array(all_data[row][1:], dtype=’|S4’)



















56 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
57 kint=np.array(sequence_kint(pr.seq))
58 ind=[] # finding index of Prolins
59 for k,l in enumerate(list(pr.seq)):
60 if l==’P’ and k!=0:
61 ind.append(k)
62 PF[ind]=’NAN’
63 PF=PF[1:]# remove the N-terminous residue from PF
64 DI=np.zeros((7,pr.Cter_resid-pr.Nter_resid))
65 for k, t in np.ndenumerate(t):
66 DI[k[1],:]=(1-np.exp(-kint/PF*t))





72 DI_MD = calc_DI_MD(base,pdsa,pdba,pdwa)
73 DI_MD_2frag = []
74 DI_exp = []
75 idxs = []
76 leng = []
77 for i in range(0, len(pr.frag) - 1):
78 idx = pr.seq.find(pr.frag[i][2])
79 if idx != -1:
80 idxs.append(idx)




84 for k, i in enumerate(idxs):




88 print(’function is =’,answ)
89 return answ
90
91 x0 = np.array([1e6])
92 bnds=[(0, 1e15)]
93
94 res = minimize(optim_fun, x0, args=(pdsa,pdba,pdwa) ,method=’nelder-mead’,bounds=bnds,
↪→ options={’xtol’: 1e-8, ’disp’: True})
95 print(res.x)
C.2.7 Model M7
Below is the python code for plotting the results for HDX model M7 (2015 Persson) [256].
1 # -*- coding: utf-8 -*-
2 """





8 from math import *
9 import numpy as np
10 import itertools as it
11 import os
12 import matplotlib.pyplot as plt









22 self.name = []
23 self.par_name = []
24 self.par_val = []











36 water = np.loadtxt( os.path.join(path,’final_water.dat’), skiprows=0)
37 polar = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
38
39 def calc_DI_MD(water, polar):





44 water_tf = (water[:, 1:] < w_ther) * 1
45 polar_tf = (polar[:, 1:] < p_ther) * 1
46 resnumber = int(((np.size(water, 1) - 1) / 3))
47 nf = int((np.size(water, 0)))
48 water_number = np.zeros([nf, resnumber])
49 polar_number = np.zeros([nf, resnumber])
50 for i in range(1, resnumber + 1):
51 water_number[:, i - 1] = np.sum(water_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
52 polar_number[:, i - 1] = np.sum(polar_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
53 open = ((water_number >= 2) * 1 & (polar_number <= 1) * 1)
54 to = np.zeros(np.size(open, 1))
55 tc = np.zeros(np.size(open, 1))
56 for i in range(0, np.size(open, 1)):
57 to[i] = open[:, i].sum()
58 tc[i] = np.size(open, 0) - open[:, i].sum()
59 PF = tc / (to+1e-6)
60 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
61 PF[indexofnan] = np.nanmax(PF)
62 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
63 kint = np.array(sequence_kint(pr.seq))
64 # PF=PF[1:]# remove the N-terminous residue from PF
65 ind = [] # finding index of Prolins
66 for k, l in enumerate(list(pr.seq)):
67 if l == ’P’:
68 ind = k
69 PF = np.insert(PF, ind, ’NAN’)
70
71 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
72 for k, t in np.ndenumerate(t):




77 DI_MD = calc_DI_MD(water, polar)
78 plotandsavedata.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of HDX model M7 (2015 Persson) [256].
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint








17 self.name = []
18 self.par_name = []
19 self.par_val = []
20 mod = model()







27 water = np.loadtxt( os.path.join(path,’final_water.dat’), skiprows=0)
28 polar = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
29
30
31 def calc_DI_MD(water, polar,ther):
32 water_tf = (water[:, 1:] < ther[0]) * 1
33 polar_tf = (polar[:, 1:] < ther[1]) * 1
34 resnumber = int(((np.size(water, 1) - 1) / 3))
35 nf = int((np.size(water, 0)))
36 water_number = np.zeros([nf, resnumber])
37 polar_number = np.zeros([nf, resnumber])
38 for i in range(1, resnumber + 1):
39 water_number[:, i - 1] = np.sum(water_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
40 polar_number[:, i - 1] = np.sum(polar_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
41 open = ((water_number >= 2) * 1 & (polar_number <= 1) * 1)
42 to = np.zeros(np.size(open, 1))
43 tc = np.zeros(np.size(open, 1))
44 for i in range(0, np.size(open, 1)):
45 to[i] = open[:, i].sum()
46 tc[i] = np.size(open, 0) - open[:, i].sum()
47 PF = tc / (to+1e-6)
48 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
49 PF[indexofnan] = np.nanmax(PF)
50 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
51 kint = np.array(sequence_kint(pr.seq))
52 # PF=PF[1:]# remove the N-terminous residue from PF
53 ind = [] # finding index of Prolins
54 for k, l in enumerate(list(pr.seq)):
55 if l == ’P’:
56 ind = k
57 PF = np.insert(PF, ind, ’NAN’)
58
59 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
60 for k, t in np.ndenumerate(t):
61 DI[k[1], :] = (1 - np.exp(-kint / (PF + 1) * t))
62 return DI
63 def optim_fun(x,water, polar):
64 ther=x
65 DI_MD = calc_DI_MD(water, polar,ther)
66 DI_MD_2frag = []
67 DI_exp = []
68 idxs = []
69 leng = []
70 for i in range(0, len(pr.frag) - 1):
71 idx = pr.seq.find(pr.frag[i][2])





77 for k, i in enumerate(idxs):




81 print(’function is =’,answ)
82 return answ
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83
84 x0 = np.array([2.6,2.6])
85 bnds=((0, 4),(0, 4))
86
87 res = minimize(optim_fun, x0, args=(water, polar) ,method=’nelder-mead’,bounds=bnds,
↪→ options={’xtol’: 1e-8, ’disp’: True})#’nelder-mead’
88 print(res.x)
C.2.8 Model M8
Below is the python code for model M8 (suggested correlation-based model based on SASA and
polar atom distance).
1
2 # -*- coding: utf-8 -*-
3 """





9 from math import *
10 import numpy as np
11 import itertools as it
12 import os
13 import matplotlib.pyplot as plt









23 self.name = []
24 self.par_name = []
25 self.par_val = []







33 sasa = np.loadtxt( os.path.join(path,’2012_Petruk_sasa_HN_all.dat’), skiprows=0)












46 msasa = np.nanmean(sasa, axis=0)
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47 PF = np.exp(a * (1 / msasa) ** b + c * (1/mpolar) ** d)
48 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
49 kint = np.array(sequence_kint(pr.seq))
50 sasa = sasa[:, 1:] # remove the N-terminous residue from PF
51 ind = [] # finding index of Prolins
52
53 for k, l in enumerate(list(pr.seq)):
54 if l == ’P’:
55 ind = k
56 PF = np.insert(PF, ind, ’NAN’)
57 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
58 for k, t in np.ndenumerate(t):




63 DI_MD = calc_DI_MD(sasa,polar)
64 plotandsavedata.func(DI_MD,pr,mod)
65 # plots1s2.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of model M8 (suggested correlation-based
model based on SASA and polar atom distance).
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint







16 self.name = []
17 self.par_name = []
18 self.par_val = []









28 self.a0 = []
29 self.a1 = []
30 self.a2 = []
31 self.a3 = []
32 self.a4 = []
33 self.b0 = []
34 self.b1 = []
35 self.b2 = []
36 self.b3 = []
37 self.b4 = []
38
39
C.2. Python codes for HDX modeling 211
40 md = MD()
41 rgs = {’0’: ’1agr’, ’1’: ’1ezt’, ’2’: ’2ihd’, ’3’: ’2ode’, ’4’: ’1cmz’}
42 pr_1agr = protein_info.get_protein_info_1agr()
43 pr_1cmz = protein_info.get_protein_info_1cmz()
44 pr_1ezt = protein_info.get_protein_info_1ezt()
45 pr_2ode = protein_info.get_protein_info_2ode()
46 pr_2ihd = protein_info.get_protein_info_2ihd()
47
48 for pp in range(0, 5):
49 path = os.getcwd() + ’/’ + rgs[str(pp)] + ’_charm/models’
50 sasa1 = np.loadtxt(os.path.join(path,’2012_Petruk_sasa_HN_all.dat’), skiprows=0)
51 polar1 = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
52 sasa1 = sasa1[:, 1:]
53 polar1 = polar1[:, 1:]
54 exec(’md.a’ + str(pp) + ’=sasa1’)




59 # polar_tf = (polar[:,:] < 2.6) * 1
60 # resnumber = int(((np.size(polar, 1)) / 3))
61 # nf = int((np.size(polar, 0)))
62 # polar_number = np.zeros([nf, resnumber])
63 # for i in range(1, resnumber + 1):
64 # polar_number[:, i - 1] = np.sum(polar_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
65 mpolar=np.nanmean(polar[:,0::3],axis=0)
66 msasa = np.nanmean(sasa, axis=0)
67 # mpolar_number= np.nanmean(polar_number, axis=0)
68 PF = np.exp(a * (1 / (msasa+e)) ** b + c *(1/mpolar) ** d)
69 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
70 kint = np.array(sequence_kint(pr.seq))
71 sasa = sasa[:, 1:] # remove the N-terminous residue from PF
72 ind = [] # finding index of Prolins
73 for k, l in enumerate(list(pr.seq)):
74 if l == ’P’ and k!=0:
75 ind = k
76 PF = np.insert(PF, ind, ’NAN’)
77 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
78 for k, t in np.ndenumerate(t):









88 err = np.zeros(5)




93 exec(’global pr; pr=pr_’ + rgs[str(pp)], globals(), locals())
94 exec(’global sasa; sasa=md.a’ + str(pp))
95 exec(’global polar; polar=md.b’ + str(pp))
96 DI_MD = calc_DI_MD(sasa,polar,a,b,c,d,e)
97 DI_MD_2frag = []
98 DI_exp = []
99 idxs = []
100 leng = []
101 for i in range(0, len(pr.frag) - 1):
102 idx = pr.seq.find(pr.frag[i][2])
103 if idx != -1:





108 for k, i in enumerate(idxs):





113 print(’function is =’,answ, err,a,b,c,d,e)
114 return answ
115
116 x0 = np.array([1.29663846e-03 , 2.63829588e+00 , 3.65422288e+01 , 1.26661531])
117 bnds=((0, 1e6), (0, 100),(0, 100),(0, 100))
118
119 res = minimize(optim_fun, x0, args=(md) ,method=’SLSQP’,bounds=bnds,options={’xtol’: 1
↪→ e-8, ’disp’: True}) #nelder-mead
120 print(res.x)
121
122 # SLSQP [1.29663846e-03 , 2.63829588e+00 , 3.65422288e+01 , 1.26661531]
123 # function is = 130.165557636 [ 19.581414 19.71070143 27.52171868 27.60260002
↪→ 35.7491235 ]
124 # Optimization terminated successfully. (Exit mode 0)
125 # Current function value: 130.165557636
126 # Iterations: 72
127 # Function evaluations: 491
128 # Gradient evaluations: 72
129 # [ 0.72243459 0.52669364 26.02122158 0.98869395]
C.2.9 Model M9
Below is the python code for model M9 (suggested residence-time-based model based on SASA
and polar atom distance).
1
2 # -*- coding: utf-8 -*-
3 """





9 from math import *
10 import numpy as np
11 import itertools as it
12 import os
13 import matplotlib.pyplot as plt










24 self.name = []
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25 self.par_name = []
26 self.par_val = []







34 sasa = np.loadtxt( os.path.join(path,’2012_Petruk_sasa_HN_all.dat’), skiprows=0)






41 polar_tf = (polar[:,:] < ther[1]) * 1
42 resnumber = int(((np.size(polar, 1)) / 3))
43 nf = int((np.size(polar, 0)))
44 polar_number = np.zeros([nf, resnumber])
45 for i in range(1, resnumber + 1):
46 polar_number[:, i - 1] = np.sum(polar_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
47 open = ((sasa[0:nf,:] > ther[0]) * 1 & (polar_number[0:nf,:] <= 1) * 1)
48 to = np.zeros(np.size(open, 1))
49 tc = np.zeros(np.size(open, 1))
50 for i in range(0, np.size(open, 1)):
51 to[i] = open[:, i].sum()
52 tc[i] = np.size(open, 0) - open[:, i].sum()
53 PF = tc / (to+1e-6)
54 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
55 PF[indexofnan] = np.nanmax(PF)
56 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
57 kint = np.array(sequence_kint(pr.seq))
58 # PF=PF[1:]# remove the N-terminous residue from PF
59 ind = [] # finding index of Prolins
60 for k, l in enumerate(list(pr.seq)):
61 if l == ’P’:
62 ind = k
63 PF = np.insert(PF, ind, ’NAN’)
64
65 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
66 for k, t in np.ndenumerate(t):
67 DI[k[1], :] = (1 - np.exp(-kint / (PF + 1) * t))
68 return DI
69
70 DI_MD = calc_DI_MD(sasa,polar)
71 plotandsavedata.func(DI_MD,pr,mod)
72 # plots1s2.func(DI_MD,pr,mod)
Below is the python code for optimization of parameters of model M9 (suggested residence-time-
based model based on SASA and polar atom distance).
1
2
3 from math import *
4 import numpy as np
5 import itertools as it
6 import os
7 import matplotlib.pyplot as plt
8 from calc_kint import sequence_kint
9 from scipy.optimize import minimize







16 self.name = []
17 self.par_name = []
18 self.par_val = []








27 self.a1 = []
28 self.a2 = []
29 self.a3 = []
30 self.a4 = []
31 self.b0=[]
32 self.b1 = []
33 self.b2 = []
34 self.b3 = []









44 for pp in range(0,5):
45 path=os.getcwd()+’/’+rgs[str(pp)]+’_charm/models’
46 sasa1 = np.loadtxt(os.path.join(path,’2012_Petruk_sasa_HN_all.dat’), skiprows=0)
47 polar1 = np.loadtxt( os.path.join(path,’final_polar.dat’), skiprows=0)
48 sasa1 = sasa1[:, 1:]






55 polar_tf = (polar[:,:] < ther[1]) * 1
56 resnumber = int(((np.size(polar, 1)) / 3))
57 nf = int((np.size(polar, 0)))
58 polar_number = np.zeros([nf, resnumber])
59 for i in range(1, resnumber + 1):
60 polar_number[:, i - 1] = np.sum(polar_tf[:, i * 3 - 3:i * 3 - 1], axis=1).astype
↪→ (’float’)
61 open = ((sasa[0:nf,:] > ther[0]) * 1 & (polar_number[0:nf,:] <= 1) * 1)
62 to = np.zeros(np.size(open, 1))
63 tc = np.zeros(np.size(open, 1))
64 for i in range(0, np.size(open, 1)):
65 to[i] = open[:, i].sum()
66 tc[i] = np.size(open, 0) - open[:, i].sum()
67 PF = tc / (to+1e-6)
68 indexofnan = [index for index, value in enumerate(PF) if np.isnan(value)]
69 PF[indexofnan] = np.nanmax(PF)
70 t = np.matrix([1, 3, 10, 30, 100, 300, 1000])
71 kint = np.array(sequence_kint(pr.seq))
72 # PF=PF[1:]# remove the N-terminous residue from PF
73 ind = [] # finding index of Prolins
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74 for k, l in enumerate(list(pr.seq)):
75 if l == ’P’ and k!=0:
76 ind = k
77 PF = np.insert(PF, ind, ’NAN’)
78
79 DI = np.zeros((7, pr.Cter_resid - pr.Nter_resid))
80 # print(’PF=’,PF.shape,’kint=’,kint.shape,pr.pdb)
81 for k, t in np.ndenumerate(t):
82 DI[k[1], :] = (1 - np.exp(-kint / (PF + 1) * t))
83 return DI
84
85 def optim_fun(x, md):
86 ther=x
87 err = np.zeros(5)




92 exec(’global pr; pr=pr_’+rgs[str(pp)],globals(), locals())
93 exec(’global sasa; sasa=md.a’+str(pp))
94 exec(’global polar; polar=md.b’+str(pp))
95 DI_MD = calc_DI_MD(sasa,polar,ther)
96 DI_MD_2frag = []
97 DI_exp = []
98 idxs = []
99 leng = []
100 for i in range(0, len(pr.frag) - 1):
101 idx = pr.seq.find(pr.frag[i][2])





107 for k, i in enumerate(idxs):





112 print(’function is =’,answ, err)
113 return answ
114
115 x0 = np.array([20,2.78])
116 bnds=((0, 20),(0, 4))
117
118 res = minimize(optim_fun, x0, args=(md) ,method=’nelder-mead’,bounds=bnds,options={’
↪→ xtol’: 1e-8, ’disp’: True})#’nelder-mead’
119 print(res.x)
120 # 9.25
121 # function is = 130.349990266 [ 22.69900915 23.7104026 26.18561858 27.57723388
↪→ 30.17772606]
122 # Optimization terminated successfully.
123 # Current function value: 130.349990
124 # Iterations: 37
125 # Function evaluations: 116
126 # [ 9.59173737 2.78384003]
127
128 # function is = 129.981766861 [ 22.79273768 23.56124522 26.34249452 28.5740201
↪→ 28.71126934]
129 # Optimization terminated successfully.
130 # Current function value: 129.981767
131 # Iterations: 55
132 # Function evaluations: 148
133 # [ 9.14827728 2.99030548]
134
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135 # nelder-mead --> mean
136 # function is = 0.663576142711 [ 0.14734772 0.14121824 0.107338 0.11664743 0.15102475]
137 # Optimization terminated successfully.
138 # Current function value: 0.663576
139 # Iterations: 56
140 # Function evaluations: 147
141 # [ 8.58328462 3.1489202 ]
C.2.10 Intrinsic kinetic rate calculations
The following code calculates the HDX intrinsic kinetic rate for an unstructured peptide using
Bai et al. correlation [255, 277]. The inputs of this program are temperature, pH, and sequence
of amino-acid residues. The output is a vector containing the HDX kinetic rates for each amide
hydrogen.
1 import os, sys, re
2 from collections import defaultdict




7 cur_dir = os.getcwd()
8 constR = 1.987/1000. #kcal/mol*K
9 AA_3to1 = {’GLY’:’G’, ’ALA’:’A’, ’VAL’:’V’, ’LEU’:’L’, ’ILE’:’I’,
10 ’MET’:’M’, ’PHE’:’F’, ’TRP’:’W’, ’PRO’:’P’, ’SER’:’S’,
11 ’THR’:’T’, ’CYS’:’C’, ’TYR’:’Y’, ’ASN’:’N’, ’GLN’:’Q’,
12 ’ASP’:’D’, ’GLU’:’E’, ’LYS’:’K’, ’ARG’:’R’, ’HIS’:’H’,
13 ’NTR’:’X’, ’CTR’:’Z’}
14 AA_1to3 = {’G’:’GLY’, ’A’:’ALA’, ’V’:’VAL’, ’L’:’LEU’, ’I’:’ILE’,
15 ’M’:’MET’, ’F’:’PHE’, ’W’:’TRP’, ’P’:’PRO’, ’S’:’SER’,
16 ’T’:’THR’, ’C’:’CYS’, ’Y’:’TYR’, ’N’:’ASN’, ’Q’:’GLN’,






23 pD_read = 7.4
24 myTemp = float(myTempC) + 273.0
25 pD_read = float(pD_read)
26 if re.search(’sec’, timeUnit):
27 timeUnitFactor = 1/60.
28 else:
29 timeUnitFactor = 1.0
30 log_AB_LR_dic = {#residue: [AL, AR, BL, BR ],
31 ’ALA’: [0.00, 0.00, 0.00, 0.00],
32 ’ARG’: [-0.59, -0.32, 0.08, 0.22],
33 ’ASN’: [-0.58, -0.13, 0.49, 0.32],
34 ’ASPd’: [0.9, 0.58, -0.30, -0.18], #D(COO-)
35 ’ASPp’: [-0.9, -0.12, 0.69, 0.6], #D(COOH)
36 ’CYS’: [-0.54, -0.46, 0.62, 0.55],
37 ’GLY’: [-0.22, 0.22, 0.27, 0.17],
38 ’GLN’: [-0.47, -0.27, 0.06, 0.20],
39 ’GLUd’: [-0.9, 0.31, -0.51, -0.15], #E(COO-)
40 ’GLUp’: [-0.6, -0.27, 0.24, 0.39], #E(COOH)
41 ’HISd’: [’NA’, ’NA’, -1.0, 0.14],
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42 ’HISp’: [-0.8, -0.51, 0.8, 0.83],
43 ’ILE’: [-0.91, -0.59, -0.73, -0.23],
44 ’ILE’: [-0.91, -0.59, -0.73, -0.23],
45 ’LEU’: [-0.57, -0.13, -0.58, -0.21],
46 ’LYS’: [-0.56, -0.29, -0.04, 0.12],
47 ’MET’: [-0.64, -0.28, -0.01, 0.11],
48 ’PHE’: [-0.52, -0.43, -0.24, 0.06],
49 ’PRO’: [’NA’, -0.19, ’NA’, -0.24], #P-trans
50 # ’PROc’: [’NA’, -0.85, ’NA’, 0.60], #P-cis
51 ’SER’: [-0.44, -0.39, 0.37, 0.30],
52 ’THR’: [-0.79, -0.47, -0.07, 0.20],
53 ’TRP’: [-0.40, -0.44, -0.41, -0.11],
54 ’TYR’: [-0.41, -0.37, -0.27, 0.05],
55 ’VAL’: [-0.74, -0.30, -0.70, -0.14],
56 ’NTR’: [’NA’, -1.32, ’NA’, 1.62],
57 ’CTRd’: [0.96, ’NA’, -1.8, ’NA’],
58 ’CTRp’: [0.05, ’NA’, ’NA’, ’NA’],
59 }
60 # print(log_AB_LR_dic[’NTR’])
61 #titrable_res_dic = {’ASP’:4.08, ’GLU’:4.53, ’HIS’:7.02, ’CTR’:7.0} # Bai et al.
↪→ 1993
62 titrable_res_dic = {’ASP’:4.50, ’GLU’:4.50, ’HIS’:6.75, ’CTR’:3.720} #, ’NTR’:8.02}
↪→ # SPHERE
63 # activation energies (kcal/mol)
64 #Ea_A = 14.0; Ea_B = 17.0; Ea_W = 19.0 # Bai 1993
65 Ea_A = 15.0; Ea_B = 2.6; Ea_W = 13.0 # SPHERE
66 """
67 Table I from Bai et al. (1993)
68 """
69 # standard reference rate constants at 293K
70 ###########################################
71 ## at high salt condition (0.5 KCl) oligo-peptide (from TableIII of Bai 1993)
72 """
73 kA_ref = (timeUnitFactor)*10**1.56 #1/(M*min)
74 kB_ref = (timeUnitFactor)*10**10.20 #1/(M*min)
75 kW_ref = (timeUnitFactor)*10**-2.3 #1/min
76 """
77 ## at high salt condition (0.5 KCl) poly-peptide (from TableIII of Bai 1993)
78 """
79 kA_ref = (timeUnitFactor)*10**1.19 #1/(M*min)
80 kB_ref = (timeUnitFactor)*10**9.900 #1/(M*min)
81 kW_ref = (timeUnitFactor)*10**-2.5 #1/min
82 """
83 # at normal lower salt condition oligo-peptide (from TableIII of Bai 1993)
84 #kA_ref = (timeUnitFactor)*10.**2.04 #1/(M*min)
85 #kB_ref = (timeUnitFactor)*10.**10.36 #1/(M*min)
86 #kW_ref = (timeUnitFactor)*10.**-1.5 #1/min
87 # logkA_ref = math.log10((timeUnitFactor)*10**2.04) #1/(M*min)
88 # logkB_ref = math.log10((timeUnitFactor)*10**10.36) #1/(M*min)
89 # logkW_ref = math.log10((timeUnitFactor)*10**-1.5) #1/min
90
91 # at normal lower salt condition poly-peptide (from TableIII of Bai 1993)
92 kA_ref = (timeUnitFactor)*10**1.62 #1/(M*min)
93 kB_ref = (timeUnitFactor)*10**10.05 #1/(M*min)
94 kW_ref = (timeUnitFactor)*10**-1.5 #1/min
95 logkA_ref = math.log10(kA_ref)
96 logkB_ref = math.log10(kB_ref)
97 logkW_ref = math.log10(kW_ref)
98
99 ###########################################
100 # pK(D, 20C) = 15.65
101 #pkD = 15.65
102 pkD = 15.05 # SPHERE; Connelly 1993
103 ##############################
104 pD_corr =pD_read + 0.4
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105 pOD_corr = pkD - pD_corr
106 ##############################
107 #Dcation = 10**-(pD_corr) # pD = -log10[D+]
108 #ODanion = 10**-(pOD_corr)
109 k_int=[]
110 seq_NH = ’x’.join(seq)
111 for k, v in enumerate(seq_NH):
112 logk_acid = 0; logk_base =0; logk_wat = 0; logk_int = 0
113 if v == ’x’:
114 res_R = AA_1to3[seq_NH[k - 1]]
115 res_L = AA_1to3[seq_NH[k + 1]]
116 special_res = titrable_res_dic.keys()
117 for s_res in special_res:
118 if res_R == s_res:
119 if pD_corr <= titrable_res_dic[s_res]:
120 res_R = res_R + ’p’
121 else:
122 res_R = res_R + ’d’
123 if res_L == s_res:
124 if pD_corr <= titrable_res_dic[s_res]:
125 res_L = res_L + ’p’
126 else:
127 res_L = res_L + ’d’
128 if log_AB_LR_dic[res_L][0] == ’NA’:
129 #A_L = 1.0
130 logA_L = 0.0
131 else:
132 #A_L = 10**(log_AB_LR_dic[res_L][0])
133 logA_L = log_AB_LR_dic[res_L][0]
134 #
135 if log_AB_LR_dic[res_R][1] == ’NA’:
136 #A_R = 1.0
137 logA_R = 0.0
138 else:
139 #A_R = 10**(log_AB_LR_dic[res_R][1])
140 logA_R = log_AB_LR_dic[res_R][1]
141 #
142 if log_AB_LR_dic[res_L][2] == ’NA’:
143 #B_L = 1.0
144 logB_L = 0.0
145 else:
146 #B_L = 10**(log_AB_LR_dic[res_L][2])
147 logB_L = log_AB_LR_dic[res_L][2]
148 #
149 if log_AB_LR_dic[res_R][3] == ’NA’:
150 #B_R = 1.0
151 logB_R = 0.0
152 else:
153 #B_R = 10**(log_AB_LR_dic[res_R][3])
154 logB_R = log_AB_LR_dic[res_R][3]
155 #kint = krc_293K * math.exp(-Ea*(1/float(myTemp)-1/293.0)/constR)
156 TempFactor = (1.0/myTemp - 1.0/293.0)/constR
157 #k_acid = (kA_ref * A_L * A_R * Dcation) * math.exp(-Ea_A*TempFactor)
158 #k_base = (kB_ref * B_L * B_R * ODanion) * math.exp(-Ea_B*TempFactor)
159 #k_wat = (kW_ref * B_L * B_R) * math.exp(-Ea_W*TempFactor)
160 #k_int = (k_acid + k_base + k_wat)
161 logk_acid = (logkA_ref + logA_L + logA_R - pD_corr)
162 logk_base = (logkB_ref + logB_L + logB_R - pOD_corr)
163 logk_wat = (logkW_ref + logB_L + logB_R)
164 #
165 k_acid = (10**(logk_acid)) * (math.exp(-Ea_A*TempFactor))
166 k_base = (10**(logk_base)) * (math.exp(-Ea_B*TempFactor))
167 k_wat = (10**(logk_wat)) * (math.exp(-Ea_W*TempFactor))
168 k_int.append(k_acid + k_base + k_wat)
169 return k_int
C.2. Python codes for HDX modeling 219
170
171 # pD_corr = 7.4
172 # myTempC = 0
173 # seq=’VSQEEVKKWAESLENLINHECGLAAFKAFLKSEYSEENIDFWISCEEYKKIKS’ \
174 # ’PSKLSPKAKKIYNEFISVQATKEVNLDSCTREETSRNMLEPTITCFDEAQKKIFNL’ \
175 # ’MEKDSYRRFLKSRFYLDLT’
176 # timeUnit = ’sec’
177 # a=sequence_kint(seq)
178 # print(a)
179 # from calc_kint import sequence_kint
Defined subfunctions used in HDX models
Script ”plotandsavedata.py” is as follow.
1 import matplotlib.pyplot as plt
2 import matplotlib as mpl
3 import matplotlib.pyplot as plt
4 import matplotlib.font_manager as font_manager
5 import os
6 import numpy as np
7
8 os.remove(’/home/hossein/.cache/matplotlib/fontList.py3k.cache’)
9 path = ’/home/hossein/.fonts/arial.ttf’
10 prop = font_manager.FontProperties(fname=path)
11 plt.rcParams["font.family"] = prop.get_name()
12
13 def func(DI_MD,pr,mod):
14 DI_MD_2frag = []
15 DI_exp = []
16 idxs = []
17 leng = []
18 frags = []
19 error=np.zeros(7)
20 pearson=np.zeros(7)
21 for i in range(0, len(pr.frag) - 1):
22 idx = pr.seq.find(pr.frag[i][2])
23 if idx != -1:
24 idxs.append(idx)
25 leng.append(len(pr.frag[i][2]))
26 DI_exp.append(pr.ex[i+1][:]) # +1 is because of the first row is for time and
↪→ the counter starts from the second row
27 frags.append(pr.frag[i][:])
28 DI_exp_res = np.zeros([1, pr.Cter_resid - pr.Nter_resid])
29 DI_MD_res = np.zeros([1, pr.Cter_resid - pr.Nter_resid])
30 for k, i in enumerate(idxs):
31 l = np.ndarray.tolist(np.nanmean(DI_MD[:, (idxs[k]-1):(idxs[k] + leng[k]-1)],
↪→ axis=1)) # -1 is used because The N-terminous resisue is missed is DI_MD
↪→ calculations (fro example: DI_MD has 127 in 1agr)
32 DI_MD_2frag.append(l)
33 DI_exp_res[:, idxs[k]-1:(idxs[k] + leng[k]-1)] = np.array(DI_exp[k][6])
34 DI_MD_res[:, idxs[k]-1:(idxs[k] + leng[k]-1)] = np.array(DI_MD_2frag[k][6])
35
36 DI_exp = np.array(DI_exp)
37 DI_MD_2frag=np.array(DI_MD_2frag)
38 frags=np.array(frags)
39 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
40 for i in range(0,np.size(DI_exp,1)):
41 DI_exp = np.array(DI_exp)
42 DI_MD_2frag = np.array(DI_MD_2frag)
43 frags = np.array(frags)
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44 error[i] = np.mean(np.abs(DI_exp[:,i] - DI_MD_2frag[:,i]))
45 pearson[i] = np.corrcoef(DI_exp[:,i],DI_MD_2frag[:,i])[0][1]
46 fig=plt.figure(figsize=(5,3))
47 ax = plt.subplot(111)
48 ax.plot(DI_exp[:,i]*100,label="Experiment",linewidth=3)
49 ax.plot(DI_MD_2frag[:,i]*100,label="MD",linewidth=3)
50 #labels=[str([frags[i, 0], ’-’, frags[i, 1]]).replace("’","").replace(",","").
↪→ replace("]","").replace("[","") for i in range(frags.shape[0])]
51 #labels=[’F’+ str(i+1) for i in range(frags.shape[0])]
52





58 ax.tick_params(axis=’y’, which=’minor’, width=2, length=5)




63 plt.axis([0, frags.shape[0]-1, 0, 101])
64 # Hide the right and top spines
65 ax.spines[’right’].set_visible(False)
66 ax.spines[’top’].set_visible(False)















81 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIresi’+’.out’, DI_MD, delimiter
↪→ =’ ’, newline=’\r\n’)
82 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIfrag’+’.out’, np.transpose(
↪→ DI_MD_2frag), delimiter=’ ’, newline=’\r\n’)
83 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIexpresi’+’.out’, DI_exp_res,
↪→ delimiter=’ ’, newline=’\r\n’)
84 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIMDtofragtoresi’+’.out’,
↪→ DI_MD_res, delimiter=’ ’, newline=’\r\n’)
85
86 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_errorandpearson’ +’.out’, np.
↪→ transpose(np.vstack([error,pearson])), delimiter=’ ’, fmt=[’%5.4f’ ,’%5.4f’])
87 plt.show();
88
89 # errorandpearson files have two columns: the first one is error and the second one is
↪→ pearson. Each row coresponds to the respective time
90 # DIfrag is DI of different fragments. Each row coresponds to the respective time
91 # DIres is DI of different residues. Each row coresponds to the respective time
The following script is “proteininfo.py”. Note that this code belongs to “1agr” pdb calculations.
For other pdbs the values of pr.pdb, pr.seq, pr.Nter resid, and pr.Cter resid should be updated.
1 import matplotlib.pyplot as plt
2 import matplotlib as mpl
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3 import matplotlib.pyplot as plt
4 import matplotlib.font_manager as font_manager
5 import os
6 import numpy as np
7
8 os.remove(’/home/hossein/.cache/matplotlib/fontList.py3k.cache’)
9 path = ’/home/hossein/.fonts/arial.ttf’
10 prop = font_manager.FontProperties(fname=path)
11 plt.rcParams["font.family"] = prop.get_name()
12
13 def func(DI_MD,pr,mod):
14 DI_MD_2frag = []
15 DI_exp = []
16 idxs = []
17 leng = []
18 frags = []
19 error=np.zeros(7)
20 pearson=np.zeros(7)
21 for i in range(0, len(pr.frag) - 1):
22 idx = pr.seq.find(pr.frag[i][2])
23 if idx != -1:
24 idxs.append(idx)
25 leng.append(len(pr.frag[i][2]))
26 DI_exp.append(pr.ex[i+1][:]) # +1 is because of the first row is for time and
↪→ the counter starts from the second row
27 frags.append(pr.frag[i][:])
28 DI_exp_res = np.zeros([1, pr.Cter_resid - pr.Nter_resid])
29 DI_MD_res = np.zeros([1, pr.Cter_resid - pr.Nter_resid])
30 for k, i in enumerate(idxs):
31 l = np.ndarray.tolist(np.nanmean(DI_MD[:, (idxs[k]-1):(idxs[k] + leng[k]-1)],
↪→ axis=1)) # -1 is used because The N-terminous resisue is missed is DI_MD
↪→ calculations (fro example: DI_MD has 127 in 1agr)
32 DI_MD_2frag.append(l)
33 DI_exp_res[:, idxs[k]-1:(idxs[k] + leng[k]-1)] = np.array(DI_exp[k][6])
34 DI_MD_res[:, idxs[k]-1:(idxs[k] + leng[k]-1)] = np.array(DI_MD_2frag[k][6])
35
36 DI_exp = np.array(DI_exp)
37 DI_MD_2frag=np.array(DI_MD_2frag)
38 frags=np.array(frags)
39 t=np.matrix([1, 3, 10, 30, 100, 300, 1000])
40 for i in range(0,np.size(DI_exp,1)):
41 DI_exp = np.array(DI_exp)
42 DI_MD_2frag = np.array(DI_MD_2frag)
43 frags = np.array(frags)
44 error[i] = np.mean(np.abs(DI_exp[:,i] - DI_MD_2frag[:,i]))
45 pearson[i] = np.corrcoef(DI_exp[:,i],DI_MD_2frag[:,i])[0][1]
46 fig=plt.figure(figsize=(5,3))
47 ax = plt.subplot(111)
48 ax.plot(DI_exp[:,i]*100,label="Experiment",linewidth=3)
49 ax.plot(DI_MD_2frag[:,i]*100,label="MD",linewidth=3)
50 #labels=[str([frags[i, 0], ’-’, frags[i, 1]]).replace("’","").replace(",","").
↪→ replace("]","").replace("[","") for i in range(frags.shape[0])]
51 #labels=[’F’+ str(i+1) for i in range(frags.shape[0])]
52





58 ax.tick_params(axis=’y’, which=’minor’, width=2, length=5)




63 plt.axis([0, frags.shape[0]-1, 0, 101])
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64 # Hide the right and top spines
65 ax.spines[’right’].set_visible(False)
66 ax.spines[’top’].set_visible(False)















81 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIresi’+’.out’, DI_MD, delimiter
↪→ =’ ’, newline=’\r\n’)
82 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIfrag’+’.out’, np.transpose(
↪→ DI_MD_2frag), delimiter=’ ’, newline=’\r\n’)
83 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIexpresi’+’.out’, DI_exp_res,
↪→ delimiter=’ ’, newline=’\r\n’)
84 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_DIMDtofragtoresi’+’.out’,
↪→ DI_MD_res, delimiter=’ ’, newline=’\r\n’)
85
86 np.savetxt(’outs/’ +mod.year+mod.name+’_’+pr.pdb+’_errorandpearson’ +’.out’, np.
↪→ transpose(np.vstack([error,pearson])), delimiter=’ ’, fmt=[’%5.4f’ ,’%5.4f’])
87 plt.show();
88
89 # errorandpearson files have two columns: the first one is error and the second one is
↪→ pearson. Each row coresponds to the respective time
90 # DIfrag is DI of different fragments. Each row coresponds to the respective time
91 # DIres is DI of different residues. Each row coresponds to the respective time
The following typical data files show how experimental data were used in python codes. Below is
“deut incor exper.dat” data file.
1 1 3 10 30 100 300 1000
2 0.1567255 0.2213669 0.3803359 0.4984604 0.6445559 0.6968758 0.6825115
3 0.1412602 0.2050054 0.3615517 0.4759400 0.6109563 0.6673170 0.6576120
4 0.0580286 0.0655902 0.0714346 0.0732698 0.0783630 0.0869249 0.0920819
5 0.0167174 0.0102922 0.0179626 0.0124530 0.0138145 0.0187863 0.0128680
6 0.0050846 0.0032648 0.0032711 0.0063105 0.0046908 0.0063105 0.0014467
7 0.1406978 0.1967006 0.3244722 0.4312298 0.5526127 0.5832695 0.5495889
8 0.0450538 0.0283075 0.0427496 0.0701290 0.1162947 0.1733676 0.2696388
9 0.0362307 0.0179980 0.0418809 0.0537927 0.0893234 0.1969362 0.3471875
10 0.0463516 0.0598539 0.0954620 0.1266807 0.2105852 0.2909196 0.3467074
11 0.0533727 0.0716148 0.1156233 0.1457377 0.2200280 0.2855975 0.2946924
12 0.0496517 0.0648081 0.1085306 0.1481462 0.2496171 0.3402721 0.3759174
13 0.2447644 0.3204327 0.4463178 0.5334227 0.5788695 0.5754578 0.5433755
14 0.2983944 0.3755573 0.5108657 0.5525323 0.6253237 0.6612673 0.6470953
15 0.2868979 0.3633099 0.4962368 0.5234257 0.5774467 0.5991577 0.5827802
16 0.2720060 0.3893975 0.5511704 0.6062504 0.6849797 0.7154627 0.7199232
17 0.1098361 0.1889636 0.3573498 0.4293931 0.4620903 0.4639683 0.4679145
18 0.1386663 0.2044902 0.3657807 0.4405281 0.4889644 0.4893735 0.4735473
19 0.1698418 0.2426050 0.3832147 0.4505416 0.4904283 0.4862827 0.4353183
20 0.1611921 0.2134451 0.3127460 0.3627734 0.4179900 0.4196210 0.4149816
21 0.3533889 0.4179983 0.5895260 0.6904303 0.8031001 0.8200740 0.8000811
22 0.0096803 0.0123712 0.0269148 0.0564731 0.1016254 0.1850138 0.3343568
23 0.0407553 0.0622870 0.0958575 0.1165402 0.1543007 0.2053706 0.2596682
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24 0.1718703 0.2490243 0.4389063 0.5780252 0.7423183 0.8107566 0.7984728
25 0.2073295 0.2305359 0.2953087 0.3273806 0.4594082 0.5723443 0.5982072
26 0.0782289 0.1116944 0.1681192 0.1883744 0.2129968 0.2343295 0.2562055
27 0.0452085 0.0611003 0.1143068 0.1438608 0.1646273 0.1781114 0.1989985
28 0.0509778 0.0633533 0.1007171 0.1300189 0.1526387 0.1645904 0.1733137
Below is “fragments.dat” data file.
1 48 63 GGSVSQEEVKKWAESL
2 48 66 GGSVSQEEVKKWAESLENL
3 67 73 INHECGL
4 74 80 AAFKAFL
5 76 80 FKAFL
6 81 87 KSEYSEE
7 88 91 NIDF
8 92 97 WISCEE
9 92 118 WISCEEYKKIKSPSKLSPKAKKIYNEF
10 97 117 EYKKIKSPSKLSPKAKKIYNE
11 98 118 YKKIKSPSKLSPKAKKIYNEF
12 116 123 NEFISVQA
13 118 129 FISVQATKEVNL
14 119 129 ISVQATKEVNL
15 123 129 ATKEVNL
16 130 143 DSCTREETSRNMLE
17 130 149 DSCTREETSRNMLEPTITCF
18 136 149 ETSRNMLEPTITCF
19 143 151 EPTITCFDE
20 144 149 PTITCF
21 150 159 DEAQKKIFNL
22 150 173 DEAQKKIFNLMEKDSYRRFLKSRF
23 158 173 NLMEKDSYRRFLKSRF
24 160 165 MEKDSY
25 160 173 MEKDSYRRFLKSRF
26 166 173 RRFLKSRF
27 166 174 RRFLKSRFY
C.3 Python code for Modeller
The following python code calls Modeller software and estimates an appropriate structure for
the coil (residue number from 719 to 747) in ectodomain part of the insulin receptor (see chapter
5).
1 # Loop refinement of an existing model
2 from modeller import *
3 from modeller.automodel import *
4 #from modeller import soap_loop
5 log.verbose()
6 env = environ()
7 # directories for input atom files
8 # env.io.atom_files_directory = [’.’, ’../atom_files’]
9 # Create a new class based on ’loopmodel’ so that we can redefine
10 # select_loop_atoms (necessary)
11 class MyLoop(loopmodel):
12 # This routine picks the residues to be refined by loop modeling
13 def select_loop_atoms(self):
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18 m = MyLoop(env,
19 inimodel=’EF_post.pdb’, # initial model of the target
20 sequence=’Loop_slow’, # code of the target
21 loop_assess_methods=assess.DOPE) # assess loops with DOPE
22 # loop_assess_methods=soap_loop.Scorer()) # assess with SOAP-Loop
23
24 m.loop.starting_model= 1 # index of the first loop model
25 m.loop.ending_model = 20 # index of the last loop model





The Amber software suite is divided into two parts: AmberTools16, a collection of freely avail-
able programs mostly under the GPL license, and Amber16, which is centered around the pmemd
simulation program, and which has a restrictive license. AmberTools is a set of programs for
biomolecular simulation and analysis. They are designed to work well with each other, and with
the “regular” Amber suite of programs. However, I used Ambertools in this thesis (chapters 6
and 7) to prepare initial coordinates for MD simulations and creating the corresponding AMBER
force-field for the system.
D.1 pdb4amber
The most PDB files require some modification before being used in AMBER. Most of the rec-
ommended modifications can be achieved with the pdb4amber program with the following options.
1 pdb4amber -i Modified.pdb -o Modified_noh.pdb --nohyd
2 # Options:
3 # --version show program’s version number and exit
4 # -h, --help show this help message and exit
5 # -i FILE, --in=FILE PDB input file (default: stdin)
6 # -o FILE, --out=FILE PDB output file (default: stdout)
7 # -y, --nohyd remove all hydrogen atoms (default: no)
8 # -d, --dry remove all water molecules (default: no)
9 # -p, --prot keep only Amber-compatible residues (default: no)
10 # --noter remove TER, MODEL, ENDMDL cards (default: no)
11 # --constantph rename GLU,ASP,HIS for constant pH simulation
12 # --most-populous keep most populous alt. conf. (default is to keep ’A’)
13 # --reduce Run Reduce first to add hydrogens. (default: no)
14 # --model=MODEL Model to use from a multi-model pdb file (integer).
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D.2 LEaP
LEaP is the generic name given to the programs teLeap and xaLeap, which are generally run via
the tleap and xleap shell scripts. These two programs share a common command language but the
xleap program has been enhanced through the addition of an X-windows graphical user interface.
The name LEaP is an acronym constructed from the names of the older AMBER software modules it
replaces: link, edit, and parm. Thus, LEaP can be used to prepare input for the AMBER molecular






6 # loadamberparams frcmod.tip4pew
7 mol = loadPdb "Modified_noh.pdb"
8 # mol = loadPdb "ionized_1agr.pdb"
9 # solvateBox mol TIP3PBOX 12.0
10 addIons2 mol Na+ 9
11 addIons2 mol Cl- 8
12 savepdb mol Modified_amber.pdb





E.1 Parallel calculations of VMD using “sbatch” on cluster nodes
VMD software has built-in parallel calculation ability using parallel command. The parallel
command enables large analysis scripts to be easily adapted for execution on large clusters and
supercomputers to support simulation, analysis, and visualization operations that would otherwise
be too computationally demanding for conventional workstations. For my thesis, I distributed job
analysis equally on n number of CPUs on the Cluster using the following code. This code invokes
VMD software n times and the results are combined after all computations on each CPU are done.
To run the following code one may copy the commands into a file (such as “run.sh”) and run it by




4 # SBATCH --nodelist=node116
5 #SBATCH -N 6
6 #SBATCH --cpus-per-task=24
7 #SBATCH --time 240:00:00
8 #SBATCH --output test.out






15 module load mpi/openmpi-x86_64
16 module load vmd/vmd-1.9.2-text
17 psf=ionized_1agr.psf
18 dcd=total.dcd
19 NumCpus=144; # the number of cpus that deployed for calculations
20 totalnf=100000; # the total length of original dcd file that should be analized
21 FramesCpu=$(($totalnf/$NumCpus+1)); # the number of frames for each cpu




25 for j in $(seq 0 $iter )
26 do
27 start=$(( $FramesCpu * $j))
28 end=$(($FramesCpu * ($j+1)-1))
29 srun --exclusive -n 1 -c 1 -s -v vmd -e intermedcalc.tcl -args $psf $dcd
↪→ $start $end out_$j.dat >& analysis_$j.log &
30 echo "last job number is : $j";




E.2 Bash (Unix shell) Scripts
Submitting NAMD jobs using Trillian, a Cary supercomputer at UNH
The following command was used to submit NAMD jobs on the Trillian supercomputer. This
command uses NAMD v 2.10, log file is nvt.log, the number of nodes is one, the name of MD job
is SMD, and the simulation continues for 24 hours on the cluster.
1 ˜rea/bin/NAMD --version 2.10 -l ’nvt.log’ --walltime 24:00:00 --numnodes 1 nvt.conf --
↪→ name ’SMD’
Submitting NAMD jobs on Premise
I used the following command for utilizing GPU nodes of the Premise cluster to carry out MD
simulation by NAMD:
1 module load namd/namd-2.11-ibverbs-smp-CUDA
2 sNAMD.py --gpus 2 --numnodes 1 --queue harish --walltime 960:00:00 --email
↪→ hm2006@wildcats.unh.edu --name 1agr_amber --logfile nvt.log ./amber_nvt.conf
I used the following command for utilizing CPU nodes of the Premise cluster to carry out MD
simulation by NAMD:
1 module load namd/namd-2.11-ibverbs-smp
2 sNAMD.py -N 1 -g 0 --queue shared --walltime 960:00:00 --email hm2006@wildcats.unh.edu
↪→ --name 1agrAmRes --logfile amber_nvt1.log ./amber_nvt1.conf
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Submitting NAMD jobs on Comet
To submit NAMD job on the Comet cluster, save the following commands to a text script and
execute the script with “qsub” command. Eq 03.conf is configuration file and Eq 03.log is log file.









8 #SBATCH -t 48:00:00
9 #SBATCH -A dxu114
10 #SBATCH --mail-type=ALL
11 #SBATCH --mail-user=hm2006@wildcats.unh.edu
12 module load namd
13 ibrun -v namd2 Eq_03.conf > Eq_03.log
E.3 catdcd
Catdcd functions much like the Unix “cat” command: it concatenates dcd files into a single
dcd file. It also allows the user to specify which atoms and which frames should be written into
the output file; thus dcds can be split as well as combined. This program was developed by
the Theoretical and Computational Biophysics Group University of Illinois at Urbana-Champaign
http://www.ks.uiuc.edu/.
Usage syntax:
1 catdcd -o outputfile [-otype <filetype>] [-i indexfile] [-stype <filetype>] [-s
↪→ structurefile] [-first firstframe] [-last lastframe] [-stride stride] [-<
↪→ filetype>] inputfile1 [-<filetype>] inputfile2 ...
Allowed input file types: cpmd pdb dcd Alchemy AMBERPREP BallStick BiosymCAR Boo-
gie Cacao CADPAC CHARMm Chem3d-1 Chem3d-2 CSSR FDAT GSTAT Feature Fractional
GAMESSoutput Z-matrix Gaussianoutput HIN Isis MacMolecule Macromodel MicroWorld MM2Input
MM2Output MM3 MMADS MDLMOL MOLIN MopacCartesian MopacInternal MopacOutput
PCModel Quanta ShelX Spartan SpartanSE SpartanMM Sybyl Sybyl2 Conjure Maccs2d Maccs3d
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UniChemXYZ XYZ XED gro g96 trr xtc crd crdbox namdbin binpos webpdb cube rst7 tinker
dlpolyhist lammpstrj xyz cor molden pqr mol2 car gamess xsf
Allowed output file types: pdb dcd trr crd crdbox namdbin binpos rst7 xyz pqr OR
1 catdcd -o <outputfile> [-i <indexfile>] [-first first] [-last last] [-stride stride] <
↪→ inputfile1 <inputfile2> ...
OR
1 catdcd -num <inputfile1> <intputfile2> ...
-o <outputfile>: Specify the output file for catdcd. Required, unless -num is present (see
below). -num: When present, no output file will be written. Instead, catdcd prints the number of
frames in each file, then exits.
-i <indexfile>: indexfile should contain the (zero-based) indices of the atoms in the dcd files
whose coordinates are to appear in the output file. The indices should be ASCII text, separated
by whitespace.
-first first: Specify the first frame to be written to the output file. Default is 1 (write starting
from the first frame read).
-last last: Specify the last frame to write. Default is the last frame in the last file.
-stride stride: Specify how many frames to skip when writing. Default is 1 (don’t skip any
frames).
Examples:
1 catdcd -num eq01.dcd eq02.dcd
Prints the number of frames in the two DCD files, then the total, then exits.
1 catdcd -o eq-pro.dcd -i protein.ind eq01.dcd
Takes only the coordinates corresponding to the indices in “protein.ind” from eq01.dcd and writes
them to eq-pro.dcd
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E.4 Modifying PDB file for the AMBER force-field
The following code should be run in Linux bash shell for modification of solvated and ionized
PDB of a protein. This code changes atom types and deletes hydrogens to be compatible with
Ambertools for further implementations.
1 sed ’s/TIP3W/WAT W/g’ ionized_1agr.pdb > Modified.pdb
2 sed -i ’s/OH2/O /g’ Modified.pdb
3 sed -i ’s/CLA/Cl/g’ Modified.pdb
4 sed -i ’s/SOD/Na/g’ Modified.pdb
5 sed -i ’s/HSD/HIS/g’ Modified.pdb
6 sed -i ’s/CD ILE/CD1 ILE/g’ Modified.pdb
7 sed -i ’s/OT1/O /g’ Modified.pdb
8 sed -i ’s/OT2/OXT/g’ Modified.pdb
9 sed -i ’/H1/ d’ Modified.pdb





After conducting SMD simulation using NAMD, the following TCL code is applied to the output
log file for the calculation of SMD forces. In this typical code, the orientation of molecules in the
simulation box was adjusted to make the SMD force along direction, otherwise, the variables nx,
ny, and nz should have appropriate values.
1 ### Open the log file for reading and the output .dat file for writing
2 set file [open cv.log r]
3 set output [open ft.dat w]
4
5 ### Gather input from user.
6 # puts "Enter a value for n_x:"
7 # set nx [gets stdin]
8 # puts "Enter a value for n_y:"
9 # set ny [gets stdin]
10 # puts "Enter a value for n_z:"
11 # set nz [gets stdin]
12 set nx 0
13 set ny 0
14 set nz 1
15 ### Loop over all lines of the log file
16 set file [open cv.log r]
17 while { [gets $file line] != -1 } {
18
19 ### Determine if a line contains SMD output. If so, write the
20 ### timestep followed by f(dot)n to the output file
21 if {[lindex $line 0] == "SMD"} {
22 puts $output "[lindex $line 1] [expr $nx*[lindex $line 5] + $ny*[lindex $line 6] +




26 ### Close the log file and the output .dat file
27 close $file
28 close $output
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F.2 Parallel calculations for HDX modeling
The following code is an intermediate code that should be named as “intermedcalc.tcl” and be
placed in the same directory in which the code in Appendix E.1 is carried out.
1 puts "$argv"
2 set psfFile [lindex $argv 0]
3 set dcdFile [lindex $argv 1]
4 set startFrame [lindex $argv 2]
5 set endFrame [lindex $argv 3]
6 set outFilename [lindex $argv 4]
7 puts "hosein $outFilename"
8 puts "Now to run:ostatecalc $psfFile $dcdFile $startFrame $endFrame $outFilename "
9 source procscalc.tcl
10
11 set mol [mol new $psfFile waitfor all]
12 mol addfile $dcdFile first $startFrame last $endFrame step 1 waitfor all molid $mol
13
14 ostatecalc $startFrame $outFilename
15 quit
The following code is called from “intermedcalc.tcl” (above code) by the command ”source proc-
scalc.tcl” to carry out trajectory analysis.
1 # ###################################################
2 proc Vendroscolo_2003_number_of_contacts_of_residue_i_with_other_residues {f HNi} {
3 # 2003_Vendroscolo --> 1-. , the number of contacts of residue i with
↪→ other residues : Contacts between two residues were defined to be
↪→ present when any pair of their atoms are closer than 8.5
4 set TIME_start [clock clicks -milliseconds]
5 puts "Start --> Vendroscolo_2003_number_of_contacts_of_residue_i_with_other_residues"
6 set cutoff 8.5
7 set atoms_in_cutoff [atomselect top "(protein and within $cutoff of (
↪→ protein and same residue as index $HNi)) and not (protein and same
↪→ residue as index $HNi)" frame $f]
8 set number_of_residue_in_cutoff [llength [lsort -unique [$atoms_in_cutoff
↪→ get resid]]]
9 set TIME_start [clock clicks -milliseconds]
10 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]







17 proc Vendroscolo_2003_hydrogen_bonds {f HNi} {
18 # 2003_Vendroscolo --> Hydrogen bonds were defined to be present if the
↪→ angle between the NH vector and the OH vector is below 0.7 rad and
↪→ the OH distance is below 2.4 .
19 set TIME_start [clock clicks -milliseconds]
20 puts "Start --> Vendroscolo_2003_hydrogen_bonds"
21
22 set cutoff 4
23 set o_in_vicinity_of_HNi [atomselect top "(oxygen) and protein and within
↪→ $cutoff of (index $HNi )" frame $f]
24 set nl [$o_in_vicinity_of_HNi num]
25 while {$nl < 4} {
26 incr cutoff
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27 set o_in_vicinity_of_HNi [atomselect top "(oxygen) and protein and
↪→ within $cutoff of (index $HNi )" frame $f]
28 set nl [$o_in_vicinity_of_HNi num]
29 }
30 set oindex [$o_in_vicinity_of_HNi get index]
31 set Nindex [[atomselect top "index $HNi"] getbonds]
32 set com_H [measure center [atomselect top "index $HNi" frame $f] weight
↪→ mass]
33 set com_N [measure center [atomselect top "index $Nindex" frame $f] weight
↪→ mass]
34 foreach jj $oindex {
35 set oatom [atomselect top "index $jj" frame $f]
36 set com_O [measure center $oatom weight mass]
37 lappend dist_and_cos_angle [list [veclength [vecsub $com_H $com_O]]
↪→ [ expr { [vecdot [vecsub $com_H $com_N] [vecsub $com_H $com_O
↪→ ]] / [veclength [vecsub $com_H $com_N]] / [veclength [vecsub
↪→ $com_H $com_O]] } ]]
38 # angle is between the NH vector and the OH vector
39 }
40
41 set dist_and_cos_angle_sorted [lrange [lsort -index 0 -real
↪→ $dist_and_cos_angle] 0 3]
42 set data [eval concat $dist_and_cos_angle_sorted]
43 unset dist_and_cos_angle_sorted
44 unset dist_and_cos_angle
45 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]
46 puts "End ($TIME_taken msec) --> Vendroscolo_2003_hydrogen_bonds"












59 return $data ; # data contains 8 lists : each pair of lists has two data:
↪→ the first list is distances of H from O and the second list is





↪→ {f HNi} {
64 # Nic is the number of contacts of the amide nitrogen with any atom
↪→ in all other residues within 6.5 ,
65 set TIME_start [clock clicks -milliseconds]
66 puts "Start --> Adhikary_2017_number_of_contacts_of_the_amide_nitrogen_with_any_atom"
67
68 set cutoff 6.5
69 set Nindex [[atomselect top "index $HNi"] getbonds]
70 set atoms_in_cutoff [atomselect top "(protein and within $cutoff of (index
↪→ $Nindex)) and not (protein and same residue as index $Nindex)"
↪→ frame $f]
71 set number_of_atoms_in_cutoff [llength [$atoms_in_cutoff get resid]]
72 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]
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78 }
79
80 proc Best_2006_number_of_contacts_of_the_amide_nitrogen_with_heavy_atom {f
↪→ HNi} {
81 # Nic is the number of contacts of the amide nitrogen with any atom
↪→ in all other residues within 6.5 ,
82 set TIME_start [clock clicks -milliseconds]
83 puts "Start --> Best_2006_number_of_contacts_of_the_amide_nitrogen_with_heavy_atom"
84
85 set cutoff 6.5
86 set Nindex [[atomselect top "index $HNi"] getbonds]
87 set atoms_in_cutoff [atomselect top "(protein and noh and within $cutoff
↪→ of (index $Nindex)) and not (protein and same residue as index
↪→ $Nindex)" frame $f]
88 set number_of_atoms_in_cutoff [llength [$atoms_in_cutoff get resid]]
89 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]








97 proc Adhikary_2017_hydrogen_bonds {f HNi} {
98 # Nih is the number of hydrogen bonds it forms, according to Gromacs,
↪→ version 4.6.7
99 set TIME_start [clock clicks -milliseconds]
100 puts "Start --> Adhikary_2017_hydrogen_bonds"
101
102 set cutoff_dis 3.5
103 set cutoff_angl 30
104 set Nindex [[atomselect top "index $HNi"] getbonds]
105 set oandN_in_vicinity_of_HNi [atomselect top "((oxygen or nitrogen) and
↪→ protein and within $cutoff_dis of (index $Nindex )) and not index
↪→ $Nindex" frame $f]
106 set oandNindex [$oandN_in_vicinity_of_HNi get index]
107 # puts [$oandN_in_vicinity_of_HNi num]
108 set com_H [measure center [atomselect top "index $HNi" frame $f] weight
↪→ mass]
109 set com_N [measure center [atomselect top "index $Nindex" frame $f] weight
↪→ mass]
110 set numberofhbond 0
111 foreach jj $oandNindex {
112 set oatom [atomselect top "index $jj" frame $f]
113 set com_O [measure center $oatom weight mass]
114 set angle [ expr { acos ( [vecdot [vecsub $com_N $com_H] [
↪→ vecsub $com_N $com_O]] / [veclength [vecsub $com_N
↪→ $com_H]] / [veclength [vecsub $com_N $com_O]] )*180/acos
↪→ (-1) } ]
115 # puts $angle




120 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]














134 proc Petruk_2012_sasa_HN {f HNi} {
135 set TIME_start [clock clicks -milliseconds]
136 puts "Start --> Petruk_2012_sasa_HN"
137 #they computed, for each residue NH (amide hydrogen (NH)), the SASA
↪→ corresponding to the initial crystal structure (xrSASA), the
↪→ average SASA (aveSASA), and the standard deviation (stdvSASA),
↪→ along each MD simulation.
138 set pr [atomselect top "protein" frame $f];
139 set sasa [measure sasa 1.4 $pr -restrict [atomselect top "index $HNi
↪→ " frame $f]];
140 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]







148 proc Petruk_2012_w_rdf {f HNi} {
149 set TIME_start [clock clicks -milliseconds]
150 puts "Start --> Petruk_2012_w_rdf"
151 # computed the water radial probability distribution function (w_rdf) for
↪→ each NH atom over the whole simulation.
152 set dr 0.2
153 set number_of_water []
154 for { set r $dr } { $r < 6 } { set r [expr { $r+$dr }] } {
155 lappend number_of_water [[atomselect top "water and name OH2
↪→ and within $r of index $HNi" frame $f] num];
156 }
157 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]
158 puts "End ($TIME_taken msec) --> Petruk_2012_w_rdf"
159
160 return $number_of_water ; # this list returns the number of water




164 proc Rasing_1999_SA {f HNi index_of_surf_1} {
165 # SA is the distance from the surface in angstroms
166 set TIME_start [clock clicks -milliseconds]
167 puts "Start --> Rasing_1999_SA"
168 set index_of_surf [[atomselect top "protein and index $index_of_surf_1 and
↪→ within 10 of index $HNi" frame $f] get index]
169 set com1 [measure center [atomselect top "index $HNi" frame $f] weight
↪→ mass]
170 set com2 [measure center [atomselect top "index [lindex $index_of_surf 0]"
↪→ frame $f] weight mass]
171 set dist_final [veclength [vecsub $com1 $com2]]
172 foreach jj $index_of_surf {
173 set com2 [measure center [atomselect top "index $jj" frame $f]
↪→ weight mass]
174 set dist [veclength [vecsub $com1 $com2]]
175 if {$dist < $dist_final } {
176 set dist_final $dist
177 }
178 }
179 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]
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184 unset dist




188 proc ostatecalc {start outFilename} {
189 package require pbctools
190 pbc wrap -compound fragment -centersel "protein" -center com -all
191 #2006_Kieseritzky --> same as 2003_Vendroscolo
192 # 2012_Petruk -->
193 # 2017_adhikary -->
194 # 2015_Persson -->
195 # 2006_Best --> 1-use 2015_persson criteria for hydrogen bond --> A cutoff
↪→ of 2.4 A between the donor hydrogen and the acceptor was used for
↪→ identifying a hydrogen bond
196 # --> 2-the number of heavy atoms within a distance of 6.5 A from the
↪→ amide nitrogen
197 # 2003_Vendroscolo -->
198
199 set file_2003_Vendroscolo_number_of_contacts [open 2003
↪→ _Vendroscolo_number_of_contacts_$outFilename w] ;# 1-. Contacts
↪→ between two residues were defined to be present when any pair of
↪→ their atoms are closer than 8.5
200 set file_2003_Vendroscolo_hydrogen_bonds [open 2003
↪→ _Vendroscolo_hydrogen_bonds_$outFilename w] ;# 2- Hydrogen bonds
↪→ were defined to be present if the angle between the NH vector and
↪→ the OH vector is below 0.7 rad and the OH distance is below 2.4 .
201 set file_2017_Adhikary_number_of_contacts [open 2017
↪→ _Adhikary_number_of_contacts_$outFilename w] ;# 1-. Contacts between
↪→ two residues were defined to be present when any pair of their
↪→ atoms are closer than 8.5
202 set file_2017_Adhikary_hydrogen_bonds [open 2017
↪→ _Adhikary_hydrogen_bonds_$outFilename w]
203 set file_2012_Petruk_sasa_HN [open 2012_Petruk_sasa_HN_$outFilename w]
204 set file_2012_Petruk_w_rdf [open 2012_Petruk_w_rdf_$outFilename w]
205 set file_1999_Rasing_SA [open 1999_Rasing_SA_$outFilename w]
206 set file_2006_Best_number_of_contacts [open 2006_Best_Nc_$outFilename w]
↪→ ;# the number of heavy atoms within a distance of 6.5 A from the
↪→ amide nitrogen
207
208 set nf [molinfo top get numframes]
209 set CA [atomselect top "protein and name CA"]
210 set Nter_resid [lindex [$CA get resid] 0]
211 set HN [atomselect top "protein and name HN and not resid $Nter_resid"]
212 set HNindex [$HN get index]
213
214 for {set f 0} {$f < $nf} {incr f} {
215 set TIME_start [clock clicks -milliseconds]
216 puts "Start --> Frame = [expr $f + $start]"
217 set pr [atomselect top "protein" frame $f];
218 set index_of_surf_1 [measure surface $pr 1.5 3.0 2.0];
219
220 puts -nonewline $file_2003_Vendroscolo_number_of_contacts "[expr $f
↪→ + $start]";
221 puts -nonewline $file_2003_Vendroscolo_hydrogen_bonds "[expr $f +
↪→ $start]";
222 puts -nonewline $file_2017_Adhikary_number_of_contacts "[expr $f +
↪→ $start]";
223 puts -nonewline $file_2017_Adhikary_hydrogen_bonds "[expr $f +
↪→ $start]";
224 puts -nonewline $file_2012_Petruk_sasa_HN "[expr $f + $start]";
225 puts -nonewline $file_2012_Petruk_w_rdf "[expr $f + $start]"
226 puts -nonewline $file_1999_Rasing_SA "[expr $f + $start]";
227 puts -nonewline $file_2006_Best_number_of_contacts "[expr $f +
↪→ $start]";
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228 foreach HNi $HNindex {
229
230 puts -nonewline $file_2003_Vendroscolo_number_of_contacts " [
↪→ Vendroscolo_2003_number_of_contacts_of_residue_i_with_other_residues
↪→ $f $HNi] " ;#3
231 puts -nonewline $file_2003_Vendroscolo_hydrogen_bonds " [
↪→ Vendroscolo_2003_hydrogen_bonds $f $HNi] " ;#3
232 puts -nonewline $file_2017_Adhikary_number_of_contacts " [
↪→ Adhikary_2017_number_of_contacts_of_the_amide_nitrogen_with_any_atom
↪→ $f $HNi] " ;
233 puts -nonewline $file_2017_Adhikary_hydrogen_bonds " [
↪→ Adhikary_2017_hydrogen_bonds $f $HNi] " ;
234 puts -nonewline $file_2012_Petruk_sasa_HN " [
↪→ Petruk_2012_sasa_HN $f $HNi] " ;
235 puts -nonewline $file_2012_Petruk_w_rdf " [ Petruk_2012_w_rdf
↪→ $f $HNi] " ;
236 puts -nonewline $file_1999_Rasing_SA " [ Rasing_1999_SA $f
↪→ $HNi $index_of_surf_1] " ;
237 puts -nonewline $file_2006_Best_number_of_contacts " [
↪→ Best_2006_number_of_contacts_of_the_amide_nitrogen_with_heavy_atom
↪→ $f $HNi] " ;
238 }
239
240 puts -nonewline $file_2003_Vendroscolo_number_of_contacts "\n" ;
241 puts -nonewline $file_2003_Vendroscolo_hydrogen_bonds "\n" ;
242 puts -nonewline $file_2017_Adhikary_number_of_contacts "\n" ;
243 puts -nonewline $file_2017_Adhikary_hydrogen_bonds "\n" ;
244 puts -nonewline $file_2012_Petruk_sasa_HN "\n" ;
245 puts -nonewline $file_2012_Petruk_w_rdf "\n" ;
246 puts -nonewline $file_1999_Rasing_SA "\n" ;
247 puts -nonewline $file_2006_Best_number_of_contacts "\n" ;
248 set TIME_taken [expr [clock clicks -milliseconds] - $TIME_start]
249 puts "End ($TIME_taken msec) --> Frame = [expr $f + $start]"
250 }
251 close $file_2003_Vendroscolo_number_of_contacts ;
252 close $file_2003_Vendroscolo_hydrogen_bonds ;
253 close $file_2017_Adhikary_number_of_contacts ;
254 close $file_2017_Adhikary_hydrogen_bonds ;
255 close $file_2012_Petruk_sasa_HN ;
256 close $file_2012_Petruk_w_rdf ;
257 close $file_1999_Rasing_SA ;
258 close $file_2006_Best_number_of_contacts ;
259 }
F.3 TCL scripts for preparing the initial coordinates of the αCT
and L1
See chapter 3.
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F.3.1 Extracting L1 and CT peptide from the pdb file
The following TCL script reads a pdb file (5j3h) and makes alignment and selections of the L1
and CT peptides.
1 # s519+IR :
2 mol new ./5j3h.pdb
3 set L1 [atomselect 0 "chain E and resid 5 to 152" frame 0]
4 set CT [atomselect 0 "chain B" frame 0]
5 # align two L domain
6 set x [measure center $L1 weight mass]
7 $L1 moveby [vecinvert $x ]
8 $CT moveby [vecinvert $x ]
9 package require Orient
10 namespace import Orient::orient
11 set I [draw principalaxes $L1]
12 set A [orient $L1 [lindex $I 0] {0 0 1}]
13 $L1 move $A
14 $CT move $A
15 $L1 writepdb aligned_L1.pdb
16 $CT writepdb aligned_CT.pdb
17 exit
F.3.2 Generating a PSF file using PSFGEN
The following code creates a PSF file for the CT and L1 peptide complex that was prepared in
Appendix F.3.1.
1 package require psfgen
2 # topology top_all22_prot_cmap.inp
3 # topology toppar_water_ions.str
4 topology top_all36_prot.rtf
5 # Alias of residues and atoms NOT properly defined in the original PDB files
6 # Alias for proteins
7 pdbalias residue HIS HSD
8 pdbalias atom ILE CD1 CD
9 pdbalias atom HOH O OH2
10 pdbalias residue HOH TIP3
11 # Protein
12 segment L1 {pdb aligned_L1.pdb}
13 coordpdb aligned_L1.pdb L1
14 guesscoord
15 segment CT {pdb aligned_CT.pdb}
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F.3.3 Solvation
The following code puts the CT and L1 peptides complex in a simulation water box and the
water molecules in vicinity of 2.4 A˚ of the peptides are deleted to avoid overlapping.
1 package require solvate
2 solvate LCTS.psf LCTS.pdb -x 10 -y 10 -z 10 +x 10 +y 10 +z 50 -b 2.4 -o LCTS_solv
3 exit
4
5 Usage: solvate <psffile> <pdbfile> <option1> <option2>...
6 Usage: solvate <option1> <option2>... to just create a water box
7 Options:
8 -o <output prefix> (data will be written to output.psf/output.pdb)
9 -s <segid prefix> (should be either one or two letters; default WT)
10 -b <boundary> (minimum distance between water and solute, default 2.4)
11 -minmax {{xmin ymin zmin} {xmax ymax zmax}}
12 -rotate (rotate molecule to minimize water volume)
13 -rotsel <selection> (selection of atoms to check for rotation)
14 -rotinc <increment> (degree increment for rotation)
15 -t <pad in all directions> (override with any of the following)
16 -x <pad negative x>
17 -y <pad negative y>
18 -z <pad negative z>
19 +x <pad positive x>
20 +y <pad positive y>
21 +z <pad positive z>
22 The following options allow the use of solvent other than water:
23 -spsf <solventpsf> (PSF file for nonstandard solvent)
24 -spdb <solventpdb> (PDB file for nonstandard solvent)
25 -stop <solventtop> (Topology file for nonstandard solvent)
26 -ws <size> (Box length for nonstandard solvent)
27 -ks <keyatom> (Atom occuring once per residue for nonstandard solvent)
F.3.4 Ionization
The following code neutralizes and sets salt concentration (mol/L) in the simulation box that
was generated in Appendix F.3.3. The default ions Na+ and Cl− are added for neutralizing and
determining ion concentration, however, the user may specify other ions by options.
1 package require autoionize
2 autoionize -psf LCTS_solv.psf -pdb LCTS_solv.pdb -o ionized_LCTS -sc 0.05
3 exit
4
5 Usage: autoionize -psf file.psf -pdb file.pdb [options]
6 Ion placement mode (choose one):
7 -neutralize -- only neutralize system
8 -sc -- neutralize and set salt concentration (mol/L)
9 -nions {{ion1 num1} {ion2 num2} ...} -- user defined number of ions
10 Other options:
11 -cation -- default: SOD
12 -anion -- default: CLA
13 -o -- output file prefix (default: ionized)
14 -from -- min. distance from solute (default: 5A)
15 -between -- min. distance between ions (default: 5A)
16 -seg -- specify new segment name (default: ION)
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17 Supported ions (CHARMM force field resnames):
18 SOD -- sodium (Na+)
19 MG -- magnesium (Mg2+)
20 POT -- potassium (K+)
21 CES -- cesium (Cs+)
22 CAL -- calcium (Ca2+)
23 ZN2 -- zinc (Zn2+)
24 CLA -- chloride (Cl-)
F.3.5 Determine the size of the simulation box and the center of box
After finalizing the initial coordinate file (solvating in water and adding ions) and generating
corresponding PDB and PSF files, the size of simulation box should be obtained using the following
code. These sizes and the center of mass of the simulation box will be used in configuration file for
carrying out MD simulation.
1 mol load pdb ionized_LCTS.pdb psf ionized_LCTS.psf
2 set outfile [open data.dat w];
3 set sel [atomselect top "all"]
4 set a [measure minmax $sel]
5 set a1 [lindex $a 0]
6 set a2 [lindex $a 1]
7 set size [vecsub $a2 $a1]
8 puts $outfile "MIN: $a1 "
9 puts $outfile "MAX: $a2 "
10 puts $outfile "SIZE: $size "
11 set b [measure center $sel]
12 puts $outfile "CENTER: $b "
13 close $outfile
14 puts "MIN: $a1 "
15 puts "MAX: $a2 "
16 puts "SIZE: $size "
17 set b [measure center $sel]
18 puts "CENTER: $b
19 exit
F.4 Analysis codes
F.4.1 Root mean squared deviation (RMSD)
The following code aligns all snapshots of RGS4 MD simulations on the first frame of trajectory
and then calculates RMSD of different helices and coils of the protein.
1 mol new 1agr.psf
2 mol addfile total_dry.dcd waitfor all
3 set outfile [open rmsd_all.dat w]
4 set nf [molinfo top get numframes]
5 set Pr [atomselect top "all"]
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6 set CA1 [atomselect top "protein and name CA "]
7 set Nter_resid [lindex [$CA1 get resid] 0]
8 set a4align1 [atomselect top "protein and name CA"]
9 set a4align [atomselect top "protein and name CA"]
10 set a1 [atomselect top "protein and name CA and resid [expr $Nter_resid] to [expr
↪→ $Nter_resid+9]"]
11 set a2 [atomselect top "protein and name CA and resid [expr $Nter_resid+10] to [expr
↪→ $Nter_resid+17]"]
12 set a3 [atomselect top "protein and name CA and resid [expr $Nter_resid+18] to [expr
↪→ $Nter_resid+32]"]
13 set l34 [atomselect top "protein and name CA and resid [expr $Nter_resid+33] to [expr
↪→ $Nter_resid+36]"]
14 set a4 [atomselect top "protein and name CA and resid [expr $Nter_resid+37] to [expr
↪→ $Nter_resid+49]"]
15 set l45 [atomselect top "protein and name CA and resid [expr $Nter_resid+50] to [expr
↪→ $Nter_resid+53]"]
16 set a5 [atomselect top "protein and name CA and resid [expr $Nter_resid+54] to [expr
↪→ $Nter_resid+67]"]
17 set l56 [atomselect top "protein and name CA and resid [expr $Nter_resid+68] to [expr
↪→ $Nter_resid+79]"]
18 set a6 [atomselect top "protein and name CA and resid [expr $Nter_resid+80] to [expr
↪→ $Nter_resid+91]"]
19 set l67 [atomselect top "protein and name CA and resid [expr $Nter_resid+92] to [expr
↪→ $Nter_resid+98]"]
20 set a7 [atomselect top "protein and name CA and resid [expr $Nter_resid+99] to [expr
↪→ $Nter_resid+108]"]
21 set a8 [atomselect top "protein and name CA and resid [expr $Nter_resid+109] to [expr
↪→ $Nter_resid+119]"]
22 set a9 [atomselect top "protein and name CA and resid [expr $Nter_resid+120] to [expr
↪→ $Nter_resid+126]"]
23 set a11 [atomselect top "protein and name CA and resid [expr $Nter_resid] to [expr
↪→ $Nter_resid+9]"]
24 set a21 [atomselect top "protein and name CA and resid [expr $Nter_resid+10] to [expr
↪→ $Nter_resid+17]"]
25 set a31 [atomselect top "protein and name CA and resid [expr $Nter_resid+18] to [expr
↪→ $Nter_resid+32]"]
26 set l341 [atomselect top "protein and name CA and resid [expr $Nter_resid+33] to [expr
↪→ $Nter_resid+36]"]
27 set a41 [atomselect top "protein and name CA and resid [expr $Nter_resid+37] to [expr
↪→ $Nter_resid+49]"]
28 set l451 [atomselect top "protein and name CA and resid [expr $Nter_resid+50] to [expr
↪→ $Nter_resid+53]"]
29 set a51 [atomselect top "protein and name CA and resid [expr $Nter_resid+54] to [expr
↪→ $Nter_resid+67]"]
30 set l561 [atomselect top "protein and name CA and resid [expr $Nter_resid+68] to [expr
↪→ $Nter_resid+79]"]
31 set a61 [atomselect top "protein and name CA and resid [expr $Nter_resid+80] to [expr
↪→ $Nter_resid+91]"]
32 set l671 [atomselect top "protein and name CA and resid [expr $Nter_resid+92] to [expr
↪→ $Nter_resid+98]"]
33 set a71 [atomselect top "protein and name CA and resid [expr $Nter_resid+99] to [expr
↪→ $Nter_resid+108]"]
34 set a81 [atomselect top "protein and name CA and resid [expr $Nter_resid+109] to [expr
↪→ $Nter_resid+119]"]
35 set a91 [atomselect top "protein and name CA and resid [expr $Nter_resid+120] to [expr
↪→ $Nter_resid+126]"]
36 set i 0
37 $a4align1 frame [expr {$i}]
38 $a11 frame [expr {$i}]
39 $a21 frame [expr {$i}]
40 $a31 frame [expr {$i}]
41 $a41 frame [expr {$i}]
42 $a51 frame [expr {$i}]
43 $a61 frame [expr {$i}]
44 $a71 frame [expr {$i}]
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45 $a81 frame [expr {$i}]
46 $a91 frame [expr {$i}]
47 $l341 frame [expr {$i}]
48 $l451 frame [expr {$i}]
49 $l561 frame [expr {$i}]
50 $l671 frame [expr {$i}]
51 for { set i 0 } {$i <=100000} {incr i} {
52 $Pr frame [expr {$i}]
53 $a4align frame [expr {$i}]
54 $a1 frame [expr {$i}]
55 $a2 frame [expr {$i}]
56 $a3 frame [expr {$i}]
57 $a4 frame [expr {$i}]
58 $a5 frame [expr {$i}]
59 $a6 frame [expr {$i}]
60 $a7 frame [expr {$i}]
61 $a8 frame [expr {$i}]
62 $a9 frame [expr {$i}]
63 $l34 frame [expr {$i}]
64 $l45 frame [expr {$i}]
65 $l56 frame [expr {$i}]
66 $l67 frame [expr {$i}]
67 set movematrix [measure fit $a4align $a4align1]
68 $Pr move $movematrix
69 puts $i
70 puts $outfile "[expr $i] [measure rmsd $a1 $a11] [measure rmsd $a2 $a21] [measure rmsd
↪→ $a3 $a31] [measure rmsd $l34 $l341] [measure rmsd $a4 $a41] [meas
71 ure rmsd $l45 $l451] [measure rmsd $a5 $a51] [measure rmsd $l56 $l561] [measure rmsd
↪→ $a6 $a61] [measure rmsd $l67 $l671] [measure rmsd $a7 $a71] [measur




F.4.2 Root mean squared fluctuation (RMSF)
The following script calculates the RMSF of Cα atoms in the protein backbone using MD
simulation snapshots.
1 set outfile [open rmsf.dat w]
2 set mol [mol new 1agr.psf waitfor all]
3 mol addfile total_dry.dcd first 0 last 100000 waitfor all molid $mol
4 set CA1 [atomselect top "protein name CA"]
5 set CA2 [atomselect top "protein name CA"]
6 set Pr [atomselect top "all"]
7 set nf [molinfo top get numframes]
8 $CA1 frame 0
9 for { set i 1 } { $i <= $nf } { incr i } {
10 $CA2 frame [expr {$i}]
11 $Pr frame [expr {$i}]
12 set movematrix [measure fit $CA2 $CA1]
13 $Pr move $movematrix
14 }
15 set CA [atomselect top "protein and name CA"]
16 puts $outfile "[measure rmsf $CA]"
17 # puts $outfile "[measure rmsf $CA first 1 last 1500 step 1]"
18 close $outfile
19 exit
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F.4.3 Solvent accessible surface area (SASA)
The following code calculates SASA of sulfur atoms in CYS residues in RGS4.
1 set filesasa [open sasa.dat w] ;# SASA
2 set mol [mol new ../1agr.psf waitfor all]
3 mol addfile ../total_dry.dcd waitfor all molid $mol
4 set nf [molinfo top get numframes];
5 set pr [atomselect top "protein"];
6 set resid [$pr get resid];
7 set resid [lsort -unique -increasing -integer $resid];
8 for {set i 0} {$i < $nf} {incr i} {
9 set SG1 [atomselect top "protein and resname CYS and resid 71 and name SG"];
10 set SG2 [atomselect top "protein and resname CYS and resid 95 and name SG" frame $i
↪→ ];
11 set SG3 [atomselect top "protein and resname CYS and resid 132 and name SG" frame
↪→ $i];
12 set SG4 [atomselect top "protein and resname CYS and resid 148 and name SG" frame
↪→ $i];
13 $pr frame $i;
14 set sasa1 [measure sasa 1.4 $pr -restrict $SG1];
15 set sasa2 [measure sasa 1.4 $pr -restrict $SG2];
16 set sasa3 [measure sasa 1.4 $pr -restrict $SG3];
17 set sasa4 [measure sasa 1.4 $pr -restrict $SG4];
18 puts -nonewline $filesasa "[expr $i] $sasa1 $sasa2 $sasa3 $sasa4"
19 $SG1 delete;unset SG1;
20 $SG2 delete;unset SG2;
21 $SG3 delete;unset SG3;
22 $SG4 delete;unset SG4;
23 unset sasa1 sasa2 sasa3 sasa4;






MD Simulations Using Anton
Anton is able to carry out MD simulations of biomolecular systems nearly two orders of mag-
nitude faster than the previous state-of-the-art as shown in Table G.1.1
Table G.1: Estimates of simulation resources on Anton
Chemical system Number of atoms Approximate performance 2
(PDB ID) (microseconds/machine-day)
DHFR (5DFR) 23,558 61.3
aSFP (1SFP) 48,423 53.0
FtsZ (1FSZ) 98,236 26.0
T7Lig (1A01) 116,650 21.9
bILAP (1BPM) 132,362 18.7
f1atpase 327,506 7.9
Tiled FDH-H 3 700,184 3.6
1This appendix has been adopted from Anton 2 documentations: https://www.psc.edu/anton-rfp,
https://wiki.psc.edu/twiki/view/Anton/WebHome.
2All simulations used 2.5-femtosecond time steps with long-range interactions evaluated at every other time step
and a Nose-Hoover thermostat applied every 100 time steps. Performance was measured on a 128-node Anton 2
machine like the one hosted by PSC. Simulation performance in microseconds/machine-day is approximately 50%
higher if 4fs time steps and Hydrogen Mass Repartitioning are used (see [296]).
3This system represents eight copies of FDH-H (formate dehydrogenase H) in a single 190 A˚ cubical box.
246 Appendix G. MD Simulations Using Anton
G.1 Recommended directory layout
All simulation input and trajectory files should be kept in the directory $RAW on anton2fs.
Never keep any of these files in your home directory.
* Input files and simulation log files should be put in
$RAW/<system name>/
* The directory where the trajectories and other simulation output data is written to during Anton
runs should be set to
$RAW/<system name>/workdir
G.2 DESRES software garden
In order to add force-fields to your system and run simuluations on Anton 2, you will use the
DESRES Software Garden. The DESRES Software Garden is a write-only file system that contains
the sofware you will need to prep and run your Anton simulations. Using scripts in the garden
via command-line is as simple as calling the garden command with the name, version, and bin
where the script lives, followed by the name of the program. This prepends the location of the
software to the $PATH and sometimes sets other relevant environment variables. To access the
garden command (in bash), you must run eval “$(/usr/bin/garden-exec)” âĂŞ it might be a good
idea to keep this in your .bashrc file. If you’re starting a new project, you probably want to pick
the latest available version of software in the garden. To get a list of all available versions, you can
call:
1 garden av $module_name
Example:






















Pay attention to the version numbers in the list. They’re not always in order.
G.3 How to convert an equilibrated NAMD simulation into the
DMS format
This topic explains how to convert topology and coordinates/velocities from NAMD into a DMS
input file required by Anton. You need to have a psf file, as well as binary coordinate (.coor), binary
velocity (.vel), and extended system file (.xsc) of your system. The binary velocity file must be
the original binary restart file written by NAMD. Otherwise, there will be a problem with unit
conversion when you use the python script below, and your simulation will blow up when you try
to run it. The conversion script requires VMD-1.9 or newer for the conversion from NAMD to dms
and viparr version 4.
On kollman.psc.edu:
Use the script convertNAMDtoDMS.py (Appendix C.1), then, run it via
1 module load vmd/1.9
2 vmd -dispdev text -python -e convertNAMDtoDMS.py -args -p <psffile> -c <binary
↪→ coordinate file> -v <binary velocity file> -x <extended system file> -o <
↪→ outfile_name> [-s -S "<selection>"]
Note that version 1.9 of vmd is the one required for the above to work. The -s parameter is optional
and will center the system based on the selection given via -S. By default the selection is ”all” and
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the system is not centered. It is in general useful to center your protein in the simulation box for
simulations on Anton. The resulting dms file will be called outfile name.dms.
For example:
1 module load vmd/1.9
2 vmd -dispdev text -python -e convertNAMDtoDMS.py -args -p pr_popcwi.psf -c
↪→ pr_popcwieq_03.restart.coor -v pr_popcwieq_03.restart.vel -x pr_popcwieq_03.
↪→ restart.xsc -o aim4
G.4 Add force-field parameters to the dms file using viparr
On anton2.psc.edu: After generating the outfile name.dms file in dms format use viparr to
add force-field parameters. The force-fields that you use should match the ones used for the original
NAMD simulation. These instructions use the CHARMM36 protein parameters and TIP3P water.
Do not forget to add ions FF if your system contains ions.
1 garden load viparr/4.5.34-st008/bin viparr-ff/1.8.18/share viparr-ff/1.8.18/bin
2 viparr -f charmm36_aminoacids -f tip3p_charmm -f charmm36_ions input.dms output.dms
For Example:
1 garden load viparr/4.5.34-st008/bin viparr-ff/1.8.18/share viparr-ff/1.8.18/bin
2 viparr -f charmm36_aminoacids -f charmm36_lipids -f charmm36_ions -f tip3p_charmm aim4
↪→ .dms aim4ff.dms
G.5 Examining the dms file
dms-info [ options] [ dms files ] writes a summary of the atom and force-field information of a
dms file. dms-info provides a summary of the contents of a dms file. Its output includes:
• Total number of atoms, bonds, residues, and chains global cell size.
• Force tables organized by category (bond, constraint, virtual, etc).
• Number of atoms each that can be selected as a protein, lipid, ions, water, or none of the
above.
For example:
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1 garden load msys/1.7.151/bin
2 dms-info aim4ff.dms
G.6 Preparing your ark File
Ark files are used as input to the Anton simulation and describe the desired simulation condi-
tions. Ark files are plain text files and can be conveniently edited with any text editor. Each ark
file may consist of several main sections (or namespaces) that specify a certain class of simulation
properties:
• anton: Controls Anton specific parameters and consists of two sub namespaces.
– tune: Options for tuning performance and controlling output. Options in this namespace
can be changed without affecting bitwise accuracy.
– chem: Parameters controlling the numerical aspect of Anton simulations including fixed
point arithmetic.
• boot: name of equilibrated input file in DMS format.
• integrator: specifies integrator and its properties. Currently supported integrators on An-
ton are NVE, Berendsen NVT and NPT (Ber NV T , Ber NPT ) and Nose-Hoover NVT
(NH NV T )
• force: parameters for force-field evaluations (cut-offs, ...)
1 # This is a sample input ark file for simulations on Anton @PSC
2 #
3 # 09/13/2010: Initial creation - Markus Dittrich
4 # 02/14/2011: Updates for anton_software version 2.4.0 and
5 # economy_flow - Markus Dittrich
6 # 09/30/2011: Updates for anton_software version 2.6.3 - Markus Dittrich
7 # 11/05/2011: Updates for multigrator, anton_software 2.6.4 - Markus Dittrich
8 # 12/04/2012: Updates for anton.chem.average_dispersion_type,
9 # anton_software 2.11.0 - Markus Dittrich
10 # 12/06/2012: Fix bug in dispersion type option
11 # 03/1/2013: Added note regarding option to write velocities: User needs to think if
12 # they will need the atomic velocities. See note before "trajectory" section in this
↪→ file. Marcela Madrid
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13 # 11/15/2013: Made Multigrator the default integrator. Marcela Madrid
14 # 11/20/2013: Added Langevin option inside Multigrator. MM.
15 # 12/25/2013: Increased checkpoint interval to 120 ns. Markus Dittrich
16 # 05/07/2014: Added comments about maximum values for Escale and Fscale and
17 # about writing energies during the trajectory. MM.
18 # 10/20/2014: Added comment about broken potential energies for <=anton-software/2.12
19 # 10/30/2015: Added options to use u series for long-range electrostatics. Options are
↪→ commented out
20 #and need to be uncomment if wanting to use u series option.





25 # Please specify the equilibrated system file in maestro format




30 #Uncommnent the following line for using u series:








39 # this is required for NPT simulations and describes
40 # how much the simulation cell is allowed to fluctuate
41 # in size. Please note the increasing this values will
42 # increase the memory footprint and potentially slow
43 # down simulations
44 max_strain = 0.1
45
46 # this is required for NPT and semi-isotropic pressure
47 # control. See
48 # arkchecker --schema=anton -? anton.chem.average_dispersion_type
49 # for more detail
50 # average_dispersion_type = "auto|manual"
51
52 # increasing Escale and Fscale from the guessed values
53 # may be necessary to handle run-time errors of the form
54 #
55 # LOCAL FATAL ERROR: CORR_ERR_LOG/PPIP_OVF=0x1
56 # or other Overflow errors. Try increasing gradually until you find values that
↪→ work.
57 # It is probably fine to go to values in the 5000-6000 range. If this does not work
↪→ ,
58 # your system might need further equilibration.
59 #
60 # The following values, e.g., are required for the bpti.cms
61 # example on the Anton wiki. The initially guessed values
62 # are 1000/3000 for Escale/Fscale.
63 #
64 #Escale = "2000.0000"
65 #Fscale = "4000.0000"
66 #
67 #Uncomment the following three lines for u series:
68 #optional{
69 # useries_accuracy_level = "0"
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74 machine_size = [8 8 8]
75
76 regenerateBondProgram = "true"
77 go_verbosity = 0
78 check_overflow = "true"
79
80 # last time step in picoseconds, use Inf to
81 # simulate forever.
82 last_time = Inf
83 DRAMMode=false
84
85 checkpoint.interval = 120000
86
87 # specify trajectory output
88 # outdir = name of output directory
89 # interval = output interval in ps
90 # first = first frame to be dumped in ps
91 # CAREFUL HERE: IF YOU NEED THE ATOMIC VELOCITIES, uncomment
92 # the line "write_velocity=true". HOWEVER: be aware that doing so
93 # greatly increases the size of the frame files.
94 # Anton can write the Kinetic energy
95 # directly without having to write the velocities. See Energy section below.
96
97 trajectory = {
98 outdir=run.atr
99 interval = 240 #picoseconds
100 first = 0 #picosenconds
101 format=dtr
102 periodicfix = true
103 # write_velocity = true #Uncomment if you need the atomic velocities. This greatly
↪→ increases the size of the
104 # output files. Anton can write Energies, including Kinetic
↪→ energy, without writing velocities




109 # IMPORTANT NOTE: Only use this option for anton-software/2.13 and later. For
↪→ earlier
110 # versions the printed potential energy is incorrect.
111 # Output the energies: Our tests show not much difference in performance when
↪→ writing energies
112 # every 240 ps. Uncommenting the following lines prints Potential and Kinetic E,
↪→ among other terms.
113 # This example will write to file workdir/framsetnumber/energy/eneseq
114 # See Desmond User Guide in the Wiki Docs section for more options, or type, on
↪→ Anton:
115 # arkchecker --schema=anton -? energy
116
117 #energy = {
118 # first=0 #picoseconds
119 # interval=240 # your interval in picoseconds (must be a multiple of dt x RESPA
↪→ OUTER)







127 # describe the integrator to be used for the simulations.
128 # Please note that a plain NVE simulation can be significantly
129 # faster than a simulation in a NVT or NPT ensemble. Multigrator is the one currently
130 # used by DESRES for their research projects.
131 # Supported values are:
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132 #
133 # - V_NVE : NVE ensemble
134 # - Ber_NVT: NVT ensemble with a Berendsen thermostat
135 # - Ber_NPT: NPT ensemble with a Berendesn thermostat/barostat
136 # - NH_NVT : NVT ensemble using Nose-Hoover thermostat




141 type = Multigrator #this is where you define which integrator to use.
142
143 # general options
144 dt=0.0020
145 remove_com_motion = true





151 # V_NVE has not options
152 V_NVE = {}
153
154 # parameters for Ber_NPT
155 Ber_NPT = {
156 thermostat_molecular_ke=true
157 barostat = {
158 kappa = 4.5e-05
159 max_expansion_per_step = 1.1
160 min_contraction_per_step = 0.95
161 tau = 2.0
162 }
163 max_velocity_scaling = 1.2
164 min_velocity_scaling = 0.85
165 tau = [1.0 ]
166 }
167
168 # parameters for Ber_NVT
169 Ber_NVT = {
170 thermostat_molecular_ke="true"
171 max_velocity_scaling = 1.2
172 min_velocity_scaling = 0.85
173 tau = [1.0 ]
174 }
175
176 # parameters for NH_NVT









186 # The multigrator allows the user to select an ensemble and a
187 # dynamics by choosing specific instances of an nve integrator,
188 # a thermostat, and a barostat; for example, by setting
189 # nve.type="Verlet", thermostat.type="none" and barostat.type="MTK",
190 # the user can sample an isobaric-isoenthalpic ensemble.
191 nve {
192 # type can be "Verlet|PLS|none"
193 #Note: for improved accuracy, use PLS with number_of_stages="3", dt = 0.002,
↪→ and RESPA 1:1:3
194 # for faster runs but lower accuracy, use Verlet with dt=0.0025 ps and RESPA
↪→ 1:1:3
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195 type = "PLS"
196 PLS {
197 number_of_stages = "3"
198 # nonbonded_far_interval can be "1"





204 # type can be "NoseHoover|Langevin|none" for the 512-node Anton"
205 # Langevin can be used inside the Multigrator with equivalent taus and
↪→ intervals as
206 # Nose Hoover. One key difference is that the Langevin thermostat should have
↪→ use_molecular_ke=false
207 # as opposed to NoseHoover (see example below), which will likely lead to a
↪→ computational slowdown.
208 # All caveats about Langevin apply (it affects diffusion, e.g.) but otherwise
↪→ can be treated like any other thermostat.
209
210 # type can only be "NoseHoover|none" for the 64-node Anton used during
↪→ Workshops.
211
212 type = "NoseHoover"
213 # interval must be a multiple of nonbonded_far_interval; to ensure
214 # this, we recommend the interval to a multiple of 12.
215 # NOTE: the actual relaxation times for the thermostat are
216 # (interval * tau), where the tau’s are the relaxation times
217 # for the NoseHoover below
218 interval = "24"
219 NoseHoover {
220 chains = [{
221 mts = "1"
222 # values of tau of 0.0416667 represent a good compromise
223 # between roundoff and truncation errors. Larger relaxation
224 # times should be achieved by increasing thermostat.interval
225 tau = ["0.0416667" "0.0416667" "0.0416667"]
226 }]
227 use_molecular_ke = "true"
228 }
229 Langevin {
230 seed = 0x98765432
231 tau = 0.3




236 # type can be "MTK|none"
237 type = "MTK"
238 # interval must be a multiple of thermostat.interval;
239 # we recommend the user sets interval to a multiple of 12
240 # NOTE: the actual relaxation time for the barostat is
241 # (interval * tau), where tau is MTK.tau below
242 interval = "240"
243 MTK {
244 T_ref = "300.00"
245 # a value of tau of 0.0416667 represents a good compromise
246 # between roundoff and truncation errors. Larger relaxation
247 # times should be achieved by increasing barostat.interval
248 tau = "0.0416667"
249 thermostat {
250 # type can be "NoseHoover|none"
251 type = "NoseHoover"
252 NoseHoover {
253 chain {
254 mts = "1"
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263 # specify pressure for NPT ensembles, can be non-isotropic
264 # (see Desmond manual)
265 pressure = {
266 isotropy = isotropic # or semi_isotropic
267 max_margin_contraction = 0.9 # Maximum contraction ratio
268 p_ref = 1 # in BAR
269 tension_ref = ["0" "0" "0" "0" "0" "0" "0" "0" "0"]
270 }
271
272 # system temperature
273 temperature=[ {T_ref=300} ]
274 }
Below is an ark file was used for membrane-IR MD simulation.
1 anton.tune {
2 machine_size = [4 4 8] # 128-node PSC machine
3 last_time = 960000 # ps (multiple of trajectory.interval)
4 trajectory {
5 interval = 240 # ps (multiple of energy.interval)
6 }
7
8 #energy { # uncomment for an optional energy trajectory
9 # format = "etr" # at a finer granularity than the trajectory interval
10 # interval = 2.4 # ps (multiple of dt*barostat.interval)














25 T_ref = "310.00"




30 mts = "4"
31 tau = ["0.0416667" "0.0416667" "0.0416667"]
32 }
33 }
34 type = "NoseHoover"
35 }
36 }
37 interval = "480" # barostat interval in timesteps (multiple of thermostat.
↪→ interval)
38 type = "MTK" # Change to "None" for NVT
39 }
40 thermostat {
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41 NoseHoover {
42 chains = [{
43 mts = "1"
44 tau = [".0416667" ".0416667" ".0416667"]
45 }]
46 use_molecular_ke = "true"
47 }
48 interval = "24" # thermostat interval in timestep (multiple of respa.
↪→ nonbonded_far_interval)




53 dt = "0.0025" # ps
54
55 pressure {
56 isotropy = "semi_isotropic" # Change to "semi_isotropic" for a membrane
57 p_ref = "1.0"
58 tension_ref = ["0." "0." "0." "0." "0." "0." "0." "0." "0."]
59 }
60
61 remove_com_motion = "true"
62
63 respa {
64 bonded_interval = "1"
65 nonbonded_far_interval = "3" # respa interval in timesteps
66 nonbonded_near_interval = "1"
67 }
68
69 temperature = [{
70 T_ref = "310.00" # thermostat temperature in K
71 }]
72
73 type = "Multigrator" # Change to "V_NVE" for NVE
74 }
G.7 Running on Anton 2
Given:
1. The dms file
2. The ark file
You can start running on Anton2:
1. Anton2 create is the command to create an Anton job, a workdir and gives you a jobid:
Example job script run1.sh
1 #!/bin/bash
2 set -u
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3 set -e





9 anton2 create $jobname --workdir $wd --cfg boot.file=bpti.dms --include psc.ark
↪→ --sw $ASW
Run with: ./run1.sh This will return: job id=427









9 anton2 prep $wd
10 Inside the job.err file in the workdir you should see: anton2-prep-helper was
↪→ successful
3. Now run with









9 anton2 submit $wd
Check status of job with anton2 lists job’s jobid. Run for longer time with: anton2 submit $jobid
–cfg anton.tune.last time=500000
Suspend job: To suspend a submitted job, use the following command: anton2 suspend WORKDIR
(or JOBID)
Below is the one-step script, instead of step-by-step as mentioned above, to run IR job and also
restart job using “update” option.
1 set -u
2 set -e
3 set -o pipefail





8 anton2 pre $wd









18 mkdir -p $cache
19 ASW=anton2_software/1.27.0
20 #anton2 create $jobname --workdir $wd --cfg boot.file=aim4ff.dms --include aim4.ark --
↪→ sw $ASW
21 #anton2 update $wd --include aim4.ark --cfg boot.file=aim4ff.dms --cfg anton.chem.
↪→ angle.permitFloppyAngles=true
22 anton2 update $wd --include aim4.ark --cfg boot.file=aim4ff.dms --cfg anton.chem.
↪→ Fscale=5500 --cfg anton.chem.angle.permitFloppyAngles=true --cfg anton.c
23 hem.Escale=5500 --cfg anton.tune.development.icb.icb_queue_std_devs_to_add=10.0
24 anton2 prep $wd
25 anton2 submit $wd
G.8 Converting the trajectory to the NAMD dcd format
The following example converts Anton trajectory to the dcd format and writes the first 3000
frames:
1 vmd -dispdev text system.dms
2 animate read dtr workdirNH_NVT/run.stk beg 0 end 300000 skip 100 waitfor all 0
3 animate write dcd short.dcd beg 1 end 3000 0




This appendix provides additional figures related to HDX analyses that are presented in chapter
7.
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